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ABSTRACT OF THE DISSERTATION
Understanding emerging biomarkers and lifestyle factors in aging and Alzheimer disease
by
Stephanie Ann Schultz
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2020
Professor Tammie L.S. Benzinger, Chair

Age-related cognitive decline and pathological brain changes are a widespread and growing
public health issue. Several environmental factors, including engagement in physical activity and
personality, have been shown to have potential protective effects in slowing cognitive decline
and preserving healthy brain aging. However, the underlying mechanisms providing exercise- or
personality-induced resilience to aging and disease remains largely unknown. Importantly, there
has been an emergence of several novel biomarkers to study healthy brain aging and age-related
neurodegenerative diseases including in vivo assessments of tau burden and brain metabolism via
positron emission tomography (PET) imaging and neurofilament light chain (NfL), a marker of
neurodegeneration, via blood-based biomarkers. During the first part of my thesis research, I
examined these emerging biomarkers within healthy aging and AD cohorts at Washington
University, in the Australian Imaging, Biomarkers, and Lifestyle (AIBL) cohort, and in the
Dominantly Inherited Alzheimer Network (DIAN) observational study (Chapters 2 – 5). For the
second part of my thesis research, I first used my new knowledge and experience with these
biomarkers to characterize and determine the influence of physical activity on cerebral glucose
metabolism (Chapter 6). Next, to better translate these findings to an exercise intervention in the

xii

future, I further completed a pilot study to determine feasibility and validity of performing a
submaximal exercise protocol in a diverse US population (Chapter 7). For the third part of my
thesis research, I discovered a cross-sectional association between personality traits and
neurofibrillary tangle pathology (Chapter 8). Taken together, the results from my thesis suggest
utility in all three emerging biomarkers examined (tau-PET, blood-based NfL, and multi-tracer
brain metabolism PET) for monitoring and understanding complex changes associated with brain
aging and disease. Additionally, this thesis research adds to the current understanding of the
potential role of increased physical activity in preservation of glycolytic metabolism in the aging
brain and increased risk of AD-related tau pathophysiology in neurotic personality traits. Further
research extending these findings to longitudinal studies are needed to help determine
directionality of the observed effects.

xiii

Chapter 1

Introduction

1

1.1 Introduction
Pathophysiological

brain

changes

that

occur

during

normal

aging

and

in

neurodegenerative diseases, such as AD, can begin several decades prior to overt cognitive
symptoms or the diagnosis of clinical dementia (J. C. Morris, 2005). The vast majority of adults
will experience age- and disease-related alterations in cognition driven by pathological changes
in the brain. Importantly, the advent of neuroimaging and fluid biomarkers to study structural,
protein, and metabolic brain changes now permits in vivo identification and monitoring of these
of complex process throughout adulthood. Investigating biomarkers throughout adulthood
uniquely allows us to understand how proteins in specific pathways are temporally and spatially
related to one another, and to the eventual manifestation of cognitive decline and disease
symptoms. To this end, there has been an emergence of several novel biomarkers to study healthy
aging and age-related neurodegenerative diseases including in vivo assessments of
tau/neurofibrillary tangle burden and brain metabolism via positron emission tomography (PET)
imaging and neurofilament light chain (NfL), a marker of neurodegeneration, via fluid biomarkers.
Additionally, there is a need to develop interventions that delay or prevent age- and
disease-related cognitive decline and pathological brain changes. Unfortunately, currently
available drugs for AD only treat AD symptoms and do not alter the course of further
pathophysiological changes. Furthermore, findings from clinical trials testing disease-modifying
therapeutics have been unsuccessful. Several modifiable lifestyle factors, including engagement
in physical activity, have been shown to have potential beneficial effects in slowing cognitive
decline and preserving healthy brain aging. However, the underlying mechanisms providing
exercise-induced resilience to aging and disease remains largely unknown. Physical activity is

2

important physiological and behavioral measures that predict health outcomes throughout the
lifespan. In adulthood, a sedentary lifestyle increases an individual’s risk for cardiovascular
disease. There is now growing interest to consider the predictive value and effects of improved
fitness on brain aging and dementia.

1.2 Alzheimer disease
AD is the most common cause of dementia, accounting for 60–80% of cases in the
United States and approximately 1 in 9 seniors in the United States have AD (Alzheimer's,
2016). As AD is primarily a disease of old age, its prevalence and associated costs for care are
projected to dramatically increase given the unprecedented expansion in the elderly segment of
the United States’ population (He et al., 2017). Given this looming epidemic posed by AD,
delaying the onset of AD symptoms and curbing the progression of the underlying disease
process has become a global public health imperative (Rosow et al., 2011). Faced by this
pressing need, there has been an increased focus on developing AD treatments. Unfortunately,
currently available drugs treat only AD symptoms. Furthermore, findings from clinical trials
testing disease-modifying therapeutics have been largely unsuccessful. The urgency of
alternative approaches for halting the global crisis posed by AD cannot be overstated.

1.3 Physical activity and brain health
An accumulation of findings from animal studies now show that physical exercise
represents an efficacious means for favorably altering not only cognitive trajectories but also the
underlying

AD

pathophysiological

processes,

including

beta-amyloid

burden,

tau

phosphorylation, hypometabolism, and neuronal loss (Adlard, Perreau, & Cotman, 2005; Adlard,
3

Perreau, Pop, & Cotman, 2005; Fuss et al., 2014; Marlatt, Potter, Lucassen, & van Praag, 2012;
K. M. Moore et al., 2016). Whereas the beneficial effects of exercise on cognition in elderly
persons have been well-studied (Angevaren, Aufdemkampe, Verhaar, Aleman, & Vanhees,
2008; Brown et al., 2016; Muller et al., 2018), investigations of the influence of exercise on
biomarkers of aging and AD pathology in humans are ongoing. The emerging evidence suggests
that physical exercise is associated with preserved brain volume in AD-vulnerable structures
such as the hippocampus (Dougherty, Schultz, Boots, et al., 2017; Erickson et al., 2009; Erickson
et al., 2011; Hamer, Sharma, & Batty, 2018; Okonkwo et al., 2014), reduced cerebral
hypometabolism (Deeny et al., 2012; Dougherty, Schultz, Kirby, et al., 2017; Okonkwo et al.,
2014), and reduced beta-amyloid burden (Head et al., 2012; Law et al., 2018; Liang et al., 2010;
Okonkwo et al., 2014; Rabin et al., 2019). Importantly, a review found that, of 7 key modifiable
risk factors for AD, physical activity had the highest impact on reducing the national prevalence
of AD (Barnes & Yaffe, 2011). Taken together, these reports raise the exciting possibility that
physical exercise might play a pivotal role in the prevention of age-and AD-related cognitive
impairment.
Even so, there remain some critical gaps in our knowledge about the relationship between
a physically active lifestyle and maintaining healthy brain function and resilience against AD.
First, because most of this research has been done in elderly persons, very little is known about
the potential influence of exercise on AD risk in early- and late-midlife, which is the life stage
within which most age and AD-related changes begin. The current thesis aims to address this
knowledge gap by studying the association of exercise on brain health across adulthood in
individuals between 25 and 85 years old.

1.4 Biomarkers for studying brain health
4

The broad neurobiological mechanisms that underlie the beneficial effects of exercise on
brain health remain largely unknown. To this end, there has been an emergence of several novel
biomarkers to study healthy aging and age-related neurodegenerative diseases including in vivo
assessments of tau burden and brain metabolism via positron emission tomography (PET) imaging
and neurofilament light chain (NfL), a marker of neurodegeneration, via blood-based biomarkers.
This thesis aims to first examine these emerging biomarkers within healthy aging and AD cohorts
at Washington University, in the Australian Imaging, Biomarkers, and Lifestyle (AIBL) cohort,
and in the Dominantly Inherited Alzheimer Network (DIAN) observational study. Next, I will
apply this knowledge and experience with these biomarkers to characterize and determine the
influence of lifestyle factors on healthy aging and AD.
Multiple clinicopathologic studies demonstrate that AD pathology is present in
individuals before clinical symptoms develop; such individuals are at elevated risk for
progression to AD dementia (Fagan et al., 2007; J. C. Morris et al., 2009; Vos et al., 2013). The
accumulation of beta-amyloid plaques and NFTs in CN individuals has been suggested to
represent preclinical AD. The 2011 National Institute of Aging (NIA) criteria, and recently
updated criteria (Jack, Bennett, et al., 2018), further propose that preclinical AD be divided into
separate stages: stage 1 with beta-amyloidosis only (A+); stage 2 with beta-amyloidosis and
indicators of pathologic tau (T+) and neurodegenerative pathology (N+); and stage 3 with betaamyloidosis, pathologic tau, neurodegeneration, and subtle cognitive decline (Jack et al., 2012;
R. A. Sperling et al., 2011). These three proposed stages of preclinical AD can be described by
surrogate markers in CSF; low CSF beta-amyloid-42 is generally accepted as a marker of betaamyloidosis, high CSF phosphorylated tau as a marker of pathologic tau, and high CSF total tau
or low hippocampal volume is generally accepted as a marker of neurodegeneration. However,
5

there are several limitations of CSF markers, including lack of direct information about
distributions or densities of beta-amyloid or of the NFTs. Additionally, increased CSF total tau
levels, commonly observed in AD, are similarly observed with other dementing diseases such as
frontotemporal lobar degeneration and traumatic brain injury, as well as normal aging (Franz et
al., 2003; Riemenschneider et al., 2002), making it non-specific for AD. In contrast, PET tracers
thought to bind to NFTs (Lowe et al., 2016; Marquie et al., 2017) reflects both total tauopathy
burden and topography, although off target binding has been noted (Lemoine, Leuzy, Chiotis,
Rodriguez-Vieitez, & Nordberg, 2018). Additionally, spatial information from tau-PET will be
critical for monitoring potential tau aggregate accumulation over time and for linking the
regional spread of pathologic tau to other key mechanisms involved in AD progression.
Furthermore, by providing this spatial information, tau-PET may help to distinguish preclinical
AD and symptomatic AD from other tauopathy-related diseases that exhibit different anatomical
patterns of tau aggregates. For this reason, PET measures of tau may be more suitable than CSF
measures for applying NIA-AA criteria for preclinical AD classification.
1.4.1 Tau-PET
While there is an established literature describing tau-PET findings in the setting of AD
dementia, the investigation of regional distribution of tauopathy in CN individuals with or
without preclinical AD (A+ or A-) remains relatively unexplored. Initial studies investigating
tau-PET ligand binding in small cohorts of CN adults have identified several brain regions that
show evidence of tauopathy in older individuals (Hanseeuw et al., 2017; Jack, Wiste, et al.,
2018; Jacobs et al., 2018; LaPoint et al., 2017; Lowe, Bruinsma, et al., 2018; Scholl et al., 2016;
Vemuri et al., 2017), and report that increased tau-PET binding inversely correlates with betaamyloid-42 levels in the cerebrospinal fluid (Chhatwal et al., 2016; B. A. Gordon et al., 2016).
6

This early work suggests tau-PET binding is elevated in preclinical AD, but further work is
needed to define the topography of tau-PET binding early in the disease course. The
characterization of regional tau accumulation in CN adults in vivo using tau-PET could be
important for identifying CN individuals most at risk of cognitive decline and might encourage
the evaluation of tau-related pharmacological interventions early in the disease course.
1.4.2 CSF and serum NfL
Secondly, there have been advancements in markers of neurodegeneration, including CSF
and blood-based markers of NfL. NfL is a component of the axonal cytoskeleton and is primarily
expressed in large caliber myelinated axons (A. Petzold, 2005; W. W. Schlaepfer & R. G. Lynch,
1977). Changes of NfL in bodily fluids have been linked to brain damage and brain atrophy in
mouse models and multiple neurological disorders including proteopathic neurodegenerative
diseases (M. Bacioglu et al., 2016; C. Barro et al., 2018; A. Brureau et al., 2017; J. Kuhle et al.,
2016; A. Petzold, 2005). Importantly, CSF collection and imaging modalities are invasive and
expensive, respectively, and therefore not well suited to routine clinical practice, making blood
biomarkers would ideal.
Recent progress in the analysis of Aβ, tau, and NfL in blood has been reported (N.
Fandos et al., 2017; N. Mattsson, U. Andreasson, H. Zetterberg, & K. Blennow, 2017; A.
Nakamura et al., 2018; V. Ovod et al., 2017; P. S. J. Weston et al., 2017), sparking interest in an
NfL blood-based biomarker that monitors neurodegeneration and disease progression. However,
longitudinal analyses are largely missing and the importance of NfL as a molecular biomarker
for the presymptomatic phase of neurodegenerative diseases remains unclear (N. Mattsson et al.,
2017; P. S. J. Weston et al., 2017; W. Zhou et al., 2017).
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1.4.2 Multitracer PET for Brain Metabolism
Lastly, aerobic glycolysis (AG) is an emerging biomarker of a group of metabolic
functions, which includes biosynthesis of glycogen, proteins, lipids, and nucleic acids; and
neuroprotection. Metabolic dysfunction appears to be a prominent feature of AD and is known to
occur early in the disease process. Recent studies suggest that a specific component of brain
glucose metabolism, that which is outside of oxidative phosphorylation (referred to as AG), not
only plays an important role in brain function, but also carries with it a risk for AD (Vlassenko et
al., 2011; Vlassenko et al., 2010).
Interestingly, similar to the known effects of exercise on the brain, it has been shown,
recently, that AG also supports developmental processes, particularly those required for synapse
formation and replacement, and has a prominent role in the regulation of neuronal activity.
Importantly, there remains a need to evaluate AG across adulthood and as a potential biomarker
of brain function.
After investigating the ability of these emerging biomarkers to detect change in
cognitively normal and cognitively impaired individuals we will apply our knowledge to better
understand the role of potential risk and resilience factors in brain aging and disease.

1.5 Physical activity and cerebral brain metabolism
Converging evidence suggests that both increased exercise and increased AG may be
beneficial for maintaining blood flow and impact Learning and Memory through similar
biological mechanisms. Importantly, preliminary data suggest that whereas the regional
topographies for cerebral blood flow (CBF) and total brain glucose (CMRGlc) and oxygen
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(CMRO2) metabolism remain relatively stable throughout the lifespan, the topography of brain
AG changes significantly with age. Overall, these findings raise the possibility that AG might
represent a key marker of ‘brain reserve’. Therefore, one proposed mechanism is that increased
physical activity promotes “youthful” brain glucose metabolism, which may impact cognition,
neurodegeneration, and healthy brain aging.
Initial findings from the Wisconsin Registry for Alzheimer’s Prevention cohort suggests
that engagement in ≥ 150 minutes of physical activity per week, assessed via self-reported physical
activity measurements, can modify age-associated changes in AD-related biomarkers, including
cerebral glucose metabolism in the posterior cingulate and Immediate Memory performance
(Okonkwo et al., 2014). These initial results suggest that physical activity can provide resilience to
deleterious brain changes, including hypometabolism, in an age-dependent manner.

1.6 Objective measurement of free-living physical activity
While studies of physical activity in cognitive neuroscience are dominated by assessment
with questionnaire-based physical activity measurements, including the above example, such
methods may be subject to recall and social desirability biases (Dyrstad, Hansen, Holme, &
Anderssen, 2014). The recent advent of the accelerometer, a device that continuously records
physical activity, has made possible the objective measurement of free-living physical activity.
Another advantage of accelerometer-measured physical activity is its ability to capture the
intensity and duration of activity. Recently, this method was used to study the relationship between
intensity-specific engagement in physical activity and cerebral glucose metabolism in older adults.
Results suggest that individuals who engage in higher levels of moderate-intensity physical activity
have correspondingly higher cerebral glucose metabolism in the rostral middle frontal gyrus
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(Dougherty, Schultz, Kirby, et al., 2017). Taken together, these prior studies support the notion that
physical activity may be beneficial for maintaining cerebral glucose metabolism and cognitive
functioning in older adults.

1.7 Exercise interventions and monitoring cardiorespiratory
fitness
While observational studies have reported positive associations between engagement in
physical activity and cognitive and brain health, limited interpretations regarding directionality
or causality can be made. Interventions aimed at improving or maintaining cognitive functioning
and brain health report mixed results on the effectiveness of improving cardiorespiratory fitness
(CRF) on brain health outcomes, with one reporting detrimental effects (Wagner et al., 2015),
many reporting null or mixed effects (Colcombe et al., 2006; J. K. Morris et al., 2017; Niemann,
Godde, & Voelcker-Rehage, 2014; Sanders et al., 2020; Steen Jensen et al., 2016), and a few
positive trials (Erickson et al., 2011; Ngandu et al., 2015; Pentikainen et al., 2019; Tamura et al.,
2015). However, such exercise interventions aimed at improving or maintaining cognition and
brain health vary drastically in their exercise intervention protocol and population involved,
ranging from 6-week to 24-week resistance or aerobic activities. Additionally, the populations
studied include both cognitively normal and cognitively impaired, as well as those who have no
cardiovascular risk factors and those who are at risk.
Lastly, while observational studies predominately use self-report or objectively-measure
physical activity levels to characterize physical activity habits intervention studies primarily
focus on measures of CRF, which is thought to reflect habitual physical activity. Assessment of
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maximal oxygen consumption (VO2max) during a graded exercise test is considered the gold
standard measure for evaluating CRF (Lea & Febiger, 1995). Obtaining a true measure of
VO2max, where a plateau in oxygen consumption is observed despite further increases in
intensity of exercise, is often challenging in certain populations, including older adults,
individuals with physical limitations, and with cognitive impairment. Submaximal exercise
testing is therefore commonly used to predict VO2max, as a proxy measure of CRF, particularly
when laboratory equipment or physician supervision is unavailable or when the target population
is unlikely to go to volitional exhaustion. A recently developed Ekblom-Bak (EB) cycle
ergometer test (Bjorkman, Ekblom-Bak, Ekblom, & Ekblom, 2016; Ekblom-Bak, Bjorkman,
Hellenius, & Ekblom, 2014) for prediction of VO2max is low-risk, easy to administer, and shown
to be valid for a wide range of aerobic capacities and ages (Vaisanen et al., 2020). Validation of
the Ekblom-Bak test in a diverse US population will improve future ability to collect accurate
CRF data in a wide range of individuals undergoing exercise interventions.

1.8 Conclusions
The overall aim of the current thesis is to rigorously characterize the relationship between
risk and resilience factors (i.e., objective measures of physical activity and personality traits) and
brain health (brain metabolism, neurodegeneration, tau). We additionally propose a pilot study
(n=15) to test the feasibility of collecting maximal CRF data, via graded exercise testing (GXT),
and validate the Ekblom-Bak submaximal test for determination of CRF levels across a diverse
population.
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Chapter 2

Widespread distribution of tauopathy in
preclinical Alzheimer disease.
This chapter is adapted from a manuscript published in Neurobiology of Aging.

Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M.
and Benzinger, T. L. S. (2018) 'Widespread distribution of tauopathy in preclinical Alzheimer's disease',
Neurobiol Aging, 72, pp. 177-185.
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2.1 Summary
The objective of this study was to examine the distribution and severity of tau-PET
binding in cognitively normal adults with preclinical Alzheimer's disease as determined by
positive beta-amyloid PET. 18F-AV-1451 tau-PET data from 109 cognitively normal older
adults were processed with 34 cortical and 9 subcortical FreeSurfer regions and averaged across
both hemispheres. Individuals were classified as being beta-amyloid positive (N = 25, A+) or
negative (N = 84, A−) based on a 18F-AV-45 beta-amyloid-PET standardize uptake value ratio
of 1.22. We compared the tau-PET binding in the 2 groups using covariate-adjusted linear
regressions. The A+ cohort had higher tau-PET binding within 8 regions: Precuneus, amygdala,
banks of the superior temporal sulcus, entorhinal cortex, fusiform gyrus, inferior parietal cortex,
inferior temporal cortex, and middle temporal cortex. These findings, consistent with preclinical
involvement of the medial temporal lobe and parietal lobe and association regions by tauopathy,
emphasize that therapies targeting tauopathy in Alzheimer's disease could be considered before
the onset of symptoms to prevent or ameliorate cognitive decline.

2.2 Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is characterized by
extracellular beta-amyloid plaques and intra- neuronal neurofibrillary tangles (NFTs); the latter
contain abnormal filaments of pathologic tau protein (Braak, Alafuzoff, Arzberger, Kretzschmar,
& Del Tredici, 2006; Braak & Braak, 1991). In vivo neuroimaging and cerebrospinal fluid
(CSF) quantification of both beta-amyloid and tau protein can now detect pathological
13

aggregates and abnormal fluid concentrations of these proteins as early as 2 decades before the
onset of clinical symptoms (R. J. Bateman et al., 2012; R. A. Sperling et al., 2011).
Multiple clinicopathologic studies demonstrate that AD pathology is present in
individuals before clinical symptoms develop; such individuals are at elevated risk for
progression to AD dementia (Fagan et al., 2007; J. C. Morris et al., 2009; Vos et al., 2013). The
accumulation of beta-amyloid plaques and NFTs in cognitively normal (CN) individuals has
been suggested to represent preclinical AD. The 2011 National Institute of Aging (NIA) criteria,
and recently updated criteria(Jack, Bennett, et al., 2018), further propose that preclinical AD be
divided into separate stages: stage 1 with beta-amyloidosis only (A+); stage 2 with betaamyloidosis and indicators of neurodegenerative pathology (N+); and stage 3 with betaamyloidosis, neurodegeneration, and subtle cognitive decline (Jack et al., 2012; R. A. Sperling et
al., 2011). These 3 proposed stages of preclinical AD can be described by surrogate markers in
CSF; low CSF beta- amyloid-42 is generally accepted as a marker of beta-amyloidosis, and high
CSF tau is generally accepted as a marker of neurodegeneration. However, there are several
limitations of CSF markers, including lack of direct information about distributions or densities
of beta-amyloid or of the NFTs. In addition, increased CSF total tau levels, commonly observed
in AD, are similarly observed with other dementing diseases such as frontotemporal lobar
degeneration and traumatic brain injury, as well as normal aging (Franz et al., 2003;
Riemenschneider et al., 2002), making it nonspecific for AD. By contrast, PET tracers thought to
bind to NFTs (Lowe et al., 2016; Marquie et al., 2017) reflect both total tauopathy burden and
topography, although off target binding has been noted (Lemoine et al., 2018). In addition,
spatial information from tau-PET will be critical for monitoring potential tau aggregate
accumulation over time and for linking the regional spread of pathologic tau to other key
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mechanisms involved in AD progression. Furthermore, by providing this spatial information,
tau-PET may help to distinguish preclinical AD and symptomatic AD from other tauopathyrelated diseases that exhibit different anatomical patterns of tau aggregates. Therefore, PET
measures of tau may be more suitable than CSF measures for applying NIA-AA criteria for
preclinical AD or ATN classification.
While the regional deposition of beta-amyloid plaques in vivo, as detected by betaamyloid-PET tracers, has been well established (Klunk et al., 2004; V. L. Villemagne et al.,
2011), experience with tau- PET to describe the distribution of tauopathy in vivo is more limited.
Nevertheless, findings with tau-PET to date appear to be fairly consistent with the spatial
distributions of tauopathy that have been as described in neuropathologic studies (Braak et al.,
2006; Braak & Braak, 1991). Initial ex vivo autoradiographic studies suggest tau-PET correlates
with postmortem tauopathy (Lowe et al., 2016; Marquie et al., 2015). Furthermore, in vivo
studies examining individuals with symptomatic AD compared with controls have found tauPET ligand binding in temporal as well as neocortical areas in a spatial pattern that is generally
consistent with, but not identical to, advanced Braak stages V and VI (Chien et al., 2013; Cho et
al., 2016; B. A. Gordon et al., 2016; Johnson et al., 2016; Schwarz et al., 2016). The spatial
pattern of binding also colocalizes with changes in hypometabolism (Bischof et al., 2016;
Ossenkoppele et al., 2016), and atrophy (L. Wang et al., 2016), observed in atypical forms of AD
(Day et al., 2017; Ossenkoppele et al., 2016), and mirrors the degree of selective cognitive
impairment in those cases.
While there is an established literature describing tau-PET findings in the setting of AD
dementia, the investigation of regional distribution of tauopathy in CN individuals with or
without preclinical AD (A+ or A-) remains relatively unexplored. Initial studies investigating
15

tau-PET ligand binding in small cohorts of CN adults have identified several brain regions that
show evidence of tauopathy in older individuals (Hanseeuw et al., 2017; Jack, Wiste, et al.,
2018; Jacobs et al., 2018; LaPoint et al., 2017; Lowe, Bruinsma, et al., 2018; Lowe, Wiste, et al.,
2018; Scholl et al., 2016; Vemuri et al., 2017) and report that increased tau-PET binding
inversely correlates with beta-amyloid- 42 levels in the cerebrospinal fluid (Chhatwal et al.,
2016; B. A. Gordon et al., 2016). This early work suggests tau-PET binding is elevated in
preclinical AD, but further work is needed to define the topography of tau-PET binding early in
the disease course. The characterization of regional tau accumulation in CN adults in vivo using
tau-PET could be important for identifying CN individuals most at risk of cognitive decline and
might encourage the evaluation of tau- related pharmacological interventions early in the disease
course.

2.3 Methods
2.3.1 Participants
Data from 109 participants from studies at the Knight Alzheimer’s Disease Research
Center, Washington University in St. Louis (including the Adult Children Study and the Healthy
Aging and Senile Dementia Study) were used. Inclusion criteria included cognitive normality
[Clinical Dementia Rating score equals 0 (J. C. Morris, 1997)] and completion of both betaamyloid and tau-PET scans. The Washington University in St. Louis Institutional Review Board
approved all procedures and each participant was provided signed informed consent for the
study.
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2.3.2 MRI
Data were acquired on a Siemens Biograph mMR (n=83) or Trio3T scanner (n=26). T1weighted images were acquired using a magnetization-prepared rapid acquisition gradient echo
(MPRAGE) sequence with the following: repetition time=2300 ms, echotime=2.95 ms, flip
angle=9,176 slices, in plane resolution 240-256, slice thickness=1.2 mm acquired in sagittal
orientation. Images underwent volumetric segmentation using FreeSurfer 5.3
[http://freesurfer.net (Fischl et al., 2004) to identify regions of interest (ROIs) used in the PET
analyses.

2.3.3 PET imaging
Beta-amyloid-PET
Participants underwent beta-amyloid-PET imaging with18F-AV-45 (florbetapir).
Participants received a single intravenous bolus of370 MBq (10 mCi) of florbetapir infused over
60 seconds. Scans were acquired on a Siemens Biograph mMR PET/MR scanner and attenuation
corrected with a corresponding CT. Data were processed using an ROI approach using
FreeSurfer software. As described previously (B. A. Gordon et al., 2016), data between the 50to70-minute post injection window were examined. In each ROI, data were converted to
standardized uptake value ratios (SUVRs) using the cerebellar gray as the reference region and
partial volume corrected using a regional spread function approach (Rousset, Ma, & Evans,
1998; Su et al., 2016; Su et al., 2015).
Tau-PET
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Tau-PET imaging was performed within 13 months (mean: 44.0 days, range: 1-373 days)
of the beta-amyloid-PET imaging session using18F-AV-1451 (flortaucipir). Participants received
a single 6.5-10 mCi intravenous bolus of flortaucipir infused over 20seconds. Data were
processed using an ROI approach using Free-Surfer and, as done in prior work using 18F-AV1451 (M. R. Brier et al., 2016; Chien et al., 2013), and data from the 80- to100-minute post
injection window were examined. Scans were acquired on a Siemens Biograph 40 PET/CT
scanner. As described previously, in each ROI, data were converted to SUVRs using the
cerebellar gray as the reference region and partial volume corrected using a regional spread
function approach (Rousset et al., 1998; Su et al., 2015). This partial volume correction method,
including nonbrain region sampling, may additionally help minimize off-target binding. TauPET SUVRs for each cortical and subcortical ROI were extracted and averaged together from the
left and right hemispheres to form 1 bilateral measure. The average amount of time between
clinical assessment and tau-PET imaging session was 103-57 days, and the average time between
beta-amyloid-PET and tau-PET imaging sessions was 82-84 days.

2.3.4 Amyloid positivity classification
As previously described, a composite beta-amyloid deposition measure was created using
the average across the left and right lateral orbitofrontal, medial orbitofrontal, rostral middle
frontal, superior frontal, superior temporal, middle temporal, and precuneus regions(Su et al.,
2013). To identify individuals who were beta-amyloid positive, we split our sample based on a
partial volume corrected florbetapir SUVR cutoff of 1.22 (Mishra et al., 2017). To generate a
cutoff value for 18F-AV-45, a previously established cutoff using 11C-Pittsburgh compound B
(B. A. Gordon et al., 2015) was translated using a linear regression from a separate cohort of 100
individuals who had both 18F-AV-45 and11C-Pittsburgh compound B imaging as part of a
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crossover study. Based on this cutoff, our current sample included 25 beta-amyloid-positive (A+)
individuals and 84 beta-amyloid-negative (A-) participants.

2.3.5 Neuropsychological assessment
Each cohort at the Knight ADRC receives slightly different cognitive batteries, and in the
interest of maximizing the available sample size, only tests that were common across all cohorts
were considered for the present analyses. This resulted in a sample size of 108 individuals. Tests
included a measure of episodic memory: the free recall score from the Free and Cued Selective
Reminding Test (Grober, Buschke, Crystal, Bang, & Dresner, 1988); a measure of working
memory: Letter Number Sequencing (Wechsler, 1997); a measure of semantic memory retrieval:
category fluency for Animal Naming (Goodglass & Kaplan, 1983); a test of processing speed:
Trail Making part A and a test of executive function: Trail Making part B (Armitage, 1946).
Tests were standardized using the sample mean and standard deviation of the cognitive
assessment that was nearest to the tau-PET scan and then averaged to form a cognitive composite
score (A. Aschenbrenner, B. Gordon, T. Benzinger, J. Morris, & J. Hassenstab, 2018).

2.3.6 Statistics
To test for group differences between A+ and A-cohorts on demographics, t-tests were
performed for age, years of education, and Mini-Mental State Examination score; chi-squared
tests were per-formed for sex and apolipoprotein E ε4 (APOE4) genotype. To visualize the
collective anatomic distribution of tau-PET SUVR in each of the groups, we created
representative group mean images. For each participant, their non partial volume corrected
SUVR images were aligned to their individual MPRAGE using a rigid body transformation,
subsequently transformed to MNI atlas space using a nonlinear warp, and resampled into a 2-mm
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isotropic resolution. Voxels across all participants in either the A+ or A- groups were then
averaged together (Figure 2.1A and 2.1B). Higher SUVRs indicate higher binding of the tracer
relative to the cerebellar reference region, which reflects more tau pathology or greater
nonspecific binding, in one group compared to the other.
Next, to statistically compare regional tau-PET SUVRs in the A+ and A- groups, we ran
linear regressions for each of the 34 cortical and 9 subcortical regions examined (see Table 2.2
for list of regions), including age and sex as covariates in the model. Covariates were selected
based on their established association with AD and brain measures. To correct for multiple
comparisons, we implemented a Benjamini-Hochberg procedure with a false discovery rate of
5%.
Next, because APOE4 status was significantly different between the A- and A+ groups,
we repeated these multivariable linear regressions, comparing regional tau-PET SUVRs in the
A+ and A- groups, for each cortical and subcortical region found to be significant in the primary
analyses, but added APOE4 status as a covariate, along with age and sex. To correct for multiple
comparisons, we implemented a Benjamini-Hochberg procedure with a false discovery rate of
5%.
Since the A+ classification was derived from a composite beta-amyloid-PET SUVR, we
wanted to explore further the relationship between regional tau-PET and this composite betaamyloid-PETSUVR value. We ran a multivariate model for each of the 8 regions identified as
having significantly higher tau-PET SUVRs in the A+ cohort compared to controls, controlled
for age and sex. We additionally report the within-group Pearson’s correlation of regional tau-

20

PET and beta-amyloid-PET for these 8 regions. To correct for multiple comparisons, we
implemented a Benjamini-Hochberg procedure with a false discovery rate of 5%.
Finally, to determine whether the regional tau deposition is related to cognition, we ran
linear regression models between18F-AV-1451 and the global cognition score, adjusting for age
and sex. To correct for multiple comparisons, we implemented a Benjamini-Hochberg procedure
with a false discovery rate of 5%.

2.4 Results
2.4.1 Participant characteristics
As shown in Table 2.1, participants in the A+ cohort were older (mean age = 71.9 years)
compared to A- individuals (mean age = 66.8 years, Fdf = 1.2591,107, p = 0.008) and had a higher
percentage of APOE4 carriers (56.0%) than the A- group (23.2%, X2 = 9.681, p = 0.002).

2.4.2 Tau distribution in A+ cohort
Linear regressions evaluating group differences between the A+ and A- groups show that
the A+ cohort had significantly higher tau- PET SUVR in 9 regions (Table 2.2), including within
the amygdala (B = 0.136, p = 0.004), banks of the superior temporal sulcus (B = 0.094, p =
0.006), entorhinal cortex (B = 0.168, p = 0.004), fusiform gyrus (B = 0.095, p = 0.001), inferior
parietal cortex (B = 0.100, p = 0.006), inferior temporal cortex (B = 0.111, p = 0.002),
parahippocampal gyrus (B = 0.086, p = 0.019), middle temporal cortex (B = 0.098, p = 0.001),
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precuneus (B = 0.110, p = 0.005). Effect size maps of regression coefficients (B values) from
significant linear regressions are presented in Figure 2.2. Violin plots show the distribution of
AV1451 in 9 significant regions of interest (Figure 2.3). Furthermore, 18F-AV-1451 signal in
these regions is highly correlated across all regions (Table 2.3).

When APOE4 status was included as a covariate, regional tau- PET SUVRs for the A+
cohort remained significantly higher compared to the A- group in 8 of the 9 regions including the
amygdala (B = 0.141, p = 0.005), banks of the superior temporal sulcus (B = 0.091, p = 0.013),
entorhinal cortex (B = 0.152, p = 0.014), fusiform gyrus (B = 0.084, p = 0.005), inferior parietal
cortex (B = 0.101, p = 0.009), inferior temporal cortex (B = 0.103, p = 0.008), middle temporal
cortex (B = 0.098, p = 0.003), and precuneus (B = 0.109, p = 0.010), with the exception being the
parahippocampal gyrus (p = 0.110). Furthermore, in these models, APOE4 status is not
significantly associated with tau-PET SUVRs in any regions examined. Full models are
presented in Table 2.4.

2.4.3 Relationship between beta-amyloid- and tau-PET
There were significant associations between regional tau-PET SUVR and composite betaamyloid SUVR levels in all 8 regions examined (Figure 2.4), including the amygdala (B
[standard error [SE] = 0.153 [0.04], p <0.001, η2 =0.121), banks of the superior temporal sulcus
(B [SE] =0.090[0.03], p =0.003, η2 =0.080), entorhinal cortex (B[SE]=0.168[0.05], p =0.001, η2
=0.098), fusiform gyrus (B [SE] =0.087[0.03], p =0.001, η2 =0.106), inferior parietal (B[SE]
=0.102[0.03], p =0.002, η2 =0.092), inferior temporal (B[SE] =0.106 [0.03], p =0.001, η2
=0.098), middle temporal (B[SE] =0.093[0.03], p =0.001, η2 =0.104), and precuneus (B[SE]
=0.135[0.03], p =<0.001, η2 =0.136). In addition, there were within-group correlations between
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tau-PET and beta-amyloid-PET in A+ individuals in the inferior parietal (r =0.498, p =0.011),
inferior temporal (r =0.453, p =0.023), and middle temporal (r =0.531, p =0.006). There was no
correlation in A- individuals between tau-PET and beta- amyloid-PET in any region examined.

2.4.4 Relationship between cognition and tau-PET
There was no relationship between tau-PET and the cognitive composite score in any of
the 8 regions examined (p > 0.101, Table 2.5).

2.5 Discussion
Clinicopathologic studies of AD propose a stereotypical spread of tauopathy based on
postmortem pathological studies. The Braak and Braak staging scheme envisions spread of NFTs
from the brainstem and transentorhinal cortex to entorhinal cortex, then into neocortical regions,
including the fusiform gyrus, medialtemporal gyrus, and insular cortex, and, later, into frontal,
parietal, and occipital cortices (Braak & Braak, 1991). Recent studies (Lowe et al., 2016;
Marquie et al., 2017) comparing 18F-AV-1451 autoradiography with tau immunohistochemistry
have found high colocalization of 18F-AV-1451 with tauopathy in AD compared to other nonAD tauopathies, particularly in the brains with advanced Braak NFT stages, supporting the use of
this tracer to map AD-associated tauopathy.
Other studies have investigated the spatial pattern of 18F-AV-1451 binding tauopathy in
vivo, using 18F-AV-1451 and PET, comparing CN individuals to older adults with symptomatic
AD. Johnson and colleagues (2016) found that participants with mild cognitive impairment and
AD had significantly higher tau-PETSUVRs in regions including the inferior temporal lobe,
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fusiform gyrus, posterior cingulate cortex, occipital cortex, parahippocampal gyrus, and
entorhinal cortex compared with CN peers. Similarly, our group (M. R. Brier et al., 2016) and
others (Cho et al., 2016; Johnson et al., 2016) have shown patterns of increased tau-PET SUVRs
in cognitively impaired individuals compared to controls in temporal and occipital neocortical
areas. This homogeneity across multiple centers suggests a consistent spatial pattern of tau-PET
binding in symptomatic AD cohorts relative to cognitively normal controls. This spatial pattern
of tau-PET binding in symptomatic AD has been stereotyped into an estimated tau-PET Braak
staging scheme (Maass et al., 2017; Scholl et al., 2016) in which the regional tau burden in
symptomatic AD participants appears consistent with higher Braak stages (V and VI).
This study adds to converging literature examining tau-PET in A+ and A- CN individuals
(Hanseeuw et al., 2017; Jack, Wiste, et al., 2018; Mishra et al., 2017; Sepulcre et al., 2016; V.
Villemagne et al., 2017). For example, Schöl land colleagues (2016) examined18F-AV-1451 tauPET, mapped on to the Braak NFT staging scheme, being distributed across all Braak stages, in a
cohort of 5 CN young adults, 33 CN older adults, and 15symptomatic AD patients. Among them,
CN older adults ranged across stages 0, I/II, and III/IV. Other studies also described regional
associations with other core AD biomarkers including beta-amyloid-PET (M. R. Brier et al.,
2016; Lockhart et al., 2017), CSF tau levels (Chhatwal et al., 2016; L. Wang et al., 2016), gray
matter volumes and cortical thinning (LaPoint et al., 2017; Sepulcre et al., 2016), and functional
connectivity MRI in CN individuals (A. P. Schultz et al., 2017). Specifically, a study
investigating difference in inherent tau-PET signal across the brain in younger adults proposed
implementation of region-specific z-score values to assess severity of NFT burden (Vemuri et
al., 2017). Results focus on the entorhinal cortex as an AD-specific tau-PET signature. Similarly,
we find an increase in tau-PET signal in the entorhinal cortex in A+ individuals compared to A-.
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However, we importantly show that there are a number of other regions also significantly
elevated in this A+ cohort, which extend outside the medial temporal lobe. Recent studies
investigating the cross-sectional and longitudinal tau-PET signal in CN and cognitively impaired
individuals additionally support our results. Using a meta-region of interest approach to assess
longitudinal change in tau, results were in alignment with the current findings, suggesting
increase in the rates of tau accumulation in regions other than the entorhinal cortex, including
midtemporal, retrosplenial, and posterior cingulate (Jack, Wiste, et al., 2018). However, the
regions characterized as an “early-AD” meta-region for longitudinal analyses included the
fusiform and posterior cingulate gyrus, therefore not completely consistent with our results.
The present study extends the work of those studies in several critical ways. First, it
focuses on the generation of a topographical map of 18F-AV-1451 signal in A+ CN individuals.
Such work aids in our interpretation of tau accumulation in preclinical AD.
Second, with its restriction specifically on a large A+ cohort, characterized clinically by
CDR and for AD pathology by beta-amyloid-PET, this study provides strong evidence that
regions of tauopathy detected by tau-PET in A+ are comparable to those identified in recent
studies of AD dementia and are comparable, but not identical to, Braak NFT staging. It is
possible that the discrepancy in our results compared to Braak NFT staging is due to differences
in specificity of 18F-AV-1451 binding of certain tau isoforms compared to classical
histochemical staining or signal contamination in 18F-AV-1451 from nonspecific binding in
nearby regions. Alternatively, this discordance could be related to subtle difference in the cohorts
studied and comparisons examined. While Braak NFT staging is primarily a classification of
presence or absence of regional NFT, our analyses more specifically examined not only the
distribution of NFT in A+ CN individuals but also the density of NFTs in these regions, as
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compared to an A- cohort. We therefore provide evidence for significant regional differences in
18F-AV-1451 signal in A+ CN individuals, compared to A- individuals.
We additionally report that APOE e4 may not be associated with tau-PET signal above
and beyond that of A- and A+ classification. This is in contrast to recent studies in animal
models suggesting a role of APOE e4 exacerbating NFT accumulation (Shi et al., 2017). It is
possible, however, that the present study may be underpowered to detect a modulating effect of
APOE e4 status within A- and A+ groups. Larger studies with a sufficient sample of APOE e4
A- individuals are needed to determine whether there are interactions between APOE e4 status
and beta-amyloid load on regional tau-PET signal. Furthermore, we report no associations
between regional 18F-AV-1451 and global cognition in our cohort. These results support
findings by Schöll and colleagues (2016) who similarly reported a lack of association between
cross-sectional global cognition and 18F-AV-1451.
Overall, results from prior studies, in addition to the present study, provide evidence that
there are associations with tau-PET and established biomarkers of AD in preclinical stage,
further strengthening the utility of tau-PET in AD research and clinical trials.
Overall, by emphasizing the presence of widespread tauopathy early in the disease
course, these findings should inform treatment strategies for preclinical AD. Having learned
from previous clinical trials that unsuccessfully targeted mild-to-moderate AD dementia (Y.
Wang et al., 2017), ongoing clinical trials are now administering anti-beta-amyloid therapies in
asymptomatic individuals who are determined to be positive by beta-amyloid-PET. The results
of those trials will provide insight into the potential benefit of targeting beta-amyloid pathology
early in the disease course. However, the results of this present study demonstrate that many
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clinical trial participants who are beta-amyloid-PET positive are also likely to have a significant
tauopathy burden. Given that both tauopathy and beta-amyloid deposits are present in
presymptomatic stages, it maybe worthwhile to consider anti-tau therapies at this early staged
either alone, or in combination with anti-beta-amyloid therapy. Indeed, combined therapy might
be more effective than either single therapy alone.
A particular strength of the present study is its large, well-characterized sample compared
with prior studies (Johnson et al., 2016; Ossenkoppele et al., 2016). However, its sample size remains relatively modest for evaluating effects at a whole-brain level, underscoring the future
need for an increasingly larger sample.
There remain several limitations of the present study. First, the current interpretation of
NFT pathophysiology through utilization of 18F-AV-1451-PET in CN individuals is a potential
limitation. It has been reported that 18F-AV-1451 may bind nonspecifically to neuromelanin,
MAO, and iron deposits, in regions including putamen and thalamus. Furthermore, most
investigations on off-target binding of 18F-AV-1451 have been conducted primarily in
individuals with impairment or dementia, and little is known about the contribution of off-target
binding in studies of CN individuals. However, the largest factor so far tied to this nonspecific
binding has been age; thus, we included age as a covariate. Even so, there is evidence, as seen in
Figure 2.2, of off-target binding, including parts of the basal ganglia and brainstem. Strong
correlations of 18F-AV-1451between brain regions suggest that associations of primary interest
are not due to off-target binding of the basal ganglia and brainstem, yet we acknowledge there
may be minimal bleeding effect of off-target binding on some regions examined, but largely
controlled by partial volume correction methods including nonbrain region sampling.
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Another potential limitation of our study is that the tau-PET imaging sessions were more
likely to occur after the collection of beta-amyloid-PET data and clinical examination; however,
we limited this interval to 12 months, so any overestimation of tauopathy in relation to betaamyloid and clinical data should be very modest. In addition, similar to many other studies in
preclinical AD and AD dementia, our A+ group was older than A- group. We accounted for this
difference by including age as a covariate in the model; however, future studies would be
improved by age-matching A- and A+ groups.
Finally, because we classified our participants categorically as A+ or A- based on betaamyloid status, it is possible that some of our beta-amyloid-negative participants are actually
subtly beta-amyloid-positive, but below threshold (Palmqvist, Mattsson, Hansson, & Alzheimer's
Disease Neuroimaging, 2016; Vlassenko et al., 2016). Furthermore, as depicted in Figure 2.3,
there are a few participants who may have elevated 18F-AV-1451 levels in contrast to their low
beta-amyloid-PET levels, representing a potential primary age-related tauopathy subset in our Agroup or generally noisy binding properties of the tracer in the absence of AD pathology. In
addition, it is possible that accumulation of tau pathology might be happening in parallel, and Aindividuals who present with high AV1451 might convert to A+ in the future. Longitudinal betaamyloid- and tau-PET studies would support more confident identification of participants with
preclinical AD.
In summary, our findings contribute to the understanding of tau pathology and illustrate
in vivo that tauopathy is widespread in preclinical AD, encompassing both the temporal and
parietal lobes. This and future studies of pathologic tau-PET in preclinical AD will be useful in
designing clinical trials for AD dementia, especially when tauopathy-related therapies are

28

administered. These results suggest that it may be worthwhile to consider anti tauopathy
therapies early in the disease course to prevent cognitive decline due to Alzheimer’s disease.
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Table 2.1. Participant characteristics.
A− (N = 84)

A+ (N = 25)

Age, y

66.8 (8.6) [46–91]

71.9 (7.4) [58–90]

0.006

Female, % (n)

50.0 (42)

60.0 (15)

0.495

APOE4 positive, % (n)

23.2 (19)

56.0 (14)

0.003

Education, y

16.1 (2.2) [12–20]

16.6 (1.6) [12–18]

0.425

GDS

1.16 (1.8) [0–10]

0.68 (1.1) [0–3]

0.104

MMSE

29.3 (1.1) [25–30]

29.5 (1.0) [27–30]

0.228

Clinical assessment and tauPET time interval, d

105.0 (54.8) [0–240]

94.9 (65.7) [0–328]

0.548

Beta-amyloid-PET and tauPET time interval, d

76.4 (80.9) [1–353]

102.8 (94.4) [1–373]

0.212

Characteristic

p-value

Values are mean (SD) [range] unless otherwise indicated.
Key: GDS, Geriatric Depression Scale, APOE4, apolipoprotein E ε4; MMSE, Mini–Mental State
Examination, A+, beta-amyloid-PET positive; A−, beta-amyloid-PET negative.
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Table 2.2. Regional tau-PET SUVR in A+ and A− cohorts.
Region

A−
mean
SUVR
(SD)

A+
mean
SUVR
(SD)

Unstandardized 95% CI
B (SE)

Partial
eta
squared

pvalue

Accumbens

1.35
(0.30)

1.40
(0.26)

−0.004 (0.07)

−0.138 0.000
to 0.130

0.958

Amygdala

1.08
(0.17)

1.24
(0.28)

0.136 (0.05)

0.044 to 0.076
0.227

0.004

Caudate

1.33
(0.25)

1.44
(0.26)

0.044 (0.06)

−0.069 0.006
to 0.157

0.441

Choroid plexus

1.82
(0.65)

1.94
(0.93)

0.063 (0.17)

−0.274 0.001
to 0.400

0.712

Banks of superior
temporal sulcus

1.23
(0.13)

1.36
(0.19)

0.094 (0.03)

0.027 to 0.069
0.160

0.006

Caudal anterior
cingulate

1.11
(0.17)

1.10
(0.20)

−0.006 (0.04)

−0.089 0.000
to 0.076

0.879

Caudal middle
frontal

1.00
(0.15)

1.08
(0.23)

0.082 (0.04)

0.003 to 0.039
0.162

0.042

Cuneus

1.22
(0.15)

1.21
(0.16)

−0.009 (0.04)

−0.080 0.001
to 0.061

0.792

Entorhinal cortex

1.03
(0.22)

1.21
(0.31)

0.168 (0.06)

0.055 to 0.077
0.281

0.004

Frontal pole

0.91
(0.34)

0.85
(0.26)

0.006 (0.06)

−0.120 0.000
to 0.133

0.921
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Region

A−
mean
SUVR
(SD)

A+
mean
SUVR
(SD)

Unstandardized 95% CI
B (SE)

Partial
eta
squared

pvalue

Fusiform

1.22
(0.12)

1.33
(0.12)

0.095 (0.03)

0.04 to
0.150

0.100

0.001

Inferior parietal

1.23
(0.15)

1.35
(0.20)

0.100 (0.04)

0.030 to 0.070
0.170

0.006

Inferior temporal

1.26
(0.15)

1.39
(0.18)

0.111 (0.04)

0.040 to 0.085
0.181

0.002

Insula

0.98
(0.13)

0.98
(0.14)

0.005 (0.03)

−0.056 0.000
to 0.066

0.878

Isthmus cingulate
cortex

1.20
(0.16)

1.32
(0.23)

0.090 (0.04)

0.010 to 0.045
0.170

0.028

Lateral occipital
cortex

1.24
(0.23)

1.30
(0.22)

0.038 (0.05)

−0.062 0.005
to 0.139

0.450

Lateral orbital
frontal cortex

1.18
(0.15)

1.25
(0.15)

0.053 (0.04)

−0.016 0.021
to 0.122

0.134

Lingual cortex

1.16
(0.14)

1.18
(0.14)

0.008 (0.03)

−0.056 0.001
to 0.072

0.808

Medial orbital
frontal cortex

1.02
(0.16)

1.06
(0.17)

0.034 (0.04)

−0.043 0.007
to 0.111

0.382

Middle temporal
cortex

1.21
(0.14)

1.31
(0.14)

0.098 (0.03)

0.039 to 0.092
0.158

0.001

Paracentral cortex

1.06
(0.18)

1.06
(0.19)

−0.005 (0.04)

−0.090 0.000
to 0.079

0.900
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Region

A−
mean
SUVR
(SD)

A+
mean
SUVR
(SD)

Unstandardized 95% CI
B (SE)

Partial
eta
squared

pvalue

Parahippocampal
gyrus

1.01
(0.15)

1.09
(0.17)

0.086 (0.04)

0.014 to 0.051
0.159

0.019

Pars opercularis

1.03
(0.15)

1.05
(0.19)

0.019 (0.04)

−0.055 0.002
to 0.092

0.617

Pars orbitalis

1.21
(0.23)

1.19
(0.19)

−0.004 (0.05)

−0.096 0.000
to 0.089

0.928

Pars triangularis

1.14
(0.18)

1.14
(0.22)

0.014 (0.04)

−0.071 0.001
to 0.099

0.747

Peri calcarine
cortex

1.19
(0.14)

1.21
(0.16)

0.001 (0.03)

−0.066 0.000
to 0.067

0.985

Post central

0.98
(0.13)

0.98
(0.15)

0.003 (0.03)

−0.058 0.000
to 0.064

0.927

Posterior cingulate
cortex

1.23
(0.14)

1.31
(0.19)

0.075 (0.04)

0.004 to 0.040
0.146

0.038

Precentral cortex

0.97
(0.12)

0.98
(0.17)

0.019 (0.03)

−0.044 0.003
to 0.082

0.556

Precuneus

1.20
(0.15)

1.32
(0.21)

0.110 (0.04)

0.034 to 0.072
0.187

0.005

Rostral anterior
cingulate cortex

1.06
(0.17)

1.05
(0.17)

−0.011 (0.04)

−0.090 0.001
to 0.068

0.784

Rostral middle
frontal cortex

0.94
(0.18)

0.95
(0.17)

−0.029 (0.04)

−0.042 0.006
to 0.100

0.419
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Region

A−
mean
SUVR
(SD)

A+
mean
SUVR
(SD)

Unstandardized 95% CI
B (SE)

Partial
eta
squared

pvalue

Superior frontal
cortex

0.88
(0.15)

0.91
(0.18)

0.024 (0.04)

−0.049 0.004
to 0.098

0.428

Superior parietal
cortex

1.05
(0.17)

1.14
(0.24)

0.072 (0.04)

−0.015 0.025
to 0.160

0.105

Superior temporal
cortex

1.01
(0.12)

1.03
(0.13)

0.033 (0.03)

−0.021 0.014
to 0.087

0.225

Supramarginal
gyrus

1.16
(0.13)

1.22
(0.15)

0.053 (0.03)

0.006 to 0.029
0.112

0.079

Temporal pole

1.00
(0.17)

1.06
(0.22)

0.077 (0.04)

0.002 to 0.034
0.157

0.057

Transverse
temporal cortex

0.98
(0.16)

1.01
(0.23)

0.036 (0.04)

−0.048 0.007
to 0.120

0.395

Hippocampus

1.21
(0.19)

1.24
(0.15)

0.005 (0.04)

−0.078 0.000
to 0.088

0.905

Pallidum

1.91
(0.34)

1.98
(0.32)

−0.039 (0.07)

−0.177 0.003
to 0.100

0.643

Putamen

1.52
(0.24)

1.62
(0.23)

0.015 (0.05)

−0.079 0.001
to 0.109

0.751

Thalamus

1.25
(0.15)

1.28
(0.13)

0.020 (0.03)

−0.047 0.003
to 0.087

0.557

Ventral
diencephalon

1.49
(0.21)

1.46
(0.18)

−0.041 (0.05)

−0.137 0.007
to 0.055

0.401
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Key: SUVR, standardized uptake value ratio; SE, standard error; CI, confidence interval, A+,
beta-amyloid-PET positive; A−, beta-amyloid-PET negative.
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Table 2.3. Regional correlation of AV-1451.

Precuneus

0.573***

0.835***

0.299**

0.609***

0.587***

0.675***

0.406***

0.727***

0.556***

0.715***

0.509***

0.811***

0.544***

0.574***

0.555***

0.388***

0.476***

0.575***

0.472***

Middle
Temporal

0.547***

0.559***

PHC

Inferior
Temporal

0.390***

0.568***

0.594***

0.622***

Inferior
Parietal

0.424***

0.535***

0.210*

Entorhinal

Fusiform

Inferior
Parietal

0.548***

Fusiform

Entorhinal

0.642***

BSTS

BSTS

Amygdala

Amygdala

0.532***

0.622***

0.818***

Inferior
Temporal

0.475***

0.534***

Middle
Temporal

0.512***

PHC

Precuneus
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Values depict Pearson correlations of AV-1451 SUVRs between the regions.
* p<0.05, ** p<0.005, *** p<0.001
Key: PHC, Parahippocampal, BSTS, Banks of the Superior Temporal Sulcus
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Table 2.4. Full models of association between regional tau-PET SUVR in A+ and A− cohorts.

B
0.793

Std.
Error
0.255

t
3.107

Sig.
0.002

Age

0.008

0.004

2.333

0.022

0.001

0.016

0.051

Sex

0.004

0.058

0.066

0.948

-0.111

0.118

0.000

-0.023

0.064

-0.360

0.720

-0.151

0.104

0.001

0.004

0.072

0.054

0.957

-0.139

0.147

0.000

0.707

0.175

4.038

0.000

0.360

1.054

0.138

Age

0.006

0.002

2.318

0.022

0.001

0.011

0.050

Sex

-0.025

0.040

-0.636

0.526

-0.104

0.053

0.004

APOE e4
Status
Amyloid
status
group
Intercept

-0.015

0.044

-0.334

0.739

-0.102

0.073

0.001

0.141

0.049

2.853

0.005

0.043

0.239

0.074

0.754

0.216

3.487

0.001

0.325

1.182

0.107

Age

0.009

0.003

2.980

0.004

0.003

0.015

0.080

Sex

-0.054

0.049

-1.108

0.271

-0.151

0.043

0.012

APOE e4
Status
Amyloid
status
group
Intercept

-0.013

0.054

-0.239

0.812

-0.121

0.095

0.001

0.049

0.061

0.797

0.427

-0.073

0.170

0.006

1.139

0.636

1.790

0.076

-0.123

2.401

0.030

Age

0.011

0.009

1.186

0.238

-0.007

0.029

0.014

Sex

-0.174

0.144

-1.212

0.228

-0.460

0.111

0.014

0.222

0.160

1.387

0.169

-0.096

0.540

0.019

-0.022

0.180

-0.123

0.902

-0.379

0.335

0.000

1.056

0.127

8.300

0.000

0.803

1.308

0.403

Age

0.003

0.002

1.508

0.135

-0.001

0.006

0.022

Sex

-0.016

0.029

-0.543

0.588

-0.073

0.041

0.003

0.009

0.032

0.296

0.768

-0.054

0.073

0.001

0.091

0.036

2.516

0.013

0.019

0.162

0.058

Dependent Variable
Accumbens
Intercept

Amygdala

Caudate

Choroid Plexus

Banks of the
superior
temporal
sulcus

95% Confidence
Interval
Lower
Upper
Bound
Bound
0.287
1.299

APOE e4
Status
Amyloid
status
group
Intercept

APOE e4
Status
Amyloid
status
group
Intercept

APOE e4
Status
Amyloid
status
group
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Partial Eta
Squared
0.086

Caudal
anterior
cingulate

Caudal middle
frontal

Cuneus

Frontal pole

Entorhinal
cortex

Fusiform

Intercept

1.145

0.158

7.256

0.000

0.832

1.457

0.340

Age

-0.001

0.002

-0.400

0.690

-0.005

0.004

0.002

Sex

0.037

0.036

1.043

0.300

-0.034

0.108

0.011

APOE e4
Status
Amyloid
status
group
Intercept

0.024

0.040

0.596

0.552

-0.055

0.102

0.003

-0.014

0.045

-0.322

0.748

-0.103

0.074

0.001

1.065

0.151

7.056

0.000

0.765

1.364

0.328

Age

-0.001

0.002

-0.564

0.574

-0.005

0.003

0.003

Sex

0.003

0.034

0.080

0.937

-0.065

0.070

0.000

-0.026

0.038

-0.680

0.498

-0.101

0.049

0.005

0.092

0.043

2.163

0.033

0.008

0.177

0.044

1.003

0.130

7.694

0.000

0.744

1.262

0.367

Age

0.003

0.002

1.362

0.176

-0.001

0.006

0.018

Sex

0.053

0.029

1.807

0.074

-0.005

0.112

0.031

APOE e4
Status
Amyloid
status
group
Intercept

0.062

0.033

1.883

0.063

-0.003

0.127

0.034

-0.032

0.037

-0.875

0.383

-0.105

0.041

0.007

0.665

0.214

3.104

0.002

0.240

1.090

0.086

Age

0.005

0.003

1.495

0.138

-0.001

0.011

0.021

Sex

0.091

0.048

1.887

0.062

-0.005

0.188

0.034

APOE e4
Status
Amyloid
status
group
Intercept

0.044

0.054

0.807

0.422

-0.063

0.151

0.006

0.152

0.061

2.499

0.014

0.031

0.272

0.058

1.268

0.238

5.326

0.000

0.796

1.741

0.218

Age

-0.008

0.003

-2.338

0.021

-0.015

-0.001

0.051

Sex

0.297

0.054

5.516

0.000

0.190

0.404

0.230

APOE e4
Status
Amyloid
status
group
Intercept

0.095

0.060

1.581

0.117

-0.024

0.214

0.024

-0.030

0.067

-0.448

0.655

-0.164

0.103

0.002

0.931

0.104

8.913

0.000

0.724

1.138

0.438

Age

0.004

0.001

2.518

0.013

0.001

0.007

0.059

Sex

0.055

0.024

2.338

0.021

0.008

0.102

0.051

APOE e4
Status

0.031

0.026

1.178

0.242

-0.021

0.083

0.013

APOE e4
Status
Amyloid
status
group
Intercept
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Inferior
parietal

Inferior
temporal

Insula

Isthmus
cingulate

Lateral
occipital cortex

Lateral orbital
frontal cortex

Amyloid
status
group
Intercept

0.084

0.030

2.843

0.005

0.025

0.143

0.073

1.065

0.134

7.936

0.000

0.799

1.331

0.382

Age

0.002

0.002

0.990

0.325

-0.002

0.006

0.010

Sex

0.079

0.030

2.592

0.011

0.018

0.139

0.062

-0.001

0.034

-0.029

0.977

-0.068

0.066

0.000

0.101

0.038

2.649

0.009

0.025

0.176

0.064

0.869

0.134

6.483

0.000

0.603

1.134

0.292

Age

0.005

0.002

2.756

0.007

0.001

0.009

0.069

Sex

0.063

0.030

2.079

0.040

0.003

0.123

0.041

APOE e4
Status
Amyloid
status
group
Intercept

0.020

0.034

0.589

0.557

-0.047

0.087

0.003

0.103

0.038

2.717

0.008

0.028

0.178

0.067

0.959

0.116

8.281

0.000

0.729

1.188

0.402

Age

0.000

0.002

0.113

0.910

-0.003

0.003

0.000

Sex

-0.008

0.026

-0.297

0.767

-0.060

0.044

0.001

0.028

0.029

0.952

0.343

-0.030

0.086

0.009

-0.004

0.033

-0.136

0.892

-0.069

0.060

0.000

1.031

0.152

6.773

0.000

0.729

1.333

0.310

Age

0.003

0.002

1.392

0.167

-0.001

0.007

0.019

Sex

-0.053

0.034

-1.534

0.128

-0.121

0.015

0.023

APOE e4
Status
Amyloid
status
group
Intercept

-0.033

0.038

-0.873

0.385

-0.109

0.043

0.007

0.103

0.043

2.393

0.019

0.018

0.188

0.053

0.867

0.186

4.653

0.000

0.498

1.237

0.175

Age

0.004

0.003

1.598

0.113

-0.001

0.009

0.024

Sex

0.141

0.042

3.352

0.001

0.058

0.225

0.099

APOE e4
Status
Amyloid
status
group
Intercept

0.080

0.047

1.716

0.089

-0.013

0.174

0.028

0.007

0.053

0.128

0.899

-0.098

0.111

0.000

0.994

0.128

7.744

0.000

0.740

1.249

0.370

Age

0.002

0.002

1.327

0.187

-0.001

0.006

0.017

Sex

0.018

0.029

0.620

0.536

-0.040

0.076

0.004

APOE e4
Status
Amyloid
status
group
Intercept

APOE e4
Status
Amyloid
status
group
Intercept
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Lingual cortex

Medial orbital
frontal cortex

Middle
temporal
cortex

Paracentral
cortex

Parahippocampal

Pars

APOE e4
Status
Amyloid
status
group
Intercept

0.061

0.032

1.898

0.060

-0.003

0.125

0.034

0.030

0.036

0.828

0.409

-0.042

0.102

0.007

1.003

0.117

8.544

0.000

0.770

1.236

0.417

Age

0.002

0.002

1.282

0.203

-0.001

0.005

0.016

Sex

-0.013

0.027

-0.495

0.622

-0.066

0.040

0.002

0.076

0.030

2.585

0.011

0.018

0.135

0.061

-0.019

0.033

-0.585

0.560

-0.085

0.046

0.003

0.919

0.146

6.297

0.000

0.629

1.208

0.280

Age

0.001

0.002

0.569

0.571

-0.003

0.005

0.003

Sex

0.015

0.033

0.452

0.652

-0.051

0.080

0.002

APOE e4
Status
Amyloid
status
group
Intercept

0.048

0.037

1.297

0.198

-0.025

0.120

0.016

0.017

0.041

0.413

0.681

-0.065

0.099

0.002

1.098

0.114

9.632

0.000

0.872

1.324

0.476

Age

0.001

0.002

0.564

0.574

-0.002

0.004

0.003

Sex

0.100

0.026

3.865

0.000

0.049

0.151

0.128

APOE e4
Status
Amyloid
status
group
Intercept

-0.001

0.029

-0.029

0.977

-0.058

0.056

0.000

0.098

0.032

3.049

0.003

0.034

0.162

0.084

1.130

0.160

7.061

0.000

0.812

1.447

0.328

Age

-0.001

0.002

-0.227

0.821

-0.005

0.004

0.001

Sex

-0.086

0.036

-2.379

0.019

-0.158

-0.014

0.053

0.047

0.040

1.178

0.241

-0.032

0.127

0.013

-0.022

0.045

-0.490

0.625

-0.112

0.068

0.002

0.798

0.134

5.937

0.000

0.531

1.064

0.257

Age

0.002

0.002

1.299

0.197

-0.001

0.006

0.016

Sex

0.054

0.030

1.762

0.081

-0.007

0.114

0.030

APOE e4
Status
Amyloid
status
group
Intercept

0.072

0.034

2.125

0.036

0.005

0.139

0.042

0.061

0.038

1.614

0.110

-0.014

0.137

0.025

1.052

0.140

7.494

0.000

0.774

1.331

0.355

APOE e4
Status
Amyloid
status
group
Intercept

APOE e4
Status
Amyloid
status
group
Intercept
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opercularis

Pars orbitalis

Pars
triangularis

Peri calcarine

Post central

Posterior
cingulate
cortex

Age

-0.001

0.002

-0.331

0.742

-0.005

0.003

0.001

Sex

0.042

0.032

1.333

0.185

-0.021

0.105

0.017

APOE e4
Status
Amyloid
status
group
Intercept

0.016

0.035

0.462

0.645

-0.054

0.086

0.002

0.014

0.040

0.340

0.734

-0.065

0.092

0.001

1.220

0.174

7.001

0.000

0.875

1.566

0.325

Age

-0.002

0.002

-0.691

0.491

-0.007

0.003

0.005

Sex

0.161

0.039

4.074

0.000

0.082

0.239

0.140

APOE e4
Status
Amyloid
status
group
Intercept

0.086

0.044

1.959

0.053

-0.001

0.173

0.036

-0.037

0.049

-0.757

0.451

-0.135

0.060

0.006

1.104

0.161

6.844

0.000

0.784

1.424

0.315

Age

-0.001

0.002

-0.305

0.761

-0.005

0.004

0.001

Sex

0.145

0.036

3.967

0.000

0.072

0.217

0.134

APOE e4
Status
Amyloid
status
group
Intercept

0.055

0.041

1.343

0.182

-0.026

0.135

0.017

-0.005

0.046

-0.110

0.913

-0.096

0.085

0.000

0.840

0.126

6.681

0.000

0.591

1.090

0.304

Age

0.005

0.002

2.662

0.009

0.001

0.008

0.065

Sex

0.049

0.028

1.732

0.086

-0.007

0.106

0.029

APOE e4
Status
Amyloid
status
group
Intercept

0.041

0.032

1.300

0.197

-0.022

0.104

0.016

-0.014

0.036

-0.392

0.696

-0.085

0.057

0.002

1.048

0.116

9.026

0.000

0.818

1.279

0.444

Age

-0.001

0.002

-0.851

0.397

-0.005

0.002

0.007

Sex

0.059

0.026

2.255

0.026

0.007

0.111

0.047

APOE e4
Status
Amyloid
status
group
Intercept

0.005

0.029

0.170

0.865

-0.053

0.063

0.000

0.001

0.033

0.043

0.966

-0.064

0.067

0.000

1.235

0.135

9.156

0.000

0.968

1.503

0.451

1.244E
-05
-0.021

0.002

-0.007

0.995

-0.004

0.004

0.000

0.030

-0.686

0.494

-0.081

0.040

0.005

0.022

0.034

0.642

0.522

-0.046

0.089

0.004

Age
Sex
APOE e4
Status
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Precentral
cortex

Precuneus

Rostral
anterior
cingulate

Rostral middle
frontal

Superior
frontal cortex

Superior
parietal cortex

Amyloid
status
group
Intercept

0.067

0.038

1.762

0.081

-0.008

0.143

0.030

0.997

0.120

8.332

0.000

0.759

1.234

0.405

Age

-0.001

0.002

-0.416

0.678

-0.004

0.003

0.002

Sex

0.029

0.027

1.063

0.290

-0.025

0.082

0.011

APOE e4
Status
Amyloid
status
group
Intercept

0.009

0.030

0.293

0.770

-0.051

0.069

0.001

0.016

0.034

0.487

0.627

-0.051

0.084

0.002

1.135

0.146

7.769

0.000

0.845

1.425

0.372

Age

0.001

0.002

0.594

0.554

-0.003

0.005

0.003

Sex

-0.039

0.033

-1.170

0.245

-0.104

0.027

0.013

APOE e4
Status
Amyloid
status
group
Intercept

0.005

0.037

0.146

0.884

-0.068

0.078

0.000

0.109

0.041

2.631

0.010

0.027

0.191

0.064

0.934

0.151

6.175

0.000

0.634

1.234

0.272

Age

0.002

0.002

0.723

0.471

-0.003

0.006

0.005

Sex

0.042

0.034

1.232

0.221

-0.026

0.110

0.015

APOE e4
Status
Amyloid
status
group
Intercept

0.018

0.038

0.470

0.640

-0.058

0.093

0.002

-0.017

0.043

-0.401

0.689

-0.102

0.068

0.002

0.883

0.134

6.586

0.000

0.617

1.149

0.298

Age

-0.001

0.002

-0.338

0.736

-0.004

0.003

0.001

Sex

0.184

0.030

6.086

0.000

0.124

0.245

0.266

APOE e4
Status
Amyloid
status
group
Intercept

0.043

0.034

1.274

0.206

-0.024

0.110

0.016

0.013

0.038

0.347

0.729

-0.062

0.088

0.001

0.929

0.140

6.635

0.000

0.652

1.207

0.301

Age

-0.001

0.002

-0.460

0.646

-0.005

0.003

0.002

Sex

0.023

0.032

0.724

0.471

-0.040

0.086

0.005

APOE e4
Status
Amyloid
status
group
Intercept

0.010

0.035

0.280

0.780

-0.060

0.080

0.001

0.021

0.040

0.540

0.590

-0.057

0.100

0.003

1.042

0.167

6.226

0.000

0.710

1.373

0.275

Age

0.000

0.002

0.073

0.942

-0.005

0.005

0.000

Sex

-0.003

0.038

-0.077

0.939

-0.078

0.072

0.000
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Superior
temporal
cortex

Supramarginal

Temporal pole

Transverse
temporal
cortex

Hippocampus

Pallidum

APOE e4
Status
Amyloid
status
group
Intercept

-0.013

0.042

-0.308

0.758

-0.096

0.071

0.001

0.077

0.047

1.629

0.106

-0.017

0.171

0.025

1.099

0.102

10.729

0.000

0.896

1.302

0.530

Age

-0.002

0.001

-1.427

0.157

-0.005

0.001

0.020

Sex

0.082

0.023

3.560

0.001

0.036

0.128

0.110

APOE e4
Status
Amyloid
status
group
Intercept

0.029

0.026

1.144

0.255

-0.022

0.081

0.013

0.023

0.029

0.808

0.421

-0.034

0.081

0.006

0.988

0.113

8.765

0.000

0.764

1.211

0.430

Age

0.002

0.002

1.224

0.224

-0.001

0.005

0.014

Sex

0.068

0.025

2.688

0.008

0.018

0.119

0.066

APOE e4
Status
Amyloid
status
group
Intercept

0.007

0.028

0.244

0.808

-0.049

0.063

0.001

0.051

0.032

1.593

0.114

-0.012

0.114

0.024

1.039

0.151

6.875

0.000

0.739

1.339

0.317

Age

-0.002

0.002

-0.799

0.426

-0.006

0.003

0.006

Sex

0.117

0.034

3.415

0.001

0.049

0.184

0.103

APOE e4
Status
Amyloid
status
group
Intercept

0.043

0.038

1.118

0.266

-0.033

0.118

0.012

0.063

0.043

1.463

0.146

-0.022

0.147

0.021

1.142

0.159

7.178

0.000

0.827

1.458

0.336

Age

-0.002

0.002

-0.977

0.331

-0.007

0.002

0.009

Sex

-0.049

0.036

-1.362

0.176

-0.120

0.022

0.018

APOE e4
Status
Amyloid
status
group
Intercept

0.050

0.040

1.244

0.216

-0.030

0.129

0.015

0.018

0.045

0.410

0.683

-0.071

0.108

0.002

0.897

0.157

5.699

0.000

0.585

1.210

0.242

Age

0.005

0.002

2.078

0.040

0.000

0.009

0.041

Sex

0.001

0.036

0.018

0.986

-0.070

0.071

0.000

APOE e4
Status
Amyloid
status
group
Intercept

0.033

0.040

0.834

0.406

-0.046

0.112

0.007

-0.008

0.045

-0.180

0.857

-0.096

0.080

0.000

0.887

0.265

3.346

0.001

0.361

1.413

0.099
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Putamen

Thalmus

Ventral
diencephalon

Age

0.016

0.004

4.327

0.000

0.009

0.024

0.155

Sex

-0.129

0.060

-2.153

0.034

-0.248

-0.010

0.043

0.015

0.067

0.225

0.822

-0.117

0.147

0.000

-0.045

0.075

-0.597

0.552

-0.194

0.104

0.003

0.603

0.179

3.366

0.001

0.248

0.958

0.100

Age

0.014

0.003

5.596

0.000

0.009

0.019

0.235

Sex

-0.066

0.040

-1.638

0.105

-0.147

0.014

0.026

APOE e4
Status
Amyloid
status
group
Intercept

-0.002

0.045

-0.038

0.970

-0.091

0.088

0.000

0.016

0.051

0.311

0.756

-0.085

0.116

0.001

1.224

0.128

9.534

0.000

0.969

1.479

0.471

Age

0.001

0.002

0.345

0.731

-0.003

0.004

0.001

Sex

-0.043

0.029

-1.470

0.145

-0.100

0.015

0.021

APOE e4
Status
Amyloid
status
group
Intercept

0.019

0.032

0.588

0.558

-0.045

0.083

0.003

0.013

0.036

0.353

0.725

-0.059

0.085

0.001

1.414

0.183

7.746

0.000

1.052

1.777

0.370

Age

0.001

0.003

0.531

0.596

-0.004

0.007

0.003

Sex

-0.045

0.041

-1.098

0.275

-0.127

0.037

0.012

0.005

0.046

0.099

0.921

-0.087

0.096

0.000

-0.043

0.052

-0.827

0.410

-0.145

0.060

0.007

APOE e4
Status
Amyloid
status
group
Intercept

APOE e4
Status
Amyloid
status
group
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Table 2.5. Associations between regional tau-PET SUVR and cognition.
Region

Unstandardized B
(SE)

pvalue

95% CI

Partial eta
squared

Amygdala

0.049 (0.03)

0.101

−0.010 to
0.108

0.026

Banks of superior
temporal sulcus

0.035 (0.02)

0.102

−0.007 to
0.078

0.026

Entorhinal

0.010 (0.04)

0.789

−0.064 to
0.083

0.001

Fusiform

−0.012 (0.02)

0.529

−0.048 to
0.025

0.004

Inferior parietal

−0.007 (0.02)

0.755

−0.053 to
0.039

0.001

Inferior temporal

−0.008 (0.02)

0.735

−0.054 to
0.038

0.001

Middle temporal

−0.001 (0.02)

0.943

−0.041 to
0.038

0.000

Precuneus

0.024 (0.03)

0.327

−0.025 to
0.073

0.009

Key: SUVR, standardized uptake value ratio; SE, standard error; CI, confidence interval.
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Figure 2.1. Mean tau distribution in A+ and A− cohorts. Mean tau deposition represented as
SUVRs for (A) A+ and (B) A− participants. Higher SUVRs indicate higher mean binding and
more tau pathology. Abbreviations: SUVR, standardized uptake value ratio; A+, beta-amyloidPET positive; A−, beta-amyloid-PET negative.
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Figure 2.2. Difference in tauopathy in A+ cohort compared to A-. Effect size maps,
depicting regression coefficients (B values), from significant linear regressions,
adjusting for age and sex, comparing A- and A+ participants. Abbreviations: AD,
Alzheimer’s disease, A+, beta-amyloid-PET positive; A-, beta-amyloid-PET
negative.
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Figure 2.3. Violin plots depicting the regional tau-PET SUVRs in A+ and A− cohorts.
Key: SUVR, standardized uptake value ratio, A+, beta-amyloid-PET positive; A−, beta-amyloidPET negative.
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Figure 2.4. Association between regional tau-PET and beta-amyloid-PET. Relationship between
composite beta-amyloid-PET measure and regional tau-PET SUVR from (A) amygdala, (B)
banks of superior temporal sulcus, (C) entorhinal cortex, (D) fusiform, (E) inferior parietal, (F)
inferior temporal, (G) middle temporal, and (H) precuneus. Abbreviations: Red, beta-amyloidPET positive; A+ and blue, beta-amyloid-PET negative; A− PET, positron emission tomography;
SUVR, standardized uptake value ratio.
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Chapter 3

Visually identified 18F-MK-6240-PET
neurofibrillary tangle pattern subtypes
are associated with distinct memory and
cognitive performance.
This chapter is adapted from a manuscript under review at Alzheimer’s & Dementia.
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3.1 Summary
Neuropathologically-defined subtypes of Alzheimer disease (AD), based on neurofibrillary
tangle (NFT) distribution, have been linked to distinct clinical phenotypes. In this study we
examined 204 participants who completed 18F-MK-6240 tau-PET imaging and
neuropsychological testing. Tau-PET scans were visually rated on a 4-point scale as Negative,
Limbic Predominant, Hippocampal Sparing or Typical. The Limbic Predominant pattern was
seen in 5% of Aß-ve cognitively normal (CN), 35% Aß+ve CN, and 25% of Aß+ve MCI and
AD. The Limbic Predominant group was older than other subgroups and had worse performance
on MMSE and Memory tasks, but preserved Non-Memory function, compared to the Negative
group. The Hippocampal Sparing (10% of MCI/AD group) and Typical groups had decrements
in all cognitive domains. NFT patterns, identified with tau-PET, are detectable and consistent
with neuropathological subtypes of AD and their associated cognitive profiles. Identification of
in vivo NFT subtypes may have implications for tau therapy trials and patient prognosis.

3.2 Introduction
Alzheimer's disease (AD) is characterized by extracellular beta-amyloid plaques and
intraneuronal neurofibrillary tangles (NFTs); the latter contain abnormal filaments of pathologic
tau protein (Braak et al., 2006; Braak & Braak, 1991). The ability to detect NFT pathology in
vivo is important for differential diagnosis of dementias, disease staging, and in monitoring
treatment response in tauopathy-related therapies. The advent of first-generation tau-PET tracers,
including AV-1451, has provided strong evidence of concordance between the spatial
distribution of NFT accumulation in vivo and earlier established NFT staging criteria through
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neuropathologic studies (Braak et al., 2006; Braak & Braak, 1991) in AD (M. R. Brier et al.,
2016; Scholl et al., 2016; S. A. Schultz et al., 2018; Schwarz et al., 2016). However, more recent
neuropathological studies (Janocko et al., 2012; Murray et al., 2014; Murray et al., 2011) have
proposed variant subtypes of AD based on the relative number of NFT counts in medial
temporal lobe (MTL) compared to cortical regions. Importantly, these subtypes have been linked
to distinct clinical phenotypes, age, and apolipoproteinE (APOE) allele differences compared to a
typical AD NFT distribution.
To date, in vivo evaluation of regional heterogeneity of NFT distribution in AD has
largely focused on small cohorts with atypical AD diagnosis including posterior cortical atrophy
(PCA), logopenic variant primary progressive aphasia (lvPPA), and corticobasal syndrome
(CBS). Such studies (Dickerson et al., 2017; Dronse et al., 2017; Ossenkoppele et al., 2016; Xia
et al., 2017) have provided initial information on the utility of tau-PET imaging in these
populations and evidence of a strong relationship between localization of NFT pathology and
clinical presentation. In addition, studies in larger cohorts of older adults with and without lateonset sporadic AD (Bejanin et al., 2017) and autosomal-dominant AD (A. Aschenbrenner et al.,
2018), further strengthen our knowledge on this relationship, demonstrating an association
between neuroanatomic NFT distribution and performance within specific cognitive domains. It
remains unknown whether in vivo tau-PET methods can be used to identify variant subtypes of
AD based on the relative distribution of NFT in MTL compared to cortical regions with visual
and quantitative methods and whether these identified groups have distinct memory and
cognitive phenotypes.
Furthermore, tau-PET ligands, including AV-1451 and THK series, have limitations such
as off-target binding that affects quantification and monitoring of NFT deposition in regions of
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interest such as the hippocampus, which may impact the identification of subtype variants of AD.
Advances in tau-PET tracers, including generation of 18F-MK-6240, have led to tracers with no
in vivo off-target binding in the basal ganglia in nonhuman primates (Hostetler et al., 2016) and,
importantly, lack off-target binding near the hippocampus (e.g., choroid plexus) in human studies
(Betthauser et al., 2019), making it an ideal tracer for investigations of NFT binding in MTL
regions.
Therefore, the objectives of this study were to determine (1) whether neuropathologically
defined subtypes of AD (i.e., hippocampal sparing, limbic predominant, and typical) are present
and detectable with 18F-MK-6240 in a well-characterized cohort, (2) whether neurofibrillary
pattern subtype classification is associated with decrements on distinct cognitive and memory
domains, and (3) whether subtype classifications are associated with demographic, clinical,
pathophysiological, and genetic characteristics.

3.3 Methods
3.3.1 Participants
215 participants enrolled in the AIBL flagship study of aging, details which have been
described elsewhere (Ellis et al., 2009), were considered for inclusion in the current study based
on successful completion of an 18F-MK-6240 tau-PET scan before July 1, 2019. Eleven
individuals were excluded due to incomplete clinical data at the time of data analyses (n=4) or a
diagnosis other than Cognitively Normal (CN), Mild Cognitive Impairment (MCI), or AD (n=7).
Of the seven individuals excluded due other diagnoses, one had a diagnosis of Dementia Not
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Otherwise Specified, one had a diagnosis of mixed AD, and five had a Frontal Temporal
Dementia diagnosis. Of the resultant 204 participants, 126 were CN, 44 were MCI, and 34 were
AD.

3.3.2 Clinical Evaluation
An expert clinical panel reviewed all available neuropsychological and psychiatric
information for participants obtained at the visit closest in time to their tau-PET imaging (mean
time between neuropsychological testing and tau-PET scan was 3.0 ± 3.2 months). They were
blinded to information about beta-amyloid burden, NFT accumulation, and APOE ε4 status, and
consensus classifications were made using standard clinical criteria for MCI and AD.

3.3.3 Neuropsychological Testing
Participants were administered the Mini Mental State Examination (MMSE) (Folstein,
Folstein, & McHugh, 1975), 30-item Boston Naming Test (BNT) (Saxton et al., 2000), Digit
Span forwards [DSp(f)] and backwards [DSp(b)] and Digit Symbol-Coding (DS-C) from the
Wechsler Adult Intelligence Scale – Third edition (WAIS-III) (Wechsler, 1997), California
Verbal Learning Test – Second edition (CVLT-II) (Delis, 2000), Rey Complex Figure Test
(RCFT) (Meyers & Meyers, 1995), letter fluency (Benton, 1968) and category fluency tasks. As
described elsewhere (Pike et al., 2007), a composite episodic memory score was calculated by
taking the average of the z scores (generated using an AIBL healthy aging group as the
reference) for RCFT (30 min) long delay and CVLT-II long delay. A composite Non-Memory
cognition score was designed to examine participants’ average performance on tasks not
involving episodic memory. This was calculated by taking the average of the z scores for the
BNT, letter fluency, category fluency, DSp(f), DSp(b), DS-C and RCFT copy.
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3.3.4 Genotyping
APOE genotype was determined from whole blood extracted DNA as per previously
described methodology (Porter et al., 2018) and was available for 128 of the study participants

3.3.5 Image acquisition
For tau, participants were injected with 185 MBq (+/- 10%) of 18F-MK-6240. 9/204
participants were recruited for a pilot dynamic 18F-MK-6240 scan performed on Phillips Gemini
TF TF64 PET/CT scanner, for the remaining 195 participants acquisition was from 90 to 110
minutes after injection (on either a Phillips Gemini TF TF64 PET/CT, Phillips Ingenuity TF
PET/CT, or Siemens Biograph mCT scanner). Similarly, for beta-amyloid, participants were
injected with 200 (+/- 10%) MBq of 18F-NAV4694 and acquisition was from 50 to 70 min after
injection.

3.3.6 Tau-PET
Visual Classification
Visual inspection for subtype scoring was first established on a set of 30 scans by two
readers (SAS and CCR); a single rater (SAS), blind to participant characteristics, then rates the
entire set of scans. 18F-MK-6240 tau-PET scans were visually inspected and rated on a 4-point
scale for classification of NFT pattern, where 0 represented no MTL or cortical NFT uptake
(Negative); 1 represented MTL uptake with no or minimal cortical uptake (Limbic Predominant);
2 represented cortical uptake with no or minimal MTL uptake (Hippocampal Sparing); and 3
represented MTL and cortical uptake (Typical). Figure 3.1 depicts the rating categories with
examples.
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Specifically, 18F-MK-6240 images, depicting raw counts, were normalized to MNI space.
Images, overlaid with AAL atlas [34], were viewed by raters with Mango software in an inverted
greyscale with scale set from 0-4500. The raters evaluated the scan by first setting the axial plane
to the top of orbital sockets at the level of the entorhinal cortex and parahippocampal gyrus and
assessing, in ascending direction through each slice, the presence or absence of tracer uptake
within the medial temporal lobe. The raters then viewed the sagittal plane starting at midline,
moving 1-2 slices laterally, and examining for tracer uptake in MTL regions including
entorhinal, hippocampal and parahippocampal regions. The raters additionally viewed MR coregistered 18F-MK-6240 scans, when available (n=169), to verify anatomical tracer binding
location. The scan was then further evaluated for cortical binding, in Mango, starting in the axial
pane. The raters moved superiorly examining the scan for presence or absence of tracer binding,
more laterally, in the inferior temporal and middle temporal, and throughout the remainder of the
cortex, including parietal, posterior cingulate, precuneus, supramarginal, and frontal regions.
Cortical tracer binding was further verified on the sagittal and coronal planes. The primary rater
additionally visually rated the 18F-MK-6240 SUVR images, viewed in spectrum colorscale with
SUVR range restricted from 0.5 to 5.5.
Quantitative classification
Tau scans were spatially normalized in the MNI space using CapAIBL, using a specific
tau atlas. A quantitative subtype classification was generated based on regional tau-PET SUVR
values from averaged left and right hemisphere uptake in MTL and remaining cortical areas. The
MTL composite included hippocampus, entorhinal, parahippocampus and amygdala, while the
Cortical composite included fusiform, inferior and middle temporal gyri, supra marginal and
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angular gyri, lateral occipital, parietal and posterior cingulate/precuneus, dorsolateral,
ventrolateral and orbitofrontal, anterior cingulate and superior temporal gyrus (V. Villemagne et
al., 2017). A positive and negative NFT classification for MTL and Cortical summary regions,
separately, were developed using a positivity cut-off value of 2 standard deviations above the
mean of a beta-amyloid negative CN cohort (n=90). For MTL ROI, an SUVR ≥ 1.30 was
considered positive and for Cortical ROI an SUVR ≥ 1.17 was considered positive. The
cerebellar grey matter was used as the reference region.
Participants were classified as Negative (MTL negative and Cortical negative), Limbic
Predominant (MTL positive and Cortical negative), Hippocampal Sparing (MTL negative and
Cortical positive), and Typical (MTL positive and Cortical positive).

3.3.7 Beta-Amyloid Image Processing
Beta-amyloid imaging was completed on 202 of the individuals. All scans were spatially
normalized in the MNI space using CapAIBL (Bourgeat et al., 2015), an adaptive MRI-Less
approach. We used the Centiloid cortical and whole cerebellum masks to compute the SUVR for
each subject and we used the CapAIBL calibration equation (Bourgeat et al., 2018) to convert all
SUVR into Centiloid units (CL). The threshold for a positive amyloid scan was set at greater
than 25 CL. The mean time between beta-amyloid-PET scan and tau-PET scan was 2.24 ± 5.0
months.

3.3.8 Statistical Analyses
Participant Characteristics
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To compare background characteristics between CN and MCI/AD groups, we performed
t-tests and chi-square tests, as appropriate.
Visual Rating and Quantitative Rating
Cohen’s kappa coefficient was assessed for agreement between visual rating and
quantitative rating classification. The relationship between visual assessment and continuous
measurements of MTL and Cortical ROI SUVRs, and a ratio of MTL-to-Cortical SUVRs were
evaluated with linear regression analyses.
NFT Subtypes and Memory and Cognitive Functioning
To determine the relationship between our visual NFT rating classification and memory
and cognitive functioning, we performed analyses of covariance (ANCOVA) where the
independent variable of intertest was the visual rating classification, fit as a fixed factor, and the
dependent variable was a cognitive test; adjusting for age, gender and years of education.
Analyses were run, for each cognitive test (i.e., MMSE, memory composite, or Non-Memory
composite), within the CN Group (n=126) and MCI/AD Group (n=77).
Next, to determine whether MMSE, Memory or Non-Memory Function was
preferentially affected within a certain NFT subtype (i.e., Limbic Predominant, Hippocampal
Sparing, or Typical), we fit a series of linear regression models, releveling the reference group as
Negative, Limbic Predominant, or Hippocampal Sparing, as appropriate. Models were adjusted
for age, gender, and years of education.
NFT Subtypes and Clinical, pathophysiological, and genetic characteristics
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To determine whether our NFT subtypes differed by diagnosis, age, APOE ε4 status, and
Centiloid levels we fit covariate-adjusted linear or logistic regression models.

3.4 Results
3.4.1 Participant characteristics
Participants’ relevant characteristics are listed in Table 3.1. The MCI/AD group was on
average older, more likely to be APOE ε4 positive and beta-amyloid positive, compared to the
CN group. They also had higher clinical dementia rating (CDR) scores and lower MMSE,
Memory and Non-Memory Function scores.

3.4.2 Visual assessment
Distinct NFT patterns were clearly identified in our cohort. Interestingly, Thirteen
percent of the CN group showed tau tracer binding, mostly limited to MTL. See Figure 3.2 for
comparison of visual rating to MTL SUVR, Cortical SUVR, and MTL SUVR/Cortical SUVR
ratio. The largest classification discordance between visual and quantitative assessment was in
the Limbic Predominant category. Specifically, within the 28 individuals visually classified as
Limbic Predominant, 8 were quantitatively classified as Negative and 9 as Typical. Furthermore,
within the 8 individuals visually classified as Hippocampal Sparing, 5 were quantitatively
classified as Typical.

3.4.3 Visual Rating and Memory and Cognitive Functioning
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Within the MCI/AD group there were relationships between the visual rating
classification and MMSE, Memory Function, and Non-Memory Function (p= 0.004, <0.001, and
<0.001, respectively; Table 3.2). However, within the CN group, the visual rating classification
was associated with MMSE (p = 0.017), but not associated with Memory or Non-Memory
Function (p = 0.472 and 0.390, respectively).
Between-group analyses revealed there was, on average, a one-point decrement on
MMSE between CN individuals with a Negative NFT pattern and those with a Limbic
Predominant NFT pattern (B [SE] = -1.08 [0.4], p = 0.006; Figure 3.3A). There were no
differences in the CN group between individuals with Negative, Limbic Predominant,
Hippocampal Sparing, or Typical NFT patterns on Memory or Non-Memory Function (Figure
3.3B-C).
Within the MCI/AD group, those who were classified as Limbic Predominant tauopathy
performed worse on tests of Memory Function (B [SE] = -0.72 [0.3], p = 0.022), but similar on
MMSE (B [SE] = -1.48 [1.0], p = 0.126) and Non-Memory Function (B [SE] = -0.51 [0.4], p =
0.196), compared to individuals with a Negative NFT pattern (Figure 3.3D-F).
Those classified as Hippocampal Sparing performed worse on MMSE (B [SE] = -2.5
[1.2], p = 0.036), Memory Function (B [SE] = -1.28 [0.4], p = 0.001), and Non-Memory
Function (B [SE] = -1.44 [0.5], p = 0.004) compared to NFT Negative individuals, and a trend
for worse on Non-Memory Function (B [SE] = -0.92 [0.6], p=0.083), but not MMSE (B [SE] = 1.02 [1.3], p = 0.427) or Memory Function B [SE] = -0.57 [0.4], (p = 0.171), compared to
Limbic Predominant group.
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Lastly, the Typical group performed worse on MMSE (B [SE] = -3.54 [0.8], p < 0.001),
Memory Function (B [SE] = -1.44 [0.3], p < 0.001), and Non-Memory Function (B [SE] = -1.12
[0.3], p = 0.001), compared to the Negative group. The Typical group performed worse on
MMSE (B [SE] = -2.07 [1.0], p = 0.040), Memory Function (B [SE] = -0.72 [0.3], p = 0.024),
and Non-Memory Function (B [SE] = -1.11 [1.0], p = 0.040), compared to the Limbic
Predominant group.

3.4.4 Visual Rating and Age, Centiloid, and APOE4 status
Within the CN group, the Limbic Predominant group was older (B [SE] = 3.80 [1.7], p =
0.023; Figure 3.4A) and had higher Centiloid values (B [SE] = 35.05 [11.2], p = 0.002; Figure
3.4C), but had similar frequency of APOE ε4 positivity (20%) compared to the Negative group
(30.9%). The Typical group also had higher Centiloid values compared to the Negative group (B
[SE]= 95.8 [21.6], p < 0.001) and the Limbic Predominant group (B [SE] = 60.70 [23.7], p =
0.012) and larger proportion of APOE ε4 positive individuals (100%) compared to the Negative
(30.9%) and Limbic Predominant groups (20.0%). There were no differences between the
Typical group and Limbic Predominant or Negative groups on age (p = 0.764 and p = 0.407,
respectively).
Within the MCI/AD group, there were no differences on age between any of the groups
(p’s < 0.139; Figure 3.4B) and no significant difference between frequencies of APOE ε4
positivity in the Negative group (57.0%) and Limbic Predominant (60.0%), Hippocampal
Sparing (33.0%), or Typical groups (83.0%).
The Negative group had lower Centiloid levels compared to the Limbic Predominant (B
[SE] = -77.89 [16.6], p < 0.001), Hippocampal Sparing (B [SE] = -69.16 [20.5], p = 0.001), and
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Typical (B [SE] = -91.63 [13.9], p < 0.001) groups (Figure 3.4D). There were no between-group
differences on Centiloid levels between Limbic Predominant, Hippocampal Sparing, or Typical
groups (p’s > 0.280).

3.5 Discussion
Our results demonstrate that in a well-characterized cohort of CN and cognitively
impaired older adults, distinct regional NFT patterns are detectable, both visually and
quantitatively, and that the predominant location of tau corresponds with the predominant
cognitive decrement when defined as memory vs other cognitive impairment. Furthermore, we
identified demographic, pathophysiological, and genetic differences among these subtypes.
Specifically, we found that 30 percent of our MCI/AD group were identified as Limbic
Predominant or Hippocampal Sparing. This is consistent with prior pathological and
neuroimaging studies investigating atypical variants of AD (Murray et al., 2011; Risacher et al.,
2017; Whitwell et al., 2012). We found that limbic predominant tau was more common in older
persons, whether CN or MCI/AD and with higher amyloid burden.
This is the first study to apply visual assessment methods for identification of NFT
subtypes with 18F-MK-6240. We identified MTL binding as the predominant pattern in CN
individuals, suggesting that 18F-MK-6240 visual assessment is sensitive to early-stage NFT
accumulation though detection in beta-amyloid negative CN was rare at 5% compared to 35% in
those with a positive amyloid scan. Our visual assessment was overall in agreement with a
quantitative ratio of MTL, particularly in the Negative and Typical groups. The discordant cases
in classification were mostly due to detection of more MTL binding by visual assessment and
may be because our quantitative assessment is based on composite ROIs. The earliest
64

accumulation of NFT pathology in AD is restricted to the entorhinal and parahippocampal area
(Braak & Braak, 1991), and therefore using a composite ROI may dilute the effect of earliest
accumulation.
With visual assessment, within the CN sample, we found decrements between Negative
and Limbic Predominant NFT groups on MMSE, suggesting that early MTL NFT accumulation,
detected visually, in CN individuals may be detrimental to global cognition. The small effect and
lack of findings on memory-specific domains may be due to our relatively small sample sizes in
MTL and typical groups. However, these findings are consistent with previous studies (Scholl et
al., 2016; S. A. Schultz et al., 2018) finding no robust association between tau and cognition in
CN individuals. In contrast, Maas and Colleagues (Maass et al., 2018) recently report unadjusted
associations between in vivo entorhinal tau and episodic memory in a CN cohort. This
discrepancy highlights the need for further investigation in CN individuals, with a comparison of
tau-PET tracers and cognitive tests used across studies.
Within the MCI/AD group we found those who had Limbic Predominant NFT performed
worse on Memory Function tests compared to Negative NFT individuals but had preserved NonMemory performance. This finding is in agreement with prior pathological and in vivo studies
(Risacher et al., 2017).
To this end, the Hippocampal Sparing group performed worse on both memory and NonMemory performance compared to Negative group. Previous reports on comparable
hippocampal-spared individuals (Risacher et al., 2017) suggest preserved memory performance
in this subtype. However, in our sample those visually classified as Hippocampal Sparing MTL
NFT pathology had some MTL NFT pathology, when inspected with quantitative values, in
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addition to substantial cortical NFT involvement. This relatively minor MTL involvement likely
contributes to the poor memory scores in this group. Alternatively, tau deposition in other parts
of the limbic memory circuit, such as the posterior cingulate gyrus might explain the memory
deficit when MTL tau appears relatively low. Further investigation in Cortical NFT only
individuals would contribute to our understanding on the impact of cortical NFT on memory
performance, in the absence of MTL NFT.
Additionally, we show that there are distinct clinical, pathological, and genetic
characteristics of the NFT subtypes. Individuals who have Limbic Predominant NFT pathology
are on average older compared to other subtypes of AD, consistent with prior studies on limbic
predominant subtypes of AD (Murray et al., 2011; Risacher et al., 2017), and suggests that we
accurately characterized a Limbic Predominant AD subtype and not early-stage typical AD.
Furthermore, Hippocampal Sparing individuals had a lower proportion of APOE4 positivity
compared to other AD subtypes, however small sample size limited the power to detect statistical
differences. Similarly, Risacher and colleagues (Risacher et al., 2017) evaluated the prevalence
of APOE4 in AD subtypes, using MRI volumetric as a proxy for NFT pathology, and found that
individuals visually classified as hippocampal sparing had a lower proportion of APOE4-positive
individuals (53%) compared to those with limbic predominant or typical AD (82% and 77%,
respectively). Another study (Mattsson et al., 2018) found that APOE4-negative AD individuals
were more likely to have a Hippocampal Sparing NFT pattern, compared to APOE4-positive AD
individuals.
While we attempted to identify NFT heterogeneity in preclinical stages of AD, our sample
was relatively small. Future studies with 18F-MK-6240 tau-PET with larger sample sizes may be
useful in identifying additional associations between preclinical NFT subtypes and subtle
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cognitive decline on domain-specific tests. Lastly, longitudinal neuroimaging and cognitive
testing in this cohort and comparison cohorts will elucidate whether the Limbic Predominant
group progresses to a typical AD distribution and whether these subtypes have distinct memory
and Non-Memory trajectories.
In summary, our findings highlight the utility for visual assessment with 18F-MK-6240 tauPET in identifying distinct NFT patterns. We further provide evidence that regional
heterogeneity in NFT pathology is associated with certain memory and Non-Memory profiles,
genetic, and pathophysiological characteristics. The ability to distinguish these subtypes with in
vivo imaging methods may prove useful for prognosis and in subject selection and monitoring of
tau-related treatments.
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Table 3.1. Participant characteristics.
Variable

Cognitively Normal
(n=126)

MCI or AD diagnosis

75.8 (5.6)

72.8 (8.1)

0.006

54.8

46.8

0.268

Yrs of Education

13.8 (2.9)

12.5 (3.3)

0.004

APOE4 positive, % (n)

22.2 (34)

65.0 (13)

0.003

84.9,15.1, 0.0

5.2, 72.7, 20.8

Age, yrs
Female, %

CDR global,
0, 0.5, ≥1, % (n)

P-value
(n=77)

<.001
(107, 19,0)

(4, 56, 16)

CDR SOB

0.1 (0.3)

3.1 (3.1)

<.001

MMSE

28.5 (1.4)

24.3 (4.6)

<.001

Memory function composite

0.0 (0.9)

-2.7 (1.2)

<.001

Non-memory function
composite

-0.2 (0.7)

-1.9 (1.3)

<.001

Beta-amyloid positive, % (n)

18.4 (23)

63.6 (49)

<.001

87.3, 10.3, 0.0, 2.4
(110,13,0,3)

36.4, 19.5, 10.4, 33.8
(28,15,8,26)

<.001

86.5, 7., 1.6, 4.8

40.8, 7.9, 6.6, 44.7

Visual Rating,
Neg, LP, HCsp, Typical, % (n)
Quantitative Rating,

<.001
Neg, LP, HCsp, Typical, % (n)

(109, 9, 2, 6)

(31, 6, 5, 34)

Mean (SD) for each group are presented, unless otherwise noted. P-values from t-tests or chisquare tests, as appropriate, to evaluate group differences between cognitively normal and
MCI/AD groups. Beta-amyloid positivity is based on a cut-off of 25 CL. APOE ε4 status
reported in a subset of 128 individuals. Beta-Amyloid positivity is reported for a subset of 202
individuals. One individual was excluded from quantitative rating analyses due to issues with
spatial normalization. Two individuals were excluded from analyses with MMSE.
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Key: MCI= Mild Cognitive Impairment; AD= Alzheimer’s disease; Yrs=years; CDR= Clinical
dementia Rating; SOB= Sum of Boxes; MMSE=Mini Mental State Exam; Neg=Negative;
LP=Limbic Predominant; HCsp= Hippocampal Sparing; CL= Centiloid.
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Table 3.2. Visual Rating NFT subtype classification is associated with decrements on cognitive
and memory domains.
Cognitively Normal

MCI or AD Diagnosis

Cognitive Test
F, ƞ2 P-value

F, ƞ2 P-value

MMSE

4.21, 0.066 0.017

6.24, 0.242 0.004

Memory composite

0.68, 0.011 0.472

11.03, 0.331 <0.001

Non-memory composite

0.76, 0.012 0.390

5.09, 0.186 < 0.001

F-statistic, ƞ2, and p-value from an ANCOVA where the IV of interest (fit as fixed factor) was
the Visual Rating and DV of interest was a cognitive test; adjusting for age, sex, and years of
education. Analyses were run, for each cognitive test, within the Cognitively Normal Group and
MCI/AD Group.
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Figure 3.1. NFT Subtype Visual Rating Representative Images.18F-MK-6240 tau-PET scans
were visually inspected and rated on a 4-point scale for classification of NFT pattern, where 0
represented no MTL or cortical NFT uptake (Negative; A); 1 represented MTL uptake with no or
minimal cortical uptake (Limbic Predominant; B); 2 represented cortical uptake with no or
minimal MTL uptake (Hippocampal Sparing; C); and 3 represented MTL and cortical uptake
(Typical; D). The grey scale was set to the same intensity for all images.
Key: NFT= Neurofibrillary tangle; PET= positron emission tomography; MTL= medial temporal
lobe.
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Figure 3.2. Association between visual NFT classification and quantitative values. Plots
depicting the relationship between visual rating NFT subtypes and MTL SUVR (A), Cortical
SUVR (B), and a ratio of MTL SUVR to Cortical SUVR (C).
Key: NFT= Neurofibrillary tangle; Negative= Negative NFT group; LP= Limbic Predominant
NFT group; HCsp= Hippocampal Sparing NFT group; Typical = Typical NFT group.
Cognitively normal=circle; MCI=triangle; AD=square. Dashed lines represent positivity cut-offs
of 1.31 (A) and 1.17 (B) for MTL and Cortical ROIs, respectively.
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Figure 3.3. Association between NFT classification and memory and cognitive functioning.
Plots depicting the relationship between visual rating NFT subtypes and MMSE (A and D),
Memory Function (B and E), and Non-Memory Function (C and F) for CN and MCI/AD group,
respectively.
Key: NFT= Neurofibrillary tangle; MMSE= Mini Mental State Examination; Negative=
Negative NFT group; LP= Limbic Predominant NFT group; HCsp= Hippocampal Sparing NFT
group; Typical = Typical NFT group. Cognitively normal=circle; MCI=triangle; AD=square.
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Figure 3.4. Association between NFT subtypes and age and Centiloid levels. Plots depicting the
relationship between visual rating NFT subtypes and Age (A and B) and Centiloid levels (C and
D) for CN and MCI/AD groups, respectively.
Key: NFT= Neurofibrillary tangle; MMSE= Mini Mental State Examination; Negative=
Negative NFT group; LP= Limbic Predominant NFT group; HCsp= Hippocampal Sparing NFT
group; Typical = Typical NFT group. Cognitively normal=circle; MCI=triangle; AD=square.
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Chapter 4

Serum neurofilament dynamics predicts
neurodegeneration and clinical progression
in presymptomatic Alzheimer disease.

This chapter is adapted from a manuscript published in Nature Medicine.

Preische, O.*, Schultz, S. A.*, Apel, A.*, Kuhle, J., Kaeser, S. A., Barro, C., Graber, S., Kuder-Buletta,
E., LaFougere, C., Laske, C., Voglein, J., Levin, J., Masters, C. L., Martins, R., Schofield, P. R., Rossor,
M. N., Graff-Radford, N. R., Salloway, S., Ghetti, B., Ringman, J. M., Noble, J. M., Chhatwal, J., Goate,
A. M., Benzinger, T. L. S., Morris, J. C., Bateman, R. J., Wang, G., Fagan, A. M., McDade, E. M.,
Gordon, B. A., Jucker, M. and Dominantly Inherited Alzheimer, N. [* denotes equal contributions].
(2019) 'Serum neurofilament dynamics predicts neurodegeneration and clinical progression in
presymptomatic Alzheimer's disease', Nat Med, 25(2), pp. 277-283.
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4.1 Summary
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly
Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that
NfL levels in the cerebrospinal fluid (n = 187) and serum (n = 405) are correlated with one
another and are elevated at the presymptomatic stages of familial Alzheimer's disease.
Longitudinal, within-person analysis of serum NfL dynamics (n = 196) confirmed this elevation
and further revealed that the rate of change of serum NfL could discriminate mutation carriers
from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that
is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked
in participants converting from the presymptomatic to the symptomatic stage and was associated
with cortical thinning assessed by magnetic resonance imaging, but less so with amyloid-β
deposition or glucose metabolism (assessed by positron emission tomography). Serum NfL was
predictive for both the rate of cortical thinning and cognitive changes assessed by the MiniMental State Examination and Logical Memory test. Thus, NfL dynamics in serum predict
disease progression and brain neurodegeneration at the early presymptomatic stages of familial
Alzheimer's disease, which supports its potential utility as a clinically useful biomarker.

4.2 Introduction
In most neurodegenerative diseases, brain changes manifest many years before clinical
symptoms become apparent. In Alzheimer’s disease, presymptomatic changes in the brain
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include cortical thinning and neuropathological depositions containing amyloid-β and tau. These
pathological changes can be assessed by magnetic resonance imaging (MRI), positron-emission
tomography (PET), and measurement of amyloid-β and tau protein levels in the cerebrospinal
fluid (CSF)(R. J. Bateman et al., 2012; Brian A Gordon et al., 2018; Jack, Bennett, et al., 2018;
Reisa A Sperling, Karlawish, & Johnson, 2013). However, CSF collection is invasive and
imaging modalities are expensive; therefore, they are not well suited to routine clinical practice.
Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking,
although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in
the blood have been reported (Noelia Fandos et al., 2017; Niklas Mattsson, Ulf Andreasson,
Henrik Zetterberg, & Kaj Blennow, 2017; Mielke et al., 2018; Akinori Nakamura et al., 2018;
Vitaliy Ovod et al., 2017; P. S. Weston et al., 2017).
NfL is a component of the axonal cytoskeleton and is primarily expressed in large-caliber
myelinated axons (Axel Petzold, 2005; W. Schlaepfer & R. Lynch, 1977). Changes of NfL in
bodily fluids have been linked to brain damage and brain atrophy in mouse models and multiple
neurological disorders including proteopathic neurodegenerative diseases (Mehtap Bacioglu et
al., 2016; Christian Barro et al., 2018; Anthony Brureau et al., 2017; Jens Kuhle et al., 2016;
Axel Petzold, 2005). Advancements in NfL measurements have revealed tight correlations
between NfL in the CSF and blood and have sparked interest in an NfL blood-based biomarker
that monitors neurodegeneration and disease progression. However, longitudinal analyses are
largely missing and the importance of NfL as a molecular biomarker for the presymptomatic
phase of neurodegenerative diseases remains unclear (Niklas Mattsson et al., 2017; P. S. Weston
et al., 2017; Wenjun Zhou et al., 2017).

4.3 Methods
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4.3.1 Participants
Participants at 50% risk of carrying an autosomal-dominant Alzheimer’s disease mutation
in one of three genes (APP, PSEN1, PSEN2) were enrolled in the DIAN observational study
(National Institute on Aging grant no. U19 AG032438; dian.wustl.edu; clinical trial no.
NCT00869817)(John C Morris et al., 2012). DIAN participants are assessed at baseline and
subsequent follow-up visits (annually to every third year). Assessment included collection of
body fluids (CSF, blood), clinical testing (CDR), neuropsychological testing (including MMSE
(raw scores) and the Logical Memory subtest of the Wechsler Memory Scale-Revised (story A),
raw scores for immediate and delayed recall), and imaging modalities (MRI, PET with
Pittsburgh Compound B (PiB-PET), and 18F-FDG) as described in earlier publications (R. J.
Bateman et al., 2012; J. C. Morris, 1997; Wechsler, 1997). The institutional review board at
Washington University in St. Louis provided supervisory review and human studies approval.
Participants or their caregivers provided informed consent in accordance with their local
institutional review boards. NfL analysis in the DIAN cohort was approved by the ethics
committee at the medical faculty of the University of Tübingen, Germany (project number
718/2014BO2). The detailed number of participants (mutation carriers, non-carriers) for baseline
and longitudinal measurements are given in Tables 4.1 and 4.2 and the legends of Figures 4.2,
4.3, and 4.4.

4.3.2 Clinical assessment and EYO
The presence of dementia (symptoms) was assessed using the CDR (J. C. Morris, 1997).
Clinical evaluators were blinded to each participant’s mutation status. For every visit a
participant’s EYO was calculated based on the participant’s age at the visit relative to their
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‘mutation-specific’ expected age at dementia onset. The mutation-specific expected age of
dementia onset was computed by averaging the reported age of dementia onset across individuals
with the same specific mutation(Ryman et al., 2014). If the mutation-specific expected age at
dementia onset was unknown, the EYO was calculated from the age at which parental cognitive
decline began. The parental age of clinical symptom onset was determined by a semi-structured
interview with the use of all available historical data. The EYO was calculated identically for
both mutation carriers and non-carriers. Mutation status was determined using PCR-based
amplification of the appropriate exon followed by Sanger sequencing (R. J. Bateman et al.,
2012).

4.3.3 NfL measurements in the CSF and blood
Fluids were collected in the morning under fasting conditions by venipuncture using a 21
gauge (G) butterfly needle and red top plain Vacutainer tubes (Becton, Dickinson and
Company). After blood collection the tubes were left upside at room temperature for 30 min to
allow clotting. After clotting, tubes were centrifuged at 2,000g for 15 min at room temperature.
Serum was taken with a disposable, non-sterile transfer pipette into a single transfer tube
(SARSTEDT AG & Co. KG) and immediately frozen on dry ice. After venipuncture, CSF was
collected by gravity drip into two 13 ml polypropylene tubes using standard lumbar puncture
procedures (L4-L5) with an atraumatic Sprotte spinal needle (22 G). As with serum, CSF was
flash-frozen upright on dry ice. Samples collected in the United States were shipped overnight on
dry ice to the DIAN biomarker core laboratory at Washington University, whereas samples
collected at non-United States sites were stored at −80 °C and shipped quarterly on dry ice to
Washington University. At the core laboratory the frozen samples were subsequently thawed,
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combined into a single polypropylene tube of serum or CSF, and aliquoted (300 or 500 μl) into
polypropylene Corning microcentrifuge tubes (Thermo Fisher Scientific), after which they were
again flash-frozen on dry ice and stored at −80 °C. For the current study, all available DIAN
serum samples (data freeze 11) were shipped to the DIAN site in Tübingen. CSF samples (data
freeze 9) were shipped to the DIAN site in Munich first and used for another analysis before
being shipped to the DIAN site in Tübingen. Thus, CSF samples had one additional freeze–thaw
cycle in Munich; however, prior work has indicated no significant effect of up to four freeze–
thaw cycles on NfL in CSF (Jens Kuhle et al., 2013).
CSF and serum NfL measurements were performed using a highly sensitive singlemolecule array assay using the capture monoclonal antibody 47:3 and the biotinylated detection
antibody 2:1 (UmanDiagnostics AB) (Disanto et al., 2017). The samples were measured in
duplicate on a Simoa HD-1 platform (Quanterix) using a two-step neat assay. Serum samples
were measured at 1:4 and CSF at 1:10 dilution (Tris-buffered saline, 0.1% Tween 20, 1% non-fat
milk powder, HeteroBlock (300 ug ml−1; Omega Biologicals)). Batch-prepared calibrators
(bovine lyophilized NfL) ranging from 0 to 10,000 pg ml−1 were stored at −80 °C (Uman
Diagnostics AB). All samples were measured blinded. For serum, the mean intra-assay
coefficient of variation of duplicate determinations for concentration was 4.2%. In the CSF, the
mean intra-assay coefficient of variation was 3.7%. Inter-assay variability was evaluated with
three native serum samples and three native CSF samples. The inter-assay coefficients of
variation for serum were 7.7% (mean concentration 13.3 pg ml−1), 2.9% (30.9 pg ml−1), and
3.7% (269.9 pg ml−1). In the CSF, the interassay coefficients of variation were 2.4% (445.4 pg
ml−1), 12.2% (1486.3 pg ml−1), and 13.3% (14,049.0 pg ml−1). Note that the concentrations (pg
ml−1) are calculated from the full-length NfL calibrator and thus may overestimate the

80

concentration of an NfL fragment in the blood.

4.3.4 Imaging
MRI was performed at the different DIAN sites on 3T scanners using the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) protocol. T1-weighted images (1.1 × 1.1 × 1.2 mm3
voxels) were acquired for all participants. The ADNI Imaging Core screened images for artifacts
and protocol compliance. FreeSurfer version 5.3 was used to perform volumetric segmentation
and cortical surface reconstruction to define subcortical and cortical regions of interest (ROIs).
Members of the DIAN Imaging Core examined each segmentation and edited them as needed.
Cortical thickness measures were averaged across hemispheres. Since the precuneus region has
been shown to be most sensitive to Alzheimer’s disease pathophysiology in autosomal-dominant
Alzheimer’s disease (Benzinger et al., 2013; Brian A Gordon et al., 2018), we focused our
analyses on this region a priori.
Amyloid-β-PET imaging was done using a bolus injection of ¹¹C-PiB. Acquisition
consisted of a 70-min scan starting at injection or a 30-min scan beginning 40 min after injection.
Data in the common 40–70 min time frame were converted to regional standardized uptake value
ratios (SUVRs) relative to the cerebellar gray matter using FreeSurfer-derived ROIs (PET
Unified Pipeline, https://github.com/ysu001/PUP). Metabolic imaging was done with 18F-FDG
PET with a 30 min dynamic acquisition beginning 30 min after injection. Data from the 40–60
min time frame were converted to SUVRs relative to cerebellar gray matter. The ADNI Imaging
Core verified that the PET images were acquired using the established protocol and free of
substantial artifacts. All PET data were partial volume-corrected using a regional spread function
technique. Scanner-specific spatial filters were applied to achieve a common resolution (8 mm)
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across PET scanners. MRI and PET data acquisition and processing has been described in detail
in previous studies (R. J. Bateman et al., 2012; Benzinger et al., 2013). Again, for the present
analyses, we averaged SUVR values from the bilateral precuneus ROIs defined on the MRI.

4.3.5 Statistical analysis
Relating baseline CSF and serum NfL
The relationship between baseline CSF and serum NfL was determined by using LMEMs
implemented in R version 3.4.2 and RStudio version 1.1.453 using the package lme4, including a
random intercept term for family and fixed effect for baseline age, sex, and baseline CSF NfL,
with baseline serum NfL as the dependent variable. Separate models were fitted for non-carriers
and mutation carriers. Baseline CSF and serum NfL values were log-transformed (due to nonnormal distribution) before being entered into the model. See also the supplementary statistical
analysis section.

Baseline CSF and serum NfL as a function of EYO
The relationship between EYO and baseline CSF and serum NfL values was estimated
using LMEMs. As previously done, to account for potential non-linear effects, EYO was
modeled as a restricted cubic spline with knots at the 0.10, 0.50, and 0.90 quantiles (Brian A
Gordon et al., 2018). The LMEMs for the baseline NfL values (CSF or serum) included: fixed
effects for mutation status; the linear EYO component; the cubic EYO component; the linear
EYO by mutation status interaction; the cubic EYO by mutation status interaction; and a random
intercept for family. Model parameters were estimated using an open source package for
Hamiltonian Markov chain Monte Carlo analyses, Stan (http://mc-stan.org/)45,46, implemented
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using R. This resampling approach leads to a distribution of parameter estimates across
iterations. From this distribution it is possible to estimate the 99% credible intervals of the model
fits at every EYO for non-carriers, mutation carriers, and the distribution of the difference
between non-carriers and mutation carriers. The first EYO where groups (non-carriers and
mutation carriers) differed was determined to be the first point where the 99% credible intervals
around the differences distribution between non-carriers and mutation carriers did not overlap 0.
See also the supplementary statistical analysis section.

Calculating the rate of change in biomarkers.
Longitudinal data was modeled using LMEMs. LMEMs are a powerful approach to
account for the covariance structure introduced by serial measurements and are ideal to deal with
imperfect timing or an unbalanced number of data points. The rate of change in log-transformed
serum NfL for each individual was modeled using an LMEM with fixed effects of time from
baseline (in years), mutation status, a time from baseline by mutation status interaction, and a
random intercept for family, as well as random slope and intercept terms for each participant.
The rate of NfL change for each individual was extracted from the model estimates for
subsequent analyses. This model was also used for generating the rate of change for cortical
thickness,18F-FDG PET, and PiB-PET, for each individual (for plotting purposes). See also the
supplementary statistical analysis section.

Longitudinal serum NfL as a function of EYO and cognitive status.
As with the cross-sectional estimates, the relationship between EYO and rate of change in
serum NfL was estimated using an LMEM in Stan. The EYO was modeled as a restricted cubic
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spline with knots at the 0.10, 0.50, and 0.90 quantiles. The LMEM model for the rate of change
in serum NfL included: fixed effects for mutation status; the linear EYO component; the cubic
EYO component; the linear EYO by mutation status interaction; the cubic EYO by mutation
status interaction; and a random intercept for family. Model parameters were estimated using
Stan. Again, this resampling approach leads to a distribution of parameters estimates across
iterations, resulting in 99% credible intervals of the model fits at every EYO for non-carriers,
mutation carriers, and the distribution of the difference between non-carriers and mutation
carriers. The first EYO where groups (non-carriers and mutation carriers) differed was
determined to be the first point where the 99% credible intervals around the differences
distribution between non-carriers and mutation carriers did not overlap 0.
To determine whether the extracted rate of change in serum NfL was significantly
different across mutation status and cognitive status we categorized mutation carriers based on
cognitive status, where presymptomatic mutation carriers were individuals who scored as CDR =
0 across all visits (n = 65), converters were mutation carriers who scored as CDR = 0 at baseline
and CDR > 0 at subsequent visits (n = 13), and symptomatic mutation carriers were individuals
who scored as CDR > 0 across all visits (n = 55). We used LMEMs, including a random
intercept for family and fixed effects for baseline age, sex, and group (that is, non-carriers,
presymptomatic mutation carriers, converters, or symptomatic mutation carriers), where group
was the term of interest, and the extracted rate of change in serum NfL was the dependent
variable. Models were computed using lme4 in R. See also the supplementary statistical analysis
section.

Association between expected age of onset and deviation from the EYO-adjusted median
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rate of change in NfL
We tested the hypothesis of whether individuals who have an earlier expected age of
onset (for example, age of onset of 30 years old versus 55 years old) have an accelerated NfL
rate of change. First, to determine if a participant deviated from its expected NfL rate of change,
given its baseline EYO, we calculated the median rate of change in NfL at each EYO, generated
from model estimates (for the calculation, see ‘Baseline CSF and serum NfL and longitudinal
NfL as a function of EYO’ in the supplementary statistical analysis section; for the depiction of
median values, see the red line in Figure 2b). We then took each participant’s extracted NfL rate
of change and subtracted the median value corresponding to its baseline EYO. This resulting
value represented the deviation from the expected value, whereby a positive value on this
deviation measure indicates that an individual has a higher rate of change in serum NfL (that is,
worse) than would be expected given their EYO. Conversely, a negative value on this deviation
measure indicates that an individual has a lower rate of change in serum NfL (that is, better) than
would be expected given their EYO. Next, to investigate if there was a relationship between
individuals with the higher deviation measure and earlier expected age of onset, we grouped
individuals by their expected age of onset (determined by their specific mutation type, grouped
as age of onset 20–39, 40–49, 50–59, and 60+). See also the supplementary statistical analysis
section.

Relating NfL rate of change to imaging rate of change.
The longitudinal relationship between the rate of change in serum NfL and concurrent
rate of change in cortical thickness, metabolism, or amyloid-β accumulation was determined
within each group of interest (that is, non-carriers, presymptomatic mutation carriers, and
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symptomatic mutation carriers). Therefore, separate models were run for each non-carrier,
presymptomatic mutation carrier, and symptomatic mutation carrier groups. The dependent term
for each model was an imaging biomarker with fixed effect terms for baseline age, sex, time
from baseline, extracted rate of change in serum NfL, and interaction between time from baseline
and rate of change in serum NfL. Models contained random slope and intercept terms for
participants and random intercepts for family. The primary term of interest was the interaction
between the rate of change in serum NfL and the time from baseline term. Models were fitted
using lme4 in R.
To determine whether the relationship between groups was different, a model for each
imaging modality containing all groups was run. Each model was fitted containing fixed effect
terms for baseline age, sex, time from baseline, extracted rate of change in serum NfL, group
(non-carriers, presymptomatic mutation carriers, or symptomatic mutation carriers), and twoand three-way interaction between time from baseline, rate of change in serum NfL, and group.
Converters were included as part of the symptomatic mutation carrier group. The models also
included random slope and intercept terms for the participants and random intercepts for family.
The dependent variables were the longitudinal measures for cortical thickness, glucose
metabolism, or amyloid-β deposition in the precuneus ROI. See also the supplementary
statistical analysis section.

Serum NfL at baseline predicts annual changes in cortical thickness and cognition
To examine whether baseline serum NfL could predict subsequent changes in cortical
thickness and cognition in mutation carriers we fitted LMEMs with random slope and intercept
terms for participants, random intercepts for family, and fixed effect terms for baseline age, sex,
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time, log-transformed baseline serum NfL, and an interaction between time and baseline serum
NfL. The interaction term was the term of interest. The dependent terms entered into the models
were longitudinal precuneus cortical thickness measurements, MMSE scores, and Logical
Memory test scores. If significant, an association of baseline serum NfL with rate of change in
cortical thickness or cognition was assumed. See also the supplementary statistical analysis
section.

Prospective prediction of cortical thickness and cognition by serum NfL rate of change.
To determine whether the rate of change in serum NfL could predict subsequent changes
in cortical thickness or cognition, we conducted a truly prospective study, whereby after
longitudinal serum collection for NfL, we collected additional imaging and neuropsychological
data on 39 mutation carriers. Twenty-eight individuals completed additional imaging and
neuropsychological testing, 9 completed only additional neuropsychological testing but no MRI,
and 2 who completed an additional MRI but not neuropsychological testing. To determine the
rate of change in cortical thickness and cognition (MMSE, Logical Memory test) between the
imaging and cognitive assessment concurrent to the participant’s last blood draw and follow-up
session, we fitted an LMEM for each participant, where the dependent variable was the imaging
or cognitive variable of interest at last serum visit and follow-up visit and the independent
variable was the time between visits. Models were run in R. We then used this rate of change for
cortical thickness or cognition as the dependent variable in an LMEM, which included fixed
effects for age, sex, and the rate of change in serum NfL, and a random intercept term for family.
The term of interest was the serum NfL rate of change. Models were fitted using lme4 in R. See
also the supplementary statistical analysis section.

87

Further statistical analyses and models.
The unstandardized regression coefficients (B), standard error of the mean (s.e.m.), and P
values from the LMEMs and linear regression models are reported in the figure legends. The
statistical analyses mentioned in the figure legends of Figures 4.7-4.9 and Tables 4.1 and 4.2
were conducted using the JMP software, version 13.0 (SAS Institute Inc.). For the analysis of
Figure 4.8 a regression model was created, which approximates the changes of non-carriers and
mutation carriers. The model uses the rate of change of log serum NfL over EYO. For noncarriers a slightly increasing line over the entire time period was created representing the NfL
increase over age. For mutation carriers the same development was taken for the very early years
until a bifurcation point indicating the divergence of non-carriers and mutation carriers. From
this point on, mutation carriers were shown with a rising slope up to a break of slope, when the
line came to a parallel increase as non-carriers. This model uses one common slope at the very
beginning, one bifurcation point, and one shift leading to two parallel slopes after symptom
onset. See also the supplementary statistical analysis section.

Supplementary statistical analysis.

Baseline CSF and serum NfL and longitudinal NfL as a function of EYO

For these analyses we represented eyo using a cubic spline. The knot positions and spline
values were calculated using the rcspline.eval function to produce a linear term and a cubic term
for eyo as follows:

splinefit=rcspline.eval(data$eyo, nk=3, norm=2, pc=FALSE, inclx=TRUE)
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Model fitting was performed using a Hamilton Markov chain Monte Carlo implemented in
version 2.17.4 of the probabilistic programming environment Stan (Carpenter et al., 2017). We
implemented the STAN software using the wrapper stan_glmer (Muth, Oravecz, & Gabry,
2018). Our R code is included below. A model was run using eight independent chains
consisting of 5,000 iterations after 5,000 warm-up samples. In order to account for
autocorrelation within a chain, we thinned he chains by limiting our analysis to every 10th
sample. As a result, all inference was performed should equal 1.0. In all of our models R was
found to be acceptably close to 1.0.

As previously done (Brian A Gordon et al., 2018; Mishra et al., 2017), this resampling approach
was taken in order to estimate credible intervals around the model fits which could in turn could
be used accurately determine when mutation carriers and non-carriers first diverged.

stan_glmer(analyte_value ~ (1|fam_id) + eyo_spline_linear + eyo_spline_cubic +mutation +
eyo*mutation + eyo_cubic*mutation,

data = data, family = gaussian(),
prior = cauchy(), prior_intercept = cauchy(), chains = 8, cores = 1, iter = 10000, thin = 10)

Relating baseline CSF and serum NfL

All subsequent analyses were performed using linear mixed-effects models implemented in R
using the lmer (https://cran.r-project.org/web/packages/lme4/lme4.pdf) package.

lmer (Serum.NfL.log ~ sex + age + CSF_NfL_log +(1|fam_id), data)

Calculating the rate of change in biomarkers
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lmer (biomarker_value ~ 1 + time + mutation + mutation*time + (time | id) + (1 | fam_id) , data)

Longitudinal serum NfL and cognitive status

lmer (change_in_nfl_value ~ baseline_age + sex + cog_group + (1 | fam_id), data))

Association between expected age of onset and deviation from the EYO-adjusted median rate
of change in NfL

lmer (deviation_from_change_in_nfl_value ~ baseline_age + sex + AO_group + (1 | fam_id),
data))

Relating Extracted NfL rate of change with imaging rate of change

Within-group assessment:
lmer(biomarker_value ~ (time | id)+ (1 | fam_id) + baseline_age + change_in_nfl_value + sex +
time + time*change_in_nfl_value, data)

Between-group assessment:
lmer (biomarker_value ~ (tim) + (1 | fam_id) + cog_group + baseline_age +
change_in_nfl_value + sex + time + time* change_in_nfl_value + time*cog_group +
change_in_nfl_value *cog_group + time* change_in_nfl_value *cog_group, data

Where cog_group is the associated mutation status and cognitive status group each individual is
categorized to: NC are coded as “0”, presymptomatic MC (individuals who scored “zero” on the
Clinical Dementia Rating (CDR) across all visits) are coded as “1”, and converters (CDR=0 at
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baseline and CDR>0 at subsequent visits) and symptomatic MC (CDR>0 across all visits) are
coded as “2”.

Serum NfL at baseline predicting of the annual changes in cortical thickness and cognition

lmer (biomarker_value ~ time + baseline_age + sex + baseline_serum_nfl_log_value*time +
(time | id) + (1 | fam_id), data)

Prospective prediction of cortical thickness and cognition by serum NfL rate of change

lmer (prospective_change_biomarker_value ~ (1 | fam_id) + baseline_age + sex +
change_in_nfl_value, data))

Abbreviations

eyo= estimated years to/from clinical symptom onset
eyo_spline_linear= eyo linear component
eyo_spline_cubic= eyo cubic spline component
analyte_value= analyte of interest (e.g., baseline CSF NfL, baseline serum NfL) fam_id= family
ID

mutation= mutation status; non-carriers= 0, mutation carriers= 1 Serum.NfL.log= log-transform
baseline serum NfL value CSF_NfL_log= log-transformed baseline CSF NfL value
Sex= male= 0, female= 1

Age= age at visit (years)
Data= data matrix
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ID= subject-specific identification number
Biomarker_value= values of biomarkers (e.g., serum NfL, cortical thickness, FDG-PET SUVR,
PiB SUVR, etc.) for each visit for every individual
Time= time from baseline blood draw or imaging session, as appropriate, for each visit for every
individual (years)
Cog_group= the associated mutation status and cognitive status group each individual is
categorized to: NC are coded as “0”, presymptomatic MC (individuals who scored “zero” on the
Clinical Dementia Rating (CDR) across all visits) are coded as “1”, converters (CDR=0 at
baseline and CDR>0 at subsequent visits) are coded as “2”, and symptomatic MC (CDR>0
across all visits) are coded as “3”
Change_in_”x”_value= extracted change slope with annual rate of change for biomarker
Baseline_age= age at baseline visit (years)
Prospective_change_biomarker_value= extracted change slope for biomarkers of interest
(cortical thickness, MMSE, or Logical Memory), between the visit associated with last blood
draw (i.e., last serum NfL measure),

4.4 Results
We made use of the Dominantly Inherited Alzheimer Network (DIAN)18 data and
biospecimens to study NfL changes in the CSF and blood of presymptomatic and symptomatic
Alzheimer’s disease. DIAN participants are members of families carrying highly penetrant
autosomal-dominant mutations in the genes encoding the amyloid beta precursor protein (APP)
or presenilin 1 (PSEN1) or 2 (PSEN2) (Moulder et al., 2013). Family members who do not carry
the mutations serve as controls. Since the age of symptom onset tends to be consistent for a given
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mutation, it is possible to calculate for participants an estimated years to symptom onset (EYO)
from the known onset of individuals with the same mutation (Ryman et al., 2014).
We used the single-molecule array immunoassay technology to measure NfL in the CSF
and blood serum of DIAN participants at their baseline (initial) visit (mutation carriers, n = 243;
non-carriers, n = 162) (see Table 4.1 for participant characteristics). Multivariate linear mixed
effects models (LMEMs) served to assess the earliest point in the disease when NfL starts to
increase in mutation carriers in relation to non-carriers (Figures 4.1a and 4.1b). Results revealed
that NfL in the CSF was significantly increased between mutation carriers and non-carriers at
−6.8 EYO (Figure 4.1a, Figure 4.5a). Almost identically, serum NfL was also increased at −6.8
EYO (Figure 4.1b; Figure 4.5b). Consistent with our earlier work13 CSF and serum NfL levels
were tightly associated (Figures 4.1c and 4.1d). No differences in CSF or serum NfL levels
between the three familial Alzheimer’s disease mutations were found (Figure 4.6).
Given the strong association between serum and CSF NfL, and the obvious advantage of
a non-invasive disease blood biomarker, we chose to focus on serum NfL for subsequent
longitudinal analyses. From the 405 participants with baseline serum, 196 returned for at least 1
and maximally 5 follow-up visits, with a mean number of 2.5 visits and a median observation
time of 3 years from the baseline visit (see Table 4.2 for the longitudinal characteristics of
participants).
Overall, the longitudinal analysis of serum NfL confirmed the cross-sectional findings
(Figure 4.2a). Using LMEMs we calculated the slope of NfL change per year for each
participant. As with cross-sectional values, the NfL rates of change were significantly elevated in
mutation carriers relative to non-carriers. Strikingly, however, the first EYO point where this
increase became significant was at − 16.2 years (Figure 4.2b; see also Figure 4.7), which is
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almost a decade earlier than the cross-sectional baseline estimates (−6.8 EYO, see earlier).
Consistent with this earlier separation of mutation carriers and non-carriers using longitudinal
measurements, the rate of change could distinguish presymptomatic mutation carriers from noncarriers more accurately compared to base-line serum NfL using receiver operating
characteristics analysis (Figure 4.8).
Next, we subdivided mutation carriers into three groups: presymptomatic mutation
carriers (individuals who scored 0 on the Clinical Dementia Rating (CDR) scale across all visits);
converters (CDR = 0 at baseline and CDR > 0 at subsequent visits); and symptomatic mutation
carriers (CDR > 0 across all visits). Then we compared the rate of change in serum NfL across
these groups. Analyses revealed that the rate of change in serum NfL peaked in the converter
group with no further increase in the symptomatic carriers (Figure 4.2c). Interestingly, flattening
or even U-shaped curves have also been observed in longitudinal studies for CSF biomarkers in
dominant and sporadic AD (McDade et al., 2018; Sutphen et al., 2018).
No differences in NfL rate of change were found between mutations in APP, PSEN1, and
PSEN2 (Figure 4.9). To analyze whether the NfL rate of change was associated with the
aggressiveness of individual mutations or EYO, we analyzed how far away the NfL rate of
change of each mutation carrier was from the median value from the model estimates at that
individual’s EYO (Figure 4.9b). Although we did not find any significant differences, it is
possible that differences become apparent when the number of individuals and longitudinal data
points increase.
To study if brain changes are coupled with changes in serum NfL, regression analysis
between NfL rates of change and rates of change in brain imaging modalities were performed.
We focused on the precuneus since previous analyses have shown this area to be most sensitive
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to Alzheimer’s disease progression (Benzinger et al., 2013). NfL rates of change in serum and
rates of precuneus cortical thinning were significantly associated in symptomatic mutation
carriers with a trend toward significance in presymptomatic mutation carriers (Figure 4.3a). The
rate of change in serum NfL and the rate of change in precuneus glucose metabolism (18Ffluorodeoxyglucose (18F-FDG) PET) were significantly associated in symptomatic mutation
carriers but not in presymptomatic mutation carriers (Figure 4.3b). Although there was a
positive relationship between NfL rate of change and the rate of change in precuneus amyloid-β
deposition (amyloid-β-PET), the association did not reach significance (Figure 4.3c). These
results indicate that NfL changes in the blood most closely reflect cortical thinning and support
the view that serum NfL is primarily a marker of neurodegeneration.
To examine the utility of serum NfL for predicting subsequent neurodegeneration and
clinical symptoms, we performed a (retrospective) pseudo-predictive analysis to ask whether
baseline serum NfL levels were predictive of subsequent cortical thinning (Figure 4.4a). In
addition, we assessed the predictability of baseline serum NfL for detecting change in two
cognitive parameters, namely the Mini–Mental State Examination (MMSE) and the Logical
Memory test (Figures 4.4b-c). Indeed, baseline NfL was highly predictive of future annualized
cortical thinning, for both presymptomatic and symptomatic mutation carriers, at subsequent
visits (Figure 4.4a) and was also predicative for a decrease in MMSE and Logical Memory
scores (Figures 4.4b-c).
To examine whether serum NfL is also predictive in a truly prospective design, the first
39 mutation carriers returning for follow-up visits after the last serum collection were included in
the analysis. (The median time between last serum collection and subsequent visit was 2.1
years.) This prospective analysis allowed us to use the serum NfL rate of change for the
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prediction of further cortical thinning and cognitive changes (from the last visit with serum
collection to the follow-up visit). Despite the small sample size, significant (predictive)
associations were found between serum NfL rate of change and cortical thinning as well as
MMSE and Logical Memory test (Figure 4.4d–f).

4.5 Discussion
Cross-sectional and longitudinal data analyses of DIAN and other large Alzheimer’s
disease cohorts have demonstrated that the pathological processes in Alzheimer’s disease begin
more than two decades before the onset of clinical symptoms. The accumulation of amyloid-β in
the brain (estimated 15–20 years before clinical onset) is followed by declines in cortical
metabolism (estimated 10–15 years before clinical onset) and brain atrophy (5–10 years before
clinical onset) (R. J. Bateman et al., 2012; Burnham et al., 2016; Brian A Gordon et al., 2018;
McDade et al., 2018). Thus, it is generally agreed that therapeutic interventions should start as
early as possible making disease bio-markers of the presymptomatic phase of utmost importance
(Jack Jr & Holtzman, 2013; Reisa A Sperling et al., 2013). The present results suggest that NfL
levels in the blood may serve as such a biomarker to monitor neurodegeneration and disease
progression already in presymptomatic Alzheimer’s disease.
The strong association between NfL levels in the CSF and blood indicates that NfL
changes in the blood reflect changes in the brain, a finding also reported for other
neurodegenerative diseases including sporadic Alzheimer’s disease (Mehtap Bacioglu et al.,
2016; Lu et al., 2015; Niklas Mattsson et al., 2017; Julio C Rojas et al., 2016). In the present
study serum was analyzed but similar levels and tight correlations have also been reported for
NfL in the plasma (Mehtap Bacioglu et al., 2016; Lu et al., 2015). The antigen detected with the
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(ultrasensitive) immunoassay used in this study is presumably a short and stable fragment (~10
kD) of the core domain of NfL (Anthony Brureau et al., 2017; Norgren, Karlsson, Rosengren, &
Stigbrand, 2002). Such a stable fragment appears well suited as a blood biomarker for
monitoring a slow neurodegenerative process in the brain.
Using serial NfL measurements we found that the NfL annual rate of change can
distinguish non-carriers and mutation carriers as early as 16 years before the estimated symptom
onset. This is almost a decade earlier than when using absolute NfL levels measured at a single
time point. Consistently, previous studies reported only non-significant or barely significant
increases in absolute NfL in the blood in presymptomatic or even mildly cognitive impaired
Alzheimer’s disease patients (Mehtap Bacioglu et al., 2016; Niklas Mattsson et al., 2017; P. S.
Weston et al., 2017). In symptomatic Alzheimer’s disease, our results suggest that the NfL rate
of change reaches a plateau, whereas absolute NfL levels continue to increase. Increased
absolute NfL levels in the blood in the symptomatic disease phase is consistent with similar
observations in progressive supranuclear palsy (Julio C Rojas et al., 2016), Huntington’s disease
(Byrne et al., 2017), and multiple sclerosis (Christian Barro et al., 2018).
The very early changes of NfL in the blood may appear surprising in light of the reported
overall brain atrophy only 5–10 years before symptom onset. However, atrophy of individual
cortical regions occurs earlier (R. J. Bateman et al., 2012; Burnham et al., 2016; Brian A Gordon
et al., 2018; McDade et al., 2018). In fact, precuneus thinning was also detected around 16 years
before symptom onset (Brian A Gordon et al., 2018), suggesting that NfL changes are sensitive
enough to pick up such early regional brain atrophy. The association between NfL and cortical
thinning, rather than amyloid-β deposition, is in line with cerebral amyloid-β aggregation being a
trigger of subsequent neurodegeneration that, however, become independent of each other at
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later disease stages (Karran, Mercken, & De Strooper, 2011). The relationship of NfL to tau in
bodily fluids needs further work. In the DIAN cohort, the increase of tau in the CSF (absolute
levels, cross-sectional) occurs as early as 15 years before the estimated age of symptom onset
(Fagan et al., 2014), which is much earlier than the increase of baseline NfL in the CSF.
While an increase of NfL levels is not specific for Alzheimer’s disease, the present
findings are relevant for understanding Alzheimer’s disease progression and highlight their
utility as a marker in clinical trials. In presymptomatic Alzheimer’s disease, the greater the NfL
rate of change, the closer an individual is to converting to symptomatic Alzheimer’s disease, a
finding also reported for cortical atrophy (Kinnunen et al., 2018). This suggests that longitudinal
measures of NfL in the serum are a reliable, relatively cheap, and fast readout of
neurodegeneration in the brain with comparable diagnostic value to neuroimaging but without
the regional resolution.
Although our prospective predication analysis was not adequately powered to
demonstrate that NfL rate of change is indeed a better predictor of disease progression
(neurodegeneration and cognitive decline) than absolute NfL values, our observations suggest
that this is the case in presymptomatic Alzheimer’s disease, while absolute NfL levels are better
predictors in the symptomatic phase. Absolute NfL levels have been successfully used to predict
brain volume changes in (symptomatic) multiple sclerosis (Christian Barro et al., 2018) and
clinical outcome in traumatic brain injury (Shahim et al., 2016). In a recent study with
Huntington’s disease patients, NfL blood levels were predictive of disease onset within three
years (Byrne et al., 2017), but NfL rate of change was not assessed.
The current study design with the 2–3 years interval between participant assessments did
not allow us to determine the relationship between the time over which the NfL rate of change
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was calculated and its clinical predictability. However, the latter appears important to advance
the NfL rate of change as a biomarker. Future analyses should also assess more accurately the
disease period at which the NfL rate of change is a better predictor of neurodegeneration and
cognitive decline than absolute NfL. Finally, it is important to translate our findings to sporadic
Alzheimer’s disease and other cerebral proteopathies (Mehtap Bacioglu et al., 2016; Jucker &
Walker, 2018). Studies have indicated that the pathogenesis of familial and sporadic Alzheimer’s
disease are very similar and share similar pathophysiology and progression (Randall J Bateman
et al., 2011; Cairns et al., 2015; Tang et al., 2016; Thomas et al., 2014). However, sporadic
Alzheimer’s disease patients are typically older and have more comorbidities, which in turn may
influence NfL levels in the blood. The latter is however a further argument that absolute NfL
levels may be less useful for prediction in early disease stages compared to the NfL rate of
change.
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Table 4.1. Baseline characteristics of DIAN participants

Baseline value of all participants. Estimated year to symptom onset (EYO), was analyzed by
two-sided t-test. Mini-Mental State Examination (MMSE) and biomarkers data were analyzed by
two-sided Wilcoxon rank sum test. CDR= Clinical Dementia Rating.

* Note that from 5 participants MMSE was not available. Moreover, CSF was only available
from 80 and 107 for NC and MC, respectively. (CSF was not collected from all participants and
the CSF samples were obtained from Data Freeze 9 while serum was obtained from Data Freeze
11. Moreover, from the originally 221 CSF samples obtained, 3 were excluded by empty tubes, 3
were excluded as no corresponding ID in Data Freeze 11 was found, 3 were excluded because
sample date did not match to data of Data Freeze 11, and 25 were excluded because CSF samples
were not from baseline visit).
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Table 4.2. Characteristics of DIAN participants with longitudinal visit

Value of all participants with multiple visits and longitudinal data. For abbreviations see Table
4.1.
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Figure 4.1. CSF and serum NfL levels are highly correlated and divert between mutation carriers
and non-carriers already in the presymptomatic phase. a, CSF NfL values of non-carriers (blue, n
= 80) and mutation carriers (red, n = 107) as a function of EYO. Shown is −27.5 until +15 years
before or after EYO, respectively. b, Serum NfL for non-carriers (n = 162) and mutation carriers
(n = 243) as a function of EYO. For a and b, the shaded areas represent the 99% credible
intervals around the model estimates. The curves and credible intervals are drawn from the actual
distributions of model fits derived by the Hamiltonian Markov chain Monte Carlo analyses (see
Methods). The first EYO where non-carriers and mutation carriers differed was determined to be
the first point where the 99% credible intervals around the difference distribution between noncarriers and mutation carriers did not overlap 0 (−6.8 years before EYO for both CSF and serum,
see Figure 4.5). Our analysis is influenced by the available number of participants. Thus, results
do not represent absolute measures, but rather relative EYO points where we could detect effects
given the limitations of sample size. c,d, Significant associations from LMEMs between CSF
NfL and serum NfL in non-carriers (n = 80; B(s.e.m.) = 0.350(0.14), P = 0.014) and mutation
carriers (n = 107; B(s.e.m.) = 0.612(0.05), P < 2.0 × 10−16) were found.
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Figure 4.2. Longitudinal serum NfL distinguishes mutation carriers from non-carriers very early
in the presymptomatic disease process, with the NfL rate of change peaking in individuals
converting from the presymptomatic to the symptomatic phase. a, Spaghetti plot showing
longitudinal serum NfL for non-carriers (blue, n = 63) and mutation carriers (red, n = 133) as a
function of EYO. The displayed x axis range is limited to −27.5 until +12.5 years before or after
EYO, respectively, to maintain blinding of some individuals contributing to this dataset. In
addition, again to maintain blinding, the EYO of two participants (one mutation carrier and one
non-carrier) was set to the mean of both EYO values. A logarithmic version of the spaghetti plot
is shown in Figure 4.8a to better appreciate that changes between mutation carriers and noncarriers already occur at presymptomatic levels. b, Estimated rate of change per year in serum
NfL (see Methods for calculation) plotted against baseline EYO for mutation carriers and noncarriers (shown is −27.5 until +12.5 years). Individual random effect slope estimates are plotted
as colored symbols. The shaded areas represent the 99% credible intervals around the model
estimates. The curves and credible intervals are drawn from the actual distributions of model fits
derived with the Hamiltonian Markov chain Monte Carlo analyses. The first EYO where groups
(non-carriers and mutation carriers) differed was determined to be the first point where the 99%
credible intervals around the difference distribution between non-carriers and mutation carriers
did not overlap 0 (−16.2 years before EYO; see Figure 4.8b). An even earlier deviation of the
two curves was calculated when linear regression analyses were performed (Figure 4.7c). c, Rate
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of change per year in serum NfL across four groups differing by mutation and cognitive status:
non-carriers (blue, n = 63); presymptomatic (Presym) mutation carriers (yellow, n = 65) are
individuals who scored as CDR= 0 across all visits; converters (orange, n = 13) are mutation
carriers who scored as CDR= 0 at baseline and CDR> 0 at subsequent visits; symptomatic (Sym)
mutation carriers (red, n = 55) are individuals who scored as CDR> 0 across all visits. The boxes
map to the median, 25th and 75th quintiles, and the whiskers extend to 1.5 × interquartile range
(IQR). Comparisons were done with LMEMs. Presymptomatic mutation carriers had a
significantly higher annual rate of change compared to non-carriers (B(s.e.m.) = 0.009(0.003), P
= 6.71 × 10−4). Converters had significantly higher rate of change compared to both non-carriers
(B(s.e.m.) = 0.024(0.004), P = 3.05 × 10−7) and presymptomatic mutation carriers (B(s.e.m.) =
0.015(0.005), P = 1.19 × 10−3). Symptomatic mutation carriers had significantly higher rates of
change compared to both non-carriers (B(s.e.m.) = 0.020(0.003), P = 8.78 × 10−12) and
presymptomatic mutation carriers (B(s.e.m.) = 0.011(0.003), P = 1.51 × 10−4). There was no
difference between converters and symptomatic mutation carriers (B(s.e.m.) = −0.004(0.005), P
= 0.445).
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Figure 4.3. Rate of change per year in serum NfL in mutation carriers mirrors rate of change in
cortical thinning. a, Relationship between estimated annual rate of change in serum NfL and
estimated annual rate of change in precuneus cortical thickness for non-carriers, presymptomatic
(Presym) mutation carriers, and symptomatic (Sym) mutation carriers (including converters to
the symptomatic phase, see Figure 4.2c). Results from LMEMs revealed a significant association
in symptomatic mutation carriers (n = 60; B(s.e.m.) = −0.914(0.367), P = 0.018) and a close to
significant association in presymptomatic mutation carriers (n = 65; B(s.e.m.) = −0.325(0.166),
P = 0.054) but not in non-carriers (n = 59; B(s.e.m.) = −0.210(0.149), P = 0.886). Between-group
comparison indicated that the rate of change in serum NfL was slightly more associated in
symptomatic than in asymptomatic mutation carriers (B(s.e.m.) = −0.573(0.305), P = 0.063). b,
Relationship between rate of change in serum NfL and rate of change in precuneus 18F-FDG
PET. Using LMEMs, a positive association was only found in symptomatic mutation carriers
(n = 55; B(s.e.m.) = −1.149(0.501), P = 0.031) but not in presymptomatic mutation carriers
(n = 64; B(s.e.m.) = −0.227(0.456), P = 0.620) or non-carriers (n = 55; B(s.e.m.) = 0.161(0.347),
P = 0.465). c, Relationship between rate of change in serum NfL and rate of change in precuneus
amyloid-β-PET. Using LMEMs, no significant association in any of the three groups was found
(non-carriers: n = 57; B(s.e.m.) = −0.468(0.547), P = 0.403; presymptomatic mutation carriers:
n = 64; B(s.e.m.) = 1.248(1.000), P = 0.216; symptomatic mutation carriers: n = 51;
B(s.e.m.) = 1.805(1.556), P = 0.266). The shaded area around each linear fit line represents
one s.e.m. Note that not all participants with longitudinal NfL measurements had imaging
parameters available, thus sample sizes (n) are slightly lower compared to those in Figure 4.2c.
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Figure 4.4. Prediction of changes in cortical thinning and cognition by baseline serum NfL
(retrospective prediction) and serum NfL rate of change (prospective prediction). a–c, Higher
baseline serum NfL levels were significantly associated with an increased rate of change in
cortical thickness (n = 125; B(s.e.m.) = −0.105(0.013), P = 4.47 × 10−13) (a), MMSE (n = 132;
B(s.e.m.) = −3.980(0.537), P = 2.38 × 10−11) (b), and Logical Memory test (immediate recall,
n = 133; B(s.e.m.) = −1.478(0.502), P = 0.004) (c). A similar significance (P = 0.015) was
obtained for the Logical Memory test delayed recall. LMEMs (see Methods) were run with all
mutation carriers together (n = 125) because of the high degree of overlap in cognitive and
biomarker levels between presymptomatic (Presym) and symptomatic (Sym) mutation carriers.
However, at least for cortical thickness, separate analyses for presymptomatic and symptomatic
mutation carriers were also significant (n = 65, presymptomatic mutation carriers (yellow):
B(s.e.m.) = −0.03(0.01), P = 0.047; n = 60, symptomatic mutation carriers (red):
B(s.e.m.) = −0.10(0.03), P = 0.002). d–f, In a true prospective design, mutation carriers returning
for follow-up visits after the last serum collection were included in the analysis. Individuals’
rates of change in serum NfL levels predicted subsequent cortical thinning (d; n = 30;
B(s.e.m.) = −1.867(0.769), P = 0.024). The same predictive associations were also significant for
the MMSE (e; n = 37; B(s.e.m.) = −52.23(20.19), P = 0.015) and Logical Memory test scores (f;
immediate recall, n = 37; B(s.e.m.) = −75.91(18.07), P = 0.0002). For descriptive purposes,
presymptomatic and symptomatic mutation carriers are plotted in yellow and red, respectively.
Note that not all participants with baseline NfL measurements had longitudinal MRI imaging and
longitudinal cognitive parameters available; thus, sample sizes (n) in a–c are slightly lower than
those in Supplementary Table 2. This was also true for the mutation carriers returning for follow-
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up visits after the last serum collection (d–f). The shaded area around each linear fit line
represents one s.e.m. from the LMEMs.
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Figure 4.5. Difference distribution curve for baseline (cross-sectional) CSF and serum NfL
levels in mutation carriers and non-carriers. a,b, Difference of posterior distribution for baseline
CSF NfL (n = 187) (a) and baseline serum NfL (n = 405) (b) as a function of EYO. The solid red
lines depict the median of the difference distribution; the shaded area represents the 99% equaltailed credible intervals. EYO was considered statistically significant if the 99% equal-tailed
credible intervals of the posterior distribution did not overlap 0 (6.8 years before EYO for both
baseline CSF and serum NfL). For the absolute values of baseline CSF and serum NfL, See
Figure 4.1a and 4.1b.
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Figure 4.6. No difference in baseline CSF and serum NfL levels among APP, PSEN1, and
PSEN2 mutation carriers. a, Two-tailed pairwise Student’s t-test comparisons of CSF NfL levels
of carriers of a mutation in APP (n = 14), PSEN1 (n = 82), or PSEN2 (n = 11). b, Same analysis,
using a two-tailed pairwise Student’s t-test for the serum NfL of carriers of a mutation in APP
(n = 39), PSEN1 (n = 185), or PSEN2 (n = 19). No differences in log(CSF NfL) or log(serum
NfL) were found between the groups (F(2, 104) = 1.8108, P = 0.1686 and F(2, 240) = 1.9205,
P = 0.1488, respectively). Similarly, no differences were found by two-tailed pairwise Student’s
t-test when age and disease status (presymptomatic, symptomatic) were treated as covariates.
The boxes map to the median, 25th and 75th quintiles, and the whiskers extend to the 1.5 × IQR.
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Figure 4.7. Longitudinal serum NfL and bifurcation of mutation carriers from non-carriers. a,
Spaghetti plot showing longitudinal serum NfL for non-carriers (NC, n = 63, blue) and mutation
carriers (MC, n = 133, red) as a function of EYO. These are the same data as in Figure 2a but
with a logarithmic scale on the y axis to better appreciate the changes during the presymptomatic
stage (for details, see Figure 2a). b, Difference of posterior distribution for serum NfL rate of
change between mutation carriers and non-carriers, as a function of EYO (n = 196). The solid red
line depicts the median of the difference distribution, and the shaded area represents the 99%
equal-tailed credible intervals. EYO was considered statistically significant if the 99% equaltailed credible intervals of the posterior distribution did not overlap 0 (16.2 years before EYO). c,
Individual estimated rate of change in serum NfL (same data as in Figure 2b, n = 63 for noncarriers and n = 133 for mutation carriers). A regression analysis was performed with two breaks
of slope (see Methods for calculation). With this model the first bifurcation point was found at
−18.6 years before EYO, the second at −5.8 years before EYO.
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Figure 4.8. Rate of change per year of serum NfL is a better parameter to distinguish
presymptomatic and symptomatic mutation carriers from non-carriers compared to single crosssectional serum NfL. Receiver operating characteristic analysis for non-carriers (NC) versus
presymptomatic mutation carriers (MC) and non-carriers versus symptomatic mutation carriers
with cross-sectional (baseline serum NfL) and longitudinal (serum NfL rate of change per year)
data. The true positive fraction (sensitivity) is on the y axis and the false positive fraction (1specificity) on the x axis. The area under the curve (AUC, accuracy), as well as the cutoff value
and χ2 P value from the logistic regression are shown. The chance level of the area under the
curve is 0.50. Converters (for rate of change, see Figure 2c) were considered presymptomatic
mutation carriers.
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Figure 4.9. No difference in serum NfL rate of change among APP, PSEN1, and PSEN2
mutation carriers and no association with estimated age of onset. a, Using two-tailed pairwise
Student’s t-tests, no differences in the rate of change of log(serum NfL) (year−1) levels among
APP (n = 24), PSEN1 (n = 104), and PSEN2 (n = 5) mutation carriers (F(2, 130) = 0.4678,
P = 0.6274) was found. Similarly, no differences were found when age and disease status
(presymptomatic, symptomatic) were treated as covariates in a two-tailed pairwise Student’s ttest. b, No difference between an individual’s deviation from the EYO-adjusted median rate of
change in NfL and their expected age of symptom onset using LMEMs. Individuals were
grouped in 4 categories with expected symptom onset at 20–39 (n = 17), 40–49 (n = 54), 50–59
(n = 56), and over 60 years of age (n = 6); group comparisons, P > 0.146. See Methods for the
calculations. The boxes map to the median, 25th and 75th quintiles, and the whiskers extend to
the 1.5 × IQR.
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Chapter 5

Serum neurofilament light chain predicts
white matter integrity in autosomal dominant
Alzheimer disease.

This chapter is adapted from a manuscript under review at Neurobiology of Disease.
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5.1 Summary
Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased
levels of NfL measured in either cerebrospinal fluid or blood is thought to be a biomarker of
neuronal damage in neurodegenerative diseases. However, there have been limited investigations
relating NfL to concurrent measures of white matter (WM) decline that it should reflect. White
matter damage is a common feature of Alzheimer disease. We hypothesized that serum levels of
NfL would associate with WM lesion volume and diffusion tensor imaging (DTI) metrics crosssectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non-carrier (NC)
familial controls as well as in a subset (N=41) of MC with longitudinal NfL and MRI data.
In MC, elevated cross-sectional NfL was positively associated with WM hyperintensity
lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and negatively with
fractional anisotropy. Greater change in NfL levels in MC was associated with larger changes in
fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of reduced WM
integrity. There were no relationships with NfL in NC. Our results demonstrate that blood-based
NfL levels reflect WM integrity and supports the view that blood levels of NfL are predictive of
WM damage in the brain. This is a critical result in improving the interpretability of NfL as a
marker of brain integrity, and for validating this emerging biomarker for future use in clinical
and research settings across multiple neurodegenerative diseases.
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5.2 Introduction
Neurodegenerative disease biomarkers have important roles in defining disease presence and
severity, predicting progression, and monitoring disease-modifying therapies. For clinical and
research settings such in vivo measures include magnetic resonance imaging (MRI), positron
emission tomography (PET), cerebrospinal fluid (CSF) assays, and blood-based tests. Bloodbased biomarkers (Lewczuk et al., 2018; Zetterberg & Blennow, 2018) have the advantages of
minimal invasiveness, subject acceptability, low cost, as well as accessibility in diverse clinical
settings, including lesser developed countries.
Neurofilaments are a component of the cytoskeleton in the neuronal axons and are critical
for the radial growth and stability of axons (Barry et al., 2012; Rao et al., 2003). Mutations in the
genes that encode neurofilament proteins lead to axonal dysfunction and degeneration
(Jordanova et al., 2003). When axonal membranes are damaged or disrupted, neurofilaments are
thought to be released into the interstitial fluid, and from there move subsequently into the CSF
and blood (Khalil et al., 2018). Neurofilament proteins measured in biofluids have one of three
basic structures with light, medium, or heavy molecular weights, with the majority of work in
neurodegenerative conditions focusing on the light subunit. Concentrations of neurofilament
light chain (NfL) are high enough in the CSF to be reliably measured with either enzyme-linked
immunosorbent assays (ELISA) or electro-chemiluminescence (ECL)-based assays (Khalil et al.,
2018; Jens Kuhle et al., 2016). The introduction of the single-molecule array (SIMOA) (D. H.
Wilson et al., 2016) platform has provided the sensitivity to reliably detect the lower
concentrations of NfL present in blood samples (Khalil et al., 2018; Jens Kuhle et al., 2016).
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Any pathological process that leads to axonal damage or neuronal death should release
neurofilament proteins into the surrounding extracellular fluid. Thus, elevations in neurofilament
protein biofluid concentrations are not specific to one disease but are a general indicator of
axonal damage. Indeed, CSF NfL has been evaluated as a potential fluid biomarker in a wide
range of neurodegenerative disorders including frontotemporal dementia (FTD), progressive
supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), multiple
sclerosis (MS), vascular dementia (VAD), dementia with Lewy bodies (DLB) as well as sporadic
and autosomal dominant Alzheimer disease (AD) (see (Bridel et al., 2019) for meta-analysis).
Comparison between NfL levels in CSF and either plasma (J. C. Rojas et al., 2018; Julio C Rojas
et al., 2016) or serum (Bergman et al., 2016; Meeter et al., 2016; Preische et al., 2019; Steinacker
et al., 2018) has shown high correlations, suggesting that blood levels reflect ongoing biological
processes in the brain (Mehtap Bacioglu et al., 2016). As with the CSF studies, blood levels of
NfL have been examined across a range of neurodegenerative conditions including PSP, ALS,
PD, MS, head trauma, and stroke as well as AD (Chitnis et al., 2018; De Marchis et al., 2018;
Disanto et al., 2017; Gaiottino et al., 2013; Hansson et al., 2017; J. Kuhle et al., 2019; Lin, Lee,
Wang, & Fuh, 2018; Niklas Mattsson et al., 2017; Meeter et al., 2016; Oliver et al., 2016; Rohrer
et al., 2016; Sanchez-Valle et al., 2018; Tiedt et al., 2018; P. S. Weston et al., 2017).
Despite the growing usage of NfL as a biomarker, only a modest number of studies have
related NfL levels to the markers of white matter (WM) health to which it should be intimately
related and mechanistically linked. Most of these studies have been performed on clinical MS
populations. Results have shown that increased levels of NfL in the CSF or blood were related to
greater WM hyperintensity (WMH) volumes and gadolinium enhancing lesions(Chitnis et al.,
2018; Dalla Costa et al., 2019; Siller et al., 2019). A similar pattern was found in patients with
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ischemic stroke (Tiedt et al., 2018) and cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL) (Gravesteijn et al., 2019). Diffusion
tensor imaging (DTI) is a particular form of diffusion-weighted imaging that characterizes the
movement of water molecules in the brain and provides a way to examine microstructural
changes of WM integrity. Prior studies found that higher levels of NfL are related to worse WM
health as captured by higher levels of mean diffusivity (MD) and lower fractional anisotropy
(FA) (Menke et al., 2015; Mielke et al., 2018; E. E. Moore et al., 2018) although this is not
always the case (Mielke et al., 2018; Racine et al., 2019).
Autosomal dominant AD (ADAD) is a form of AD caused by heritable mutations in
genes that are involved in the production of beta-amyloid (Aβ). The young age at onset (30-60
years) of ADAD means individuals are largely free of age-related comorbidities (i.e. vascular
health) that can contribute to WM disease. The relatively predictable age of dementia onset in
ADAD also means that one can align asymptomatic individuals relative to their estimated
disease onset. This makes it possible to investigate decades’ worth of the disease course from
large cross-sectional samples. Such studies of ADAD have shown that CSF and blood NfL levels
are elevated in symptomatic individuals and begin to increase 10 to 20 years before symptom
onset (Preische et al., 2019; Sanchez-Valle et al., 2018; P. S. Weston et al., 2017), consistent
with the notion that WM damage is an early event in AD. There is an emerging recognition that
frank WM lesions as well as changes observed with DTI are a core feature of ADAD (Araque
Caballero et al., 2018; Lee et al., 2016). As a result, ADAD can serve as a model to test whether
elevated levels of NfL are related to changes in WM over the course of the disease. In the current
work we test the sensitivity of NfL as a measure of white matter decline in neurodegenerative
disorders. We hypothesize that serum levels of NfL are associated with WM hyperintensity
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lesion volume and diffusion metrics in both cross-sectional and longitudinal cohorts with
ADAD.

5.3 Methods
5.3.1 Participants
Participants were from the Dominantly Inherited Alzheimer Network (DIAN) observational
study recruited from 14 study sites in the USA, UK, Germany, and Australia. DIAN participants
are from families with known mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and
amyloid precursor protein (APP) genes and have a 50% risk of inheriting the mutation from their
affected parent at a relatively similar, and therefore predicable, age at onset within families.
Participants who completed genetic, clinical, neuroimaging, and blood draw assessments, and
whose data passed quality control as part of the 11th DIAN data release were considered for this
study. The sample was restricted to those who had at least one serum NfL measurement and one
DTI scan within one year of serum NfL measurement. The average number of days between
blood draw for NfL and DTI scan was 0.92 ± 0.66 (mean ± SE) days. This sample included a
subset of DIAN participants previously described (Preische et al., 2019).
The final cross-sectional sample consisted of data from 117 mutation carriers (MC; 87
PSEN1, 12 PSEN2, and 18 APP) and 84 familial non-carrier (NC) controls. Of the 117 MC with
baseline data, 41 had two or more visits with serum NfL measurement, DTI scan, and FLAIR
scan available for longitudinal analyses (one had four visits, four had three visits, and 36 had two
visits).
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The institutional review board at Washington University in St. Louis provided
supervisory review and human studies approval. Participants or their caregivers provided written
informed consent in accordance with their local institutional review board. Participants’ relevant
background characteristics are listed in Table 5.1.

5.3.2 Clinical
Cognitive and functional status was assessed using the Clinical Dementia Rating (CDR).
‘Presymptomatic’ was defined as CDR = 0, and ‘symptomatic’ as CDR > 0. For each visit, a
participant's estimated years from expected symptom onset (EYO) was calculated based upon the
participant's current age relative to either the family mutation-specific expected age at onset of
cognitive symptoms or parental age at first progressive cognitive decline if onset for the mutation
was unknown. EYO was established identically for both MC and NC family members. The
presence or absence of an autosomal dominant AD mutation was determined using PCR-based
amplification of the appropriate exon followed by Sanger sequencing (R. J. Bateman et al.,
2012). Clinical evaluators were blind to the mutation status of participants.

5.3.3 Imaging
DIAN Imaging data was screened for protocol compliance and artifacts. All sites used a 3T
scanner, which was qualified for use at study initiation and was required to pass regular quality
control assessments. Volumetric T1-weighted images (repetition time = 2300 ms, echo time =
2.95 ms, flip angle = 9°, 1.1 x 1.1 x 1.2 mm3 resolution) were acquired for all participants and
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were processed using FreeSurfer 5.3 (http://surfer.nmr.mgh.harvard.edu/)(Fischl, 2012) and the
Desikan atlas to produce regional estimates of grey matter for use in PET processing.
To characterize diffusion, whole brain DTI data were acquired using T2*-echo planar
imaging with one reference volume (b0, b = 1000 mm2) and 64 diffusion directions (repetition
time = 6000/7800/11000 ms, echo time = 87/85 ms, flip angle = 90°, b-value=1000/s mm2
2.5mm isotropic voxels). Only DTI data collected on a Siemens scanner was included in the
current study.

5.3.4 DTI preprocessing
Preprocessing included correction for motion and eddy-current distortions followed by skull
stripping with FMRIB software library (FSL) 5.0.9. Rigorous motion inspection was applied
after eddy-current correction. Participants who moved >3.5 mm in more than 10% of the
diffusion directions were removed (n=35).
The diffusion tensor model was fit using dtifit within the FMRIB’s Diffusion Toolbox
included in FSL. Fractional anisotropy (FA) measures how much water movement is restricted to
one primary direction. FA ranges from zero to one, with zero being complete isotropic diffusion
and one being anisotropic diffusion. Axial diffusivity (DA) and radial diffusivity (DR)
respectively reflect the movement of water parallel and perpendicular to (axis of) the fiber
bundle. Mean diffusivity (MD) reflects the total amount of diffusion present in all directions. FA
images from all subjects were nonlinearly aligned to the FMRIB58 atlas, which is a diffusion
specific template in MNI space, and averaged to create a mean FA image. A skeletonized atlas
was generated from this mean image using a threshold of 0.2, which excluded any voxels not
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overlapping in at least 80% of participants. Each diffusion metric (FA, DA, DR, and MD) was
smoothed with a 2-mm kernel and projected onto the skeletonized atlas using the nonlinear
registration. Voxel-wise analyses were performed on the skeletonized maps using tract based
spatial statistics (TBSS) in FSL (Smith et al., 2006).

5.3.5 DTI regions of interest creation
Well-studied, anatomically derived tracts provide an alternative approach to voxel-wise analyses.
For this approach, all DTI metrics were also analyzed using previously defined regions of
interest (ROIs) (Strain et al., 2018) from a group of younger adults from a separate cohort (Van
Essen et al., 2013). Briefly, deterministic tractography was performed with the MedINRIA
software in native space, and each participant’s tracts were then transformed to MNI space.
Tracts were combined across individuals and limited to only those voxels present in a majority of
individuals. This resulted in the creation of 20 tracts including cingulum (left and right), superior
and inferior longitudinal fasciculus (left and right), corticospinal (left and right), frontal aslant
tract (left and right), perforant pathway (left and right), uncinate fasciculus (left and right),
fronto-occipital fasciculus (left and right), forceps major, forceps minor, anterior corpus
callosum, and posterior corpus callosum. These WM ROIs were overlaid to the TBSS derived
skeletonized atlas and the averaged WM metrics (FA, MD, DA, and DR) were calculated in each
ROI. We averaged values from the left and right for each ROI, as applicable, resulting in a total
of 12 final ROIs. MD, DA, and DR values were re-scaled by a factor of 1000 before being
entered into our analyses in order to generate more interpretable regression coefficients.

122

5.3.6 WM hyperintensities
WMH were quantified on T2-weighted fluid-attenuated inversion recovery (FLAIR) scans
(repetition time = 9000 ms, echo time = 90 ms, TI = 2500 ms, flip angle = 150°, 0.9 x 0.9 x 5.0
mm3 resolution) using maps generated with the open-source lesion segmentation tool for SPM
that includes a lesion growth algorithm (Schmidt et al., 2012). This algorithm identifies voxels
likely to be WMH. For the current analyses, we used the global volume of identified WMH.
WMH volumes were not normally distributed, thus a log-transformation was applied.

5.3.7 Aβ-Amyloid PET
Aβ-amyloid (Aβ) PET imaging was performed after a bolus injection of [11C]Pittsburgh
Compound B (PiB). Acquisition consisted of a 70-minute scan starting at injection or a 30minute scan beginning 40 minutes post-injection. Data in the 40–70 minutes post-injection
window were converted to regional standardized uptake value ratios (SUVRs) relative to the
cerebellar grey matter using FreeSurfer-derived ROIs, (Su et al., 2013) and were partial volume
corrected using a regional spread function technique (Rousset et al., 1998; Su et al., 2015). A
global measure of mean cortical uptake of Aβ burden was derived from cortical regions
previously shown to have elevated signal in AD (Su et al., 2013). Global Aβ positivity was
defined as a mean cortical SUVR ≥1.42.

5.3.8 Serum NfL measurements
All available DIAN serum samples through the 11th annual data release were shipped to the
University of Tübingen for analysis. These processed data were originally published by Preische
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and colleagues (2019), and a subset was used in the current study. As previously described
(Preische et al., 2019), fluids were collected in the morning under fasting conditions. After blood
collection, the tubes were left at room temperature for 30 minutes to allow clotting, and then
centrifuged at 2,000 g for 15 min. Serum was placed into a single transfer tube (#60.541, Sarstedt
AG&CO.KG, Nümbrecht, Germany) and immediately frozen on dry ice. NfL measurements
were performed using a highly sensitive Single Molecule Array (SIMOA) assay using the
capture monoclonal antibody (mAB) 47:3 and the biotinylated detector antibody mAB 2:1
(Uman Diagnostics, Umeå, Sweden). The samples were measured in duplicate on a Simoa HD-1
platform (Quanterix) using a 2-step neat assay. All samples were measured blinded. As NfL
levels were non-normally distributed, we applied a log-transformation to this measure.

5.3.9 Statistics
Participant Characteristics
To compare background characteristics between mutation MC and NC, we performed t-tests and
chi-square tests, as appropriate.
White matter hyperintensities within MC
As done in prior analyses examining NfL and WM(Chitnis et al., 2018; Dalla Costa et al., 2019;
Gravesteijn et al., 2019; J. Kuhle et al., 2019), we examined WMH volumes. All linear mixed
effect (LME) models were constructed and evaluated using the lme4 and lmerTest packages in
the R statistical environment. Log transformed WMH volume was entered as the dependent
variable; age, sex, and NfL as fixed effects; a separate term for family was included as a random
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intercept. This family term represents the specific family a participant comes from. NfL was the
predictor of interest. Analyses were performed only in MC since, due to their young age, NC are
unlikely to have any WMH; whereas WMH have been shown to be a common feature in ADAD
(Lee et al., 2016). We wanted to determine if the relationship between WMH and NfL levels
were simply driven by WM microstructural changes as measured by DTI. Therefore, we repeated
our original analysis after including a global MD metric as a covariate.

Voxel-wise analyses of DTI
To examine whether the associations between baseline WM metrics of interest and NfL levels
varied by mutation status at the voxel level, we implemented linear regression models with
skeletonized maps of either MD, FA, DA, or DR as the dependent variable and age at visit, sex,
NfL, mutation status, and a NfL x mutation status interaction as predictor terms. The initial focus
was on the interaction between NfL and mutation status. Statistical modeling was performed
with the Randomise toolbox in FSL (Winkler et al., 2014), a nonparametric statistical approach
using permutation testing implemented with 5000 permutations. Significant clusters were
identified using threshold-free cluster enhancement (TFCE) with a family-wise error corrected
significance level of p = 0.05 (Smith and Nichols, 2009).
Prior work indicates that NfL levels are most informative within MC (Preische et al.,
2019), suggesting a priori that the interaction term will be highly significant. Therefore, as a
follow-up analysis, we examined the relationship between baseline DTI metrics and NfL within
each mutation status group to better interpret the interaction and to understand the relationship
between NfL and voxel-wise measures of WM within MC and NC, separately. We restricted
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these analyses to voxels that were significant in the interaction analyses described above. We ran
separate models predicting MD, FA, DA, or DR, as a function of age, sex, and NfL.

ROI analyses of DTI within MC
An alternate approach to voxel-wise analyses is to use ROIs representing specific WM tracts. To
determine if the relationship between WM integrity and NfL is tract specific, we ran a series of
LME models in each ROI treating age, sex, and NfL as fixed effects and including a random
intercept for family. Dependent variables were the average WM metrics (FA, MD, DA, and DR)
from each ROI. As we primarily expected the effects to be in MCs (Preische et al., 2019), we
restricted the analyses to this group.
To correct for multiple comparisons, we implemented a Benjamin-Hochberg procedure
with a false discovery rate of 5%. Although analyses were performed for each tract, we focused
on the posterior corpus callosum, superior longitudinal fasciculus, and corticospinal tracts for
visualization. These regions were selected as exemplar ROIs as: 1) posterior corpus callosum is a
region with early WM disruption in ADAD and shows the most robust association between NfL
and WM metrics in our primary analyses; 2) superior longitudinal fasciculus is associated with
default mode network and executive functioning; and 3) corticospinal tract, as a control, is
relatively spared in AD until very late stages.
Prior work has shown dramatic changes in Aβ PET, structural MRI, and WMH(R. J.
Bateman et al., 2012; Benzinger et al., 2013; Lee et al., 2016; McDade et al., 2018) in the DIAN
cohort as the disease progresses. In a cohort such as DIAN where there are dramatic changes
occurring as the disease progresses there is always a concern that statistical relationships can be
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observed due to the parallel timing of biomarker changes rather than true biological
relationships. To rule out if the association between NfL and DTI was simply driven by other,
more overt changes in the disease we additionally include global Aβ-amyloid, total WMH load
and precuneus cortical thickness measures. These covariates account for the general disease
stage of an individual (Aβ-amyloid), overt white matter lesions (WMH), or atrophy that could
drive Wallerian degeneration (structural MRI). Of the 117 MC included in primary analyses, 97
had completed a baseline Aβ PET scan. We repeated our original ROI models, with particular
focus on the posterior corpus callosum, superior longitudinal fasciculus, and corticospinal tracts,
after adding a global Aβ PET, precuneus cortical thickness, and total WMH volume measures as
covariates to examine whether they altered the relationship between NfL and DTI metrics. We
additionally provide scatter plots of serum NfL, global Aβ PET, precuneus cortical thickness,
and total WMH volume to DR in posterior corpus callosum and correlation matrix in the
supplemental material to better interpret the relationship amongst these biomarkers.

White matter integrity markers and NfL across the course of the disease
ADAD has a long preclinical phase evolving over decades (Bateman et al., 2012). To evaluate
the relationship of NfL and DTI metrics as a function of disease progression, our MC sample
was categorized by baseline CDR score into presymptomatic (CDR=0, n= 76) and symptomatic
(CDR>0, n= 28) groups. The presymptomatic group was further subdivided by Aβ positivity into
early (summary Aβ SUVR <1.42; Aβ-, n= 35) and late (summary Aβ SUVR ≥1.22; Aβ+, n=34)
groups. These analyses were restricted to the investigation of FA and MD DTI metrics as these
are the most common DTI metrics presented in the literature. We predicted FA and MD values in
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the posterior corpus callosum using LME models that included sex, NfL, group (presymptomatic
Aβ-, presymptomatic Aβ+, and symptomatic), and a NfL x group interaction as the fixed effects
and family as the random effect. If a significant interaction was present, we compared the
relationship between NfL and the corresponding diffusion metric between each group.

Longitudinal relationship between white matter integrity markers and NfL
Longitudinal data were analyzed using LME models as these models can account for covariance
introduced by serial measurements within the model and are more ideally suited for dealing with
variability in timing or an unbalanced number of data points. The rate of change in NfL (NfL)
for each individual was modeled using an LME with fixed effects of time from baseline in years,
and a random intercept for family, as well as random slope and intercept terms for each
participant. The NfL for each individual was extracted from the model estimates for subsequent
analyses. The NfL was then used for a second LME model where the dependent term for each
model was a WM measure of interest (MD, FA, DA, and DR DTI measures in posterior corpus
callosum ROI and WMH volume) with fixed effect terms for baseline age, sex, time from
baseline, extracted NfL, and a time from baseline x NfL interaction. Models contained
random slope and intercept terms for participants and random intercepts for family. The primary
term of interest was the interaction between the NfL and the time from baseline term. Models
were fitted using lme4 in R. For plotting purposes, LMEs were also used to generate individual
rates of change for WM integrity markers (ROI MD, FA, DA, and DR measures and WMH
volume).
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5.4 Results
5.4.1 Participant characteristics
Demographics are presented in Table 5.1.

5.4.2 Relationship between NfL and WMH in MCs
Within the MC cohort there was an association between NfL and total WMH volume (B[SE]=
2.54 [0.56], p= 1.44e-05). Figure 5.1. When evaluating whether the relationship between NfL
and WMH remained after accounting for a global DTI MD measure (as a proxy for overall WM
changes measured with DTI) we found the relationship between WMH and NfL was reduced to a
trend (B[SE]= 1.15 [0.58], p= 0.05). This suggests that at least a proportion of the association
between NfL and WMH is captured by DTI metrics.
Voxel-wise relationship between NfL and baseline DTI metrics
There were interactions between NfL and mutation status on all four DTI metrics (FA,
MD, axial diffusivity [DA], and radial diffusivity [DR]; see Figure 5.2). As there was a
significant interaction between NfL and mutation status, we next looked within each mutation
status group for a main effect of NfL on DTI metrics. Within MCs, a strong association between
higher NfL levels and low FA was observed throughout the skeletonized atlas (Figure 5.3A).
Similarly, there was a strong association between higher NfL levels and higher MD, DA and DR
levels across all WM tracts (Figure 5.3B, C, and D, respectively). The threshold free cluster
enhancement (TFCE) method (see Methods) within our voxel-wise analyses resulted in an
inclusive cluster of much of the WM voxels, emphasizing a robust and widespread association
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between NfL and WM metrics. To better understand subtle tract-specific variations, we
subsequently generated a mask containing all significant voxels surviving multiple comparisons
correction and applied this mask to our voxel-wise uncorrected statistical map (Figure 5.4).
Within NCs there was no association between NfL levels and FA, MD, DA, or DR across
the entire cortex (data not shown).

5.4.3 Regional association between NfL and baseline DTI metrics in MC
As an alternative to voxel-wise analyses we utilized 12 ROIs that summarized important white
matter tracts. There were significant associations between higher NfL levels and lower FA levels
across all 12 ROIs examined. There were consistent associations between higher NfL and higher
MD, DA, and DR levels in all tracts examined, with the exception of the corticospinal tract.
Regression coefficients and p-values from statistical models are presented in Table 5.2.
Representative plots are shown depicting the relationship between NfL and FA, MD, DA, and
DR in the posterior corpus callosum (Figure 5.5A, 5.5D, 5.5G, and 5.5J), superior longitudinal
fasciculus (Figure 5.5B, 5.5E, 5.5H, and 5.5K), and corticospinal (Figure 5.5C, 5.5F, 5.5I, and
5.5L) tracts. For exploratory purposes, to better understand whether there were unique
relationships within specific mutation types (i.e., PSEN1, PSEN2, and APP), we evaluated the
association between NfL and a singular region and DTI metric of RD in the posterior corpus
callosum within each mutation type. (Figure 5.6).
Including Aβ PET, cortical thickness, and WMH as additional covariates in ROI models
for posterior corpus callosum, superior longitudinal fasciculus, and corticospinal tracts in a
subset of 97 individuals with Aβ PET available, the relationship between NfL and DTI metrics
persisted (p values = 5.78e-04, 4.21e-04, 0.020, 4.68e-04 for FA, MD, DA, and DR in posterior
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corpus callosum, and p’s= 0.029, 0.002, 0.038, 0.003 for FA, MD, DA, and DR in superior
longitudinal fasciculus). The relationship between FA, MD and DR in corticospinal tract and
NfL remained significant (p’s= 0.028, 0.046, 0.015, respectively) and relationship between DA
in the corticospinal tract and NfL remained nonsignificant in the revised models with Aβ PET
and WMH as additional covariates. (Full models in Table 5.3). These results suggest that the
association between NfL and FA or MD is not driven solely by Aβ pathology, thinning grey
matter, or WMH load.

5.4.4 White matter integrity markers and NfL across the course of the disease
We stratified MC into Symptomatic individuals and Presymptomatic Late (Aβ +), and Early
(Aβ-) groups. There was a group x NfL effect on MD (F=4.3, p=0.017), DA (F=4.49, p=0.014),
and a trend for DR (F=2.52, p=0.087), but not for FA (F=0.89, p=0.415) in the posterior corpus
callosum.
Between-group comparisons revealed that the relationship between NfL and MD in the
posterior corpus callosum in the Symptomatic group was stronger than that of the
Presymptomatic Early group (B [SE]= 0.285 [.10], p=0.004), and similar to that of the
Presymptomatic Late group (B [SE]= .169 [.10], p=0.095) (Figure 5.7). Similarly, the
relationship between NfL and DA or DR in the posterior corpus callosum in the Symptomatic
group was stronger than that of the Presymptomatic Early group (B [SE]= .448 [.15], p=0.004
and B [SE]= .239 [.11], p=0.029, respectively), and not different from that of the
Presymptomatic Late group on DA (B [SE]= .288 [.16], p=0.068) or DR (B [SE]= .164 [.14],
p=0.143) (Figure 5.7C-D). There were no differences between Presymptomatic Early and
Presymptomatic Late groups across any of the DTI metrics examined (p’s > 0.278). These results
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suggest that the relationship between NfL and WM is most robust in those with cognitive
symptoms but may begin in cognitively normal MCs with significant Aβ pathology and continue
or even intensify with the onset of cognitive symptoms.

5.4.5 Longitudinal relationship between white matter integrity markers and
NfL
Rate of change in NfL (NfL) was associated with rate of change in FA, MD, and DR in
posterior corpus callosum (B[SE]= -0.238 [.05], p=1.74e-05; B[SE]=.0004 [9.0e-05], p=3.02e04; and B[SE]=.0005 [8.64e-05], p=1.42e-06, respectively), but not with rate of change in DA
(B[SE]= .0002[1.58e-04], p=0.287) or rate of change in WMH (B[SE]= 1.04[.65], p=0.121)
(Figure 5.8 and Figure 5.9a-d) consistent with the view that changes in NfL reflect increasing
white matter changes in this cohort as measured with DTI.

5.5 Discussion
NfL is a promising fluid biomarker to study neurodegeneration across multiple neurological
diseases. Although NfL is thought to reflect damage to large myelinated axons there is a paucity
of work systematically examining how NfL levels relate to established markers of
macrostructural and microstructural WM damage. In the current work we examined how levels
of serum NfL predict WM lesion volumes and DTI metrics of WM integrity. Across all
measures, we found that elevated levels of serum NfL were significantly associated with
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increased levels of WM pathology. This indicates that a blood-based measure of NfL does
indeed track WM damage in the brain.
Due to its predictable age of dementia onset and low comorbidities, ADAD serves as a
useful model to understand the evolution of AD pathology (R. J. Bateman et al., 2012). Prior
work established increases in WMH volumes (Lee et al., 2016) as well as alterations in DTI
metrics (Araque Caballero et al., 2018) as core features of ADAD. Across multiple neurological
conditions, increased NfL levels in CSF and blood have been tied to greater WMH volumes
(Chitnis et al., 2018; Dalla Costa et al., 2019; Gravesteijn et al., 2019; Kuhle et al., 2019, 2013;
Siller et al., 2019; Tiedt et al., 2018). Consistent with this work, we found that in MC, higher
serum NfL levels at baseline predicted greater WMH lesion volumes. However, when we
included a global MD DTI measure for microstructural WM integrity as a covariate, the
relationship between NfL and WMH was no longer present. This suggests that at least some of
the information contained by global WMH volumes is also reflected in DTI metrics. For
exploratory purposes, a correlation matrix depicting the relationship between biomarkers
examined is presented in Figure 5.10. In the subset with longitudinal data, there was a trend that
a greater increase in serum NfL was related to increases in WMH volume, but this did not
approach significance (B[SE]= 1.04[.65], p=0.121).
WMH represent macrostructural WM insults in the brain. In addition to such overt
damage, microstructural changes in WM can be assayed using DTI. There have been inconsistent
results establishing whether CSF and blood levels of NfL are sensitive to such microstructural
changes in WM detectable using DTI (Menke et al., 2015; Mielke et al., 2019; Moore et al.,
2018; Racine et al., 2019; Tiedt et al., 2018). When examining baseline DTI data using voxelwise- and ROI-based approaches we found that higher levels of serum NfL were negatively
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associated with FA, and positively associated with MD, RD, and DA throughout the entire
cortex, although effects were strongest in posterior regions (Table 5.2 and Figure 5.4). Lower
FA and higher MD, RD, and DA are indicative of a less constrained flow of water molecules and
are generally viewed as markers of WM damage. This widespread pattern of WM decline is
consistent with prior work in ADAD (Araque Caballero et al., 2018; Gordon et al., 2018). The
strong observed relationship suggests that NfL is a robust marker of active microstructural WM
damage beyond overt lesions.
As the mutations in ADAD lead to such a dramatic disease phenotype, there is always a
concern that significant relationships between biomarkers may be due simply to a common time
course rather than measures being truly interrelated. Even when including Aβ PET and cortical
thickness as a markers of general disease progression and WMH volume to account for
macrostructural WM damage, we still found highly significant associations between serum NfL
levels and DTI metrics. The relationship between NfL and DTI was present not only at baseline
but was consistent over time. In the subsample of MC with longitudinal data, a greater rate of
serum NfL change predicted greater WM declines in FA, and increases in MD, and RD.
Establishing such a longitudinal relationship is critical to be able to use CSF and blood-based
measures of NfL to monitor disease progression and to potentially use NfL as a marker of
response to disease intervention in clinical trials for AD as well as other neurodegenerative
disorders.
The heritability in the onset of dementia in ADAD families provides the unique ability to
stage individuals relative to their expected time of cognitive decline. Stratifying by CDR and Aβ
positivity status, we were able to examine the relationship between NfL and WM integrity across
the course of the disease. In asymptomatic MC without advanced disease progression (Aβ-),
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levels of NfL were low and WM, assessed with DTI, was healthy. As the disease progressed
(Aβ+), levels of NfL increased and WM health declined in individuals who were still classified
as asymptomatic but Aβ+. Finally, there were even further increases in NfL and declines in DTI
metrics in symptomatic individuals. The distribution of the groups overlapped and within the
entire cohort NfL and DTI measures were tightly coupled. This suggests that continuous levels
of the biomarkers add to the assessment of the health of the brain over and above Aβ positivity
status and staging by CDR alone.
The current work is a critical step towards establishing NfL as a marker of
neurodegeneration that reflects likely WM damage and decline. Still, there are limitations to the
current analyses. ADAD is a continually progressive neurodegenerative condition with relatively
stereotyped phenotypes and rates of progression, and manifests during a younger age range,
during which, secondary comorbidities are uncommon. These features make ADAD a very
useful model of AD pathobiology and a model to test the relationship between NfL and WM
damage. However, these features may affect the generalizability of the current findings to late
onset AD. For example the degree of pathology seen in ADAD is also higher than that seen in
late onset AD (B. A. Gordon et al., 2019), and as a result NfL may not be as useful a predictor in
the sporadic form of the disease.
Although longitudinal relationships between NfL and WM are rarely examined, our
longitudinal sample is modest. CSF and blood-based biomarkers reflect properties of the brain
and body at the time of collection. Prior work suggested that CSF biomarkers of neuronal injury
decline at symptomatic stages of AD (Sutphen et al., 2018), which could lead to a mismatch
between biofluid and imaging markers in later stages of disease. Further work is needed to test

135

whether the relationship between imaging and NfL measures changes at more advanced stages of
neurodegenerative conditions.
Finally, further examinations relating neuroimaging and biofluid measures across
multiple neurological disorders are needed. In ADAD we showed that neuroimaging and biofluid
measure are highly related. Although elevated in most neurodegenerative conditions (Bridel et
al., 2019), the degree that NfL becomes abnormal varies widely between disorders. In other
diseases the strength of the relationship between neuroimaging and biofluid measures may be
more or less robust.
Biomarkers provide the ability to measure the health of the central nervous system in vivo
to aid disease diagnosis and prognosis. Blood-based markers are minimally invasive and
relatively low cost but few have been validated against neuroimaging biomarkers (Lewczuk et
al., 2018). NfL in the blood is highly correlated with measures in the CSF and is becoming
widely adopted in diagnosing and monitoring multiple diseases. Our current work supports the
view that blood levels of NfL are predictive of WM damage in the brain at least as measured
with neuroimaging. This is a critical result in improving the interpretability of NfL as a marker
of brain integrity, and for validating this novel biomarker for future use in clinical and research
settings.
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Table 5.1. Baseline sample characteristics.

Characteristic

Non-Carrier

Mutation-Carrier

p-

(N= 84)

(N=117)

Age (yrs), mean (SD)

40.5 (10.7)

38.6 (10.8)

.230

Sex, female (%)

58.3

50.8

.293

Serum NfL (pg/mL), mean (SD)

23.7 (12.5)

33.4 (23.1)

.001

EYO (yrs), mean (SD)

-

-8.5 (11.0)

-

MMSE, mean (SD)

29.2 (1.2)

27.2 (4.1)

<.001

Clinical Dementia Rating, 0, 0.5, ≥ 1,

81 (96.4), 3 (3.6), 0

76 (65.0), 32 (27.4), 9

<.001

n (%)

(0)

(7.6)

value

Key: NfL= Neurofilament light chain; EYO = estimated years from expected symptom onset;
MMSE = Mini-Mental State Examination.
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Table 5.2. Main effect of serum NfL on DTI metrics in MC.

WM Tract

Fractional Anisotropy

Mean Diffusivity

Axial Diffusivity

Radial Diffusivity

B (SE)

p

B (SE)

p

B (SE)

p

B (SE)

p

Inferior Longitudinal
Fasciculus

-.062 (.01)

2.82E-06

.090 (.02)

2.58E-05

.065 (.02)

0.00893

.102 (.02)

2.88E06

Superior Longitudinal
Fasciculus

-.048 (.01)

0.00025

.091 (.02)

2.8E-06

.090 (.02)

4.07E-05

.094 (.02)

7.65E06

Frontal Occipital Fasciculus

-.071 (.01)

1.06E-08

.108 (.02)

2.96E-08

.084 (.02)

3.59E-05

.124 (.02)

5.3E-09

Perforant Pathway

-.106 (.02)

1.15E-06

.150 (.02)

6.78E-08

.084 (.04)

0.020267

.162 (.03)

2.79E08

Uncinate Fasciculus

-.048 (.01)

6.49E-05

.060 (.02)

0.00024

.037 (.02)

0.041739

.071 (.02)

4.86E05

Cingulum

-.088 (.02)

2.08E-07

.133 (.02)

1.97E-08

.091 (.03)

0.0012

.153 (.02)

3.09E09

Frontal Aslant

-.060 (.01)

2.48E-07

.089 (.02)

6.37E-05

.088 (.03)

0.002341

.101 (.02)

1.04E05

Corticospinal

-.027(.01)

0.012

.032 (.02)

0.070468

.007 (.03)

0.785

.042 (.02)

0.00893

Anterior Corpus Callosum

-.119 (.02)

5.72E-06

.284 (.04)

4.14E-09

.301 (.06)

1.03E-06

.279 (.04)

2.88E08

Posterior Corpus Callosum

-.155 (.02)

4.14E-09

.321 (.04)

8.78E-11

.276 (.06)

6.68E-06

.344 (.04)

1.94E10

Forceps Minor

-.074 (.01)

3.77E-08

.099 (.02)

3.84E-07

.086 (.02)

0.000448

.114 (.02)

3.97E08

Forceps Major

-.087 (.01)

2.29E-08

.122 (.02)

6.72E-08

.082 (.02)

0.000145

.146 (.02)

1.88E08

Unstandardized regression coefficient B and adjusted p-values for serum NfL from a series of
linear mixed effect models in each ROI, which included random intercepts for family, and fixed
effects for age, sex, and NfL. Dependent variables were the average WM metrics (FA, MD, DA,
and DR) from each ROI. N=117.
Key: WM = White matter; NfL = Neurofilament light chain; ROI = region of interest; SE =
standard error.
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Table 5.3. Full models.
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Unstandardized regression coefficient and adjusted p-values for fixed effects from a series of
linear mixed effect models in PCC, SLF, and CST, which included random intercepts for family,
and fixed effects for age, sex, precuneus cortical thickness, global Aβ-amyloid, total WMH
volume, and serum NfL. Dependent variables were the average WM metrics (FA, AD, DA, and
DR) from each ROI. N=97.

Key: WMH = White matter hyperintensity; NfL = Neurofilament light chain; FA = fractional
anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial diffusivity; PCC =
posterior corpus callosum; SLF = superior longitudinal fasciculus; CST = corticospinal tract.
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Figure 5.1. Relationship between serum NfL and total white matter hyperintensity volume in
mutation carriers. Scatterplot showing the relationship between total WMH volume and serum
NfL in MC (n=117). The shaded area around the linear fit line represents one standard error of
the mean from the LME model.
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Figure 5.2. Interaction between serum NfL and mutation status on DTI metrics. P-value map
(red-yellow) of statistically significant voxel-wise interactions of NfL x mutation status and (A)
lower fractional anisotropy, (B) higher mean diffusivity, (C) higher axial diffusivity, and (D)
higher radial diffusivity superimposed on the white matter skeleton (blue). N=201. Family-wise
error-corrected at p = 0.05.

143

Figure 5.3. Main Effect of serum NfL on DTI metrics in MC. P-value map (red-yellow) of
statistically significant voxel-wise associations of higher NfL and (A) lower fractional
anisotropy, (B) higher mean diffusivity, (C) higher axial diffusivity, and (D) higher radial
diffusivity superimposed on the white matter skeleton (blue), within mutation carriers (n=117).
Familywise error-corrected at p = 0.05.
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Figure 5.4. Uncorrected voxel-wise associations of NfL and DTI metrics. Uncorrected T-value
map (red-yellow) of voxel-wise associations of higher NfL and (A) lower fractional anisotropy,
(B) higher mean diffusivity, (C) higher axial diffusivity, and (D) higher radial diffusivity
superimposed on the white matter skeleton (blue), within mutation carriers (n=117). Uncorrected
maps were restricted to significant clusters identified using threshold-free cluster enhancement
(TFCE) with a family-wise error corrected significance level of p = 0.05, presented in Figure 5.3.
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Figure 5.5. Tract-specific white matter measures are associated with serum NfL in MC.
Scatterplots depicting the relationship between serum NfL and DTI metrics from FA, MD, DA,
and DR within three representative ROIs (PCC, SLF, and CST) in MC (n=117). The shaded area
around each linear fit line represents one SE from LME models.
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Key: FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial
diffusivity; PCC = posterior corpus callosum; SLF = superior longitudinal fasciculus; CST =
corticospinal tract; NfL = neurofilament light chain; DTI = diffusion tensor imaging; ROIs=
regions of interest; MC = mutation carriers; SE = standard error.
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Figure 5.6. Relationship between serum NfL and radial diffusivity within posterior corpus
callosum by mutation type. Graphical depiction, for exploratory purposes, of the relationship
between serum NfL and radial diffusivity in the posterior corpus callosum within each mutation
type. Those with mutations in PSEN1 (N= 87) are blue, PSEN2 are yellow (N=12), and APP are
purple (N=18). Individuals who are Presymptomatic (CDR=0) are coded as squares and
Symptomatic (CDR>0) as triangles. The shaded area around each linear fit line represents one
SE.
Key: DR = radial diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain;
SE = standard error.
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Figure 5.7. Interaction between serum NfL and disease progression on DTI metrics. Scatterplots
depicting the relationship between serum NfL and DTI metrics from FA, MD, DA, and DR
within PCC for Presymptomatic MC early (gray circles), Presymptomatic MC late (yellow
triangles), and Symptomatic MC (red diamonds).
The shaded area around each linear fit line represents one SE from LME models.
Key: FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial
diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain; DTI = diffusion
tensor imaging; SE = standard error.
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Figure 5.8. Longitudinal relationship between serum NfL and WMH in MC. Scatterplot showing
the relationship between the estimated annual rate of change in total WMH volume and the
estimated annual rate of change in NfL in MC (n=41). The shaded area around the linear fit line
represents one SE from the LME model.
Key: NfL = neurofilament light chain; WMH= white matter hyperintensity; ROIs= regions of
interest; MC = mutation carriers; SE = standard error.
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Figure 5.9. Longitudinal relationship between NfL and DTI metrics in PCC. Scatterplot showing
the relationship between the estimated annual rate of change in serum NfL and the estimated
annual rate of change in (A) FA in PCC, (B) MD in PCC, (C) DA in PCC, and (D) DR in PCC in
MC (n=41). The shaded area around each linear fit line represents one SE from LME models.
Key: FA = fractional anisotropy; MD = mean diffusivity; DA = axial diffusivity; DR = radial
diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain; DTI = diffusion
tensor imaging; SE = standard error.
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E

Figure 5.10. Relationship between biomarkers and radial diffusivity within posterior corpus
callosum in MC. Depiction of the relationship between radial diffusivity within posterior corpus
callosum in MC and serum NfL (A), total WMH volume (B), global beta-amyloid (C), and
cortical thickness in the precuneus (D). A correlation matrix (E) of Pearson correlation
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coefficients amongst all biomarkers considered is presented to better understand these
relationships.
Key: DR = radial diffusivity; PCC = posterior corpus callosum; NfL = neurofilament light chain;
WMH= white matter hyperintensity.
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Chapter 6.

Relationship between physical activity and
brain metabolism in adults.
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6.1. Summary
The objective of this study was to examine the relationship between engagement in
physical activity (PA) and the loss or preservation of brain metabolism in older adults.
Ninety cognitively healthy individuals (age 25 – 85 years old) participated in this crosssectional study. They wore an accelerometer (ActiGraph GT3+) for seven consecutive days to
measure free-living PA and underwent multi-tracer positron emission tomography to evaluate
total glucose use (CMRglc), oxygen metabolism (CMRO2), and AG which were normalized to
literature-based whole brain metabolism estimates. Participants were categorized as either having
met physical activity recommendations (PAR) or not based on the US Department of Health and
Human Services recommendations of 150 minutes of moderate-to-vigorous physical activity per
week. We focused our initial analysis on the rostral middle frontal gyrus, based on previously
published results on the association between physical activity and CMRglc in this region.
Older age is associated with lower levels of total PA (r = -0.339) and lower normalized
CMRglc in rostral middle frontal gyrus (r = -0.594). Hierarchical testing first aimed to examine
the relationship between rostral middle frontal CMRglc and PA in older individuals (60+ years
old, N = 64). Using analyses of covariance (ANCOVA) adjusted for age and gender, we confirm
that individuals who meet PAR had higher rostral middle frontal CMRglc compared to those
who do not meet PAR (F = 9.18, p = 0.004). Further analyses show a similar association of
meeting PAR on AG (F = 6.35, p = 0.014), but not CMRO2 (F = 0.04, p = 0.836).
In this cross-sectional study we confirm that meeting PAR is associated with maintained
CMRglc in the rostral middle frontal cortex, which is more likely due to a difference in AG than
CMRO2. These results suggest that maintaining PA might be specifically associated with better

155

preservation of glycolytic metabolism in the aging brain, and further analysis of other brain
regions is now ongoing.

6.2 Introduction
There are robust brain changes, including the brain’s use of glucose, that occur
throughout adulthood. Specifically, brain aerobic glycolysis (AG)—which represents the use of
glucose beyond that required for oxidative phosphorylation—is higher in young adults and
decreased in many older individuals. Maintaining a physically active lifestyle is at the forefront
of recommended areas of focus to promote healthy brain aging, including preserving AG
pathways, but the relationship between the two remain to be determined.
Engagement in physical activity increases peripheral metabolic fitness (Laye, Nielsen,
Hansen, Knudsen, & Pedersen, 2015), decreases risk for metabolic disorders (Lavie et al., 2014;
Tuomilehto et al., 2001), and is associated with beneficial cerebral glucose metabolism
(Dougherty, Schultz, Kirby, et al., 2017), suggesting potential link between physical activity and
metabolic pathways.
Research on the relationship between physical activity levels and cerebral metabolism
functioning has focused on examining total cerebral glucose use (CMRGlc) as measured
by fluorodeoxyglucose (18F-FDG) positron emission tomography (PET). For example, a recent
study found middle-aged individuals who engaged in free-living physical activity had higher
CMRGlc levels in the rostral middle frontal regions. However, advances in PET studies now
allow multiple tracers to measure of AG, CMRGlc, and oxygen (CMRO2) metabolism in the
same individual. Investigating these three measures concurrently may provide insight into
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specific metabolic dysregulation pathways. For example, AG may support specific metabolic
functions of biosynthesis of glycogen, proteins, and lipids; neuroprotection by managing reactive
oxygen species and apoptosis; production of lactate, a potential fuel and signaling molecule
(Suzuki et al., 2011); and supports synaptic formation and turnover (Goyal, Hawrylycz, Miller,
Snyder, & Raichle, 2014; Goyal et al., 2017). Taking an integrative approach to the study of
brain metabolism may elucidate pathways by which physical activity protect brain metabolism
mechanisms.
Accordingly, the objective of this study was to examine the relationship between
engagement in physical activity (PA) and the loss or preservation of brain metabolism, using a
multi-tracer PET design, in older adults.

6.2 Methods
6.2.1 Participants
The Washington University in St. Louis Institutional Review Board approved all study
procedures, and informed consent was obtained from all individual participants. Ninety
cognitively healthy individuals (age 25 – 85 years old) participated in this cross-sectional study.
All 90 individuals wore an accelerometer (ActiGraph GT3+) for seven consecutive days to
measure free-living PA and underwent multitracer positron emission tomography to evaluate
total glucose use (CMRglc), oxygen metabolism (CMRO2), and AG.
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6.2.2 Physical activity assessment
A triaxial accelerometer (Actigraph GT3X+, Actigraph LLC, Pensacola, FL) measured PA over
7 consecutive days. Participants were instructed to place the accelerometer on their hip, affixed
to an elastic belt, and to wear the device during all waking hours, with the exception of when
showering, swimming, or bathing. Standard accelerometry inclusion criteria consisted of at least
10 hours of valid wear time per day for a minimum of 3 weekdays and 1 weekend day (Troiano
et al., 2008). Accelerometer data (in 1-s epochs) were processed using the sojourn-3 axis method
(Staudenmayer, Pober, Crouter, Bassett, & Freedson, 2009) to calculate time spent in 3 wellestablished intensity categories of PA, that is LPA, MPA, VPA, and time spent sedentary. This
method utilizes information from all three axes (vertical, anterior-posterior, and medial-lateral)
to identify independent bout intervals— the time between starting one activity (e.g., sitting,
standing, walking, running, jumping, etc.) and transitioning to another— by instances of rapid
acceleration or deceleration.
Within the sojourn-3 axis method (Lyden, Keadle, Staudenmayer, & Freedson, 2014),
estimated metabolic equivalents (METs) are determined for each bout interval using a validated
neural network approach (Staudenmayer et al., 2009), as opposed to the traditional counts-perminute approach. The MET values were classified into PA intensity categories thus: <1.5
METs = sedentary, 1.5-2.99 METs = LPA, 3–6 METs = MPA, and >6 METs = vigorous VPA
(Troiano et al., 2008). Average total minutes/day of activity were calculated for each participant
by coming average total minutes/day spent engaging in LPA, MPA, and VPA. Participants were
categorized as either having met physical activity recommendations (PAR) or not based on the
US Department of Health and Human Services recommendations of 150 minutes of moderate-to-
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vigorous physical activity per week. An example day of actigraphy data from an Active and
Sedentary individual is displayed in Figure 6.1

6.3.3 MRI
MRI scans were obtained on a 3T PRISMA scanner using a high resolution (0.8 mm isotropic)
T1-weighted magnetization-prepared rapid gradient-echo sequence.
FreeSurfer 5.3 (http://freesurfer.net) HCP structural Pipeline was used to segment the MRI into
cortical and subcortical regions of interest (ROIs). These ROIs were used for regional estimation
of all PET measures.

6.3.4 PET
All participants underwent one FDG scan and 2 sets of 15O-CO, 15O-H2O, and 15OO2 scans. 18F-FDG and 15O PET scans were performed on a Siemens ECAT Exact HR+ PET
scanner as described previously (Vlassenko et al., 2010).
FDG scans were performed after injection of ∼5 mCi of FDG. Cerebral blood volume
was measured with a 5-minute emission scan beginning 2 minutes after brief inhalation of
∼75 mCi of [15O]CO in room air. Dynamic scans of 3 minutes were acquired after injection of
∼50 mCi [15O]H2O in saline or inhalation of 60 mCi of [15O]O2 in room air. The
CMRO2 parametric image was derived from these 15O scans and corrected for cerebral blood
volume.
The local-to-global images obtained as described previously for CMRGlc, CMRO2 were
summarized to the FreeSurfer ROIs. These were then multiplied by age-specific literature-based
whole-brain estimates for each of the metabolic parameters (Goyal et al., 2014; Goyal et al.,
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2017; Vlassenko et al., 2018). AG was calculated by dividing the CMRO2 values by six, and then
subtracting this resultant value from the CMRGlc values.
We focused our initial analysis on the rostral middle frontal gyrus, based on previously
published results on the association between physical activity and CMRglc in this region.

6.3.5 Statistics
Pearson correlation coefficients were calculated between age and average daily total activity and
brain metabolism measures in the rostral middle frontal gyrus.
Hierarchical testing first aimed to examine the relationship between rostral middle frontal
CMRglc and PA in older individuals (60+ years old, N = 64). Analyses of covariance
(ANCOVA) adjusted for age and gender, were performed to examine whether individuals who
meet PAR had higher rostral middle frontal CMRglc compared to those who do not meet PAR. If
a relationship was observed, we further examined associations between meeting PAR and both
AG as well as CMRO2.

6.4 Results
Participant demographic, physical functioning, and biometric characteristics are reported in
Tables 6.1-6.3.
Older age is associated with lower levels of total PA (r = -0.339; Figure 6.2A) and lower
normalized CMRGlc (r = -0.594, p = 6.6e-10; Figure 6.2B) and AG ( r = -0.523, p = 1.2e-07;
Figure 6.2C) in rostral middle frontal gyrus, but not with CMRO2 (r = -0.1187, p = 0.078;
Figure 6.2D).
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We confirm that individuals who meet PAR had higher rostral middle frontal CMRglc
compared to those who do not meet PAR (F = 9.18, p = 0.004; Figure 6.3A). Further analyses
show a similar association of meeting PAR on AG (F = 6.35, p = 0.014; Figure 6.3B), but not
CMRO2 (F = 0.04, p = 0.836; Figure 6.3C).

6.5 Discussion
In this cross-sectional study found that brain metabolism measures, and to a lesser extent
physical activity, decrease across adulthood. Additionally, we report that individuals who met
PAR had maintained CMRGlc in the rostral middle frontal cortex, compared to inactive
individuals.
Furthermore, this maintenance of CMRGlc is more likely due to a difference in AG than
CMRO2. These results, performed in a independent cohort of similar age, cognitive status, and
physical activity levels, confirm the findings by Dougherty and colleagues (2017) suggesting that
engagement in physical activity is associated with higher CMRGlc in the rostral medial frontal
gyrus.
Importantly, we extend these prior findings by showing a novel relationship between
physical activity and AG in the rostral middle frontal gyrus, suggesting a mechanism by which
physical activity may provide resilience aging brain aging and dysfunction.
Overall, these results suggest that maintaining PA might be specifically associated with
better preservation of glycolytic metabolism in the aging brain, and further analysis of other
brain regions is now ongoing.
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Table 6.1. Background characteristics.
Variable

Range

Mean (SD) or %

Mean (SD) or %

Full Sample

Full Sample

60 years +

Age, years

25.1-85.3

64.6 (14.7)

72.3 (5.9)

Met National PA Rec, %

-

32.2

28.1

Female, %

-

60.0

59.4

Prefrail or Frail, %

-

41.0

44.5

Caucasian, %

-

84.5

78.4

Diabetes, %

-

6.1

7.0

*MoCA

15-30

25.4 (3.1)

24.8 (2.8)

*MMSE

28-30

29.4 (0.6)

29.5 (0.6)

*N= 64 for MoCA and N = 26 for MMSE in Full Sample. N = 41 for MoCA and N = 24 for
MMSE in 60+ Sample.
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Table 6.2. Physical functioning characteristics.
Variable

Range

Mean (SD) or %

Mean (SD) or %

Full Sample

Full Sample

60 years +

Avg total daily minutes of
activity

682-1,318

907 (96)

896 (103)

Avg daily steps

822-24,610

6,372 (4,426)

5,173 (2,854)

Avg daily sedentary minutes

408-1,133

707 (113)

709 (123)

Avg daily light minutes

33-304

133 (51)

129 (52)

Avg daily moderate minutes

6-156

53 (30)

51 (29)

Avg daily vigorous minutes

0-132

12 (21)

7 (8)

BMI

17.4-44.2

27.4 (5.6)

27.9 (5.5)

Grip Strength, kg

11.3-50.3

29.3 (9.0)

29.1 (8.6)

Gait Test, sec.

2.1-5.6

3.3 (0.7)

3.5 (0.7)

Systolic BP,

92-198,

135 (19),

136 (19),

Diastolic BP

56-108

79 (9)

78 (8)
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Table 6.3. Lab values.
Variable

Range

Mean (SD) or %

Mean (SD) or %

Full
Sample

Full Sample

60 years +

HBA1C, %

4-7

5.4 (0.5)

5.4 (0.5)

Glucose, mg/dL

67-177

96.3 (14.3)

97.4 (14.4)

Lactate, mmol/L

0-5

1.2 (0.6)

1.2 (0.6)

Triglycerides, mg/dL

40-328

104.2 (50.9)

109.5 (51.8)

Total Cholesterol, mg/dL

111-283

179.2 (34.6)

179.1 (36.1)

HDL, mg/dL

26-124

63.7 (19.6)

62.1 (19.5)

LDL, mg/dL

30-165

94.6 (27.5)

95.1 (29.9)
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.
Figure 6.1. Example actigraphy data. An example of vector magnitude values, binned into 60
second intervals, across a single day for an Active (blue) and an Inactive (purple) individual are
plotted.
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Figure 6.2. Activity and brain metabolism measures across adulthood. Relationship between
age and (A) average active minutes per day, (B) mean rostral middle frontal CMRGlc, (C) mean
rostral middle frontal AG, and (D) mean rostral middle frontal CMRO2.
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Figure 6.3. Association between meeting PAR and brain metabolism. Values of mean rostral
middle frontal (A) CMRGlc, (B) AG, and (C) CMRO2 in those who are Active compared to
Inactive. Individual data points are color-coded by level of average daily total active minutes.
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Chapter 7

Feasibility and validation of the Ekblom-Bak
submaximal test in a diverse adult US
population.

This chapter is adapted from a manuscript under review at Frontiers in Physiology.
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7.1 Summary
Cardiorespiratory fitness (CRF) is routinely investigated in diverse populations, including in
older adults of varying physical activity levels; however, the most appropriate testing method for
evaluating CRF in this population and more diverse populations is not well
understood. Commonly performed maximal exercise testing protocols are often inadequate for
older individuals who may have physical or cognitive impairment, underestimating CRF due to
early test termination. The goal of the current study was to determine feasibility of performing
the Ekblom-Bak (EB) submaximal exercise test and validity of this method to determine CRF in
a diverse, Midwestern United States population. Fifteen individuals were included in this study
who were either “Young” (25-34 years old) or “Older” (55-75 years old) as well as either
sedentary or highly active. Participants completed the EB submaximal exercise test, followed
immediately by a maximal exercise test. We found that all fifteen individuals were able to
successfully perform the EB submaximal testing method, showing feasibility of this protocol in a
diverse population. Importantly, we observed strong correlations between the EB method
estimated volume of maximal oxygen consumption (VO2max) values and the observed VO2max
values (rrange = 0.97 - 0.98), without significant bias, as observed with Bland-Altman Plot
analyses. Our findings thus suggest that the EB method likely retains similar validity in a diverse
US cohort as has been found in Scandinavian cohorts. Future studies further assessing validity in
cognitively impaired populations will be useful for assessing utility of exercise interventions
aimed at increase CRF in this population.
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7.2 Introduction
Cardiorespiratory fitness (CRF) and physical activity are important physiological and behavioral
measures that predict health outcomes throughout the lifespan. In adulthood, poor CRF and
sedentary lifestyle are associated with risk for cardiovascular disease (Kodama et al., 2009), type
2 diabetes (Lavie et al., 2014), and Alzheimer disease (Silva et al., 2019). Improvement of CRF,
through engagement in regular physical activity, leads to a significant improvement in health
outcomes including lowering risk of all-cause mortality (Harber et al., 2017), cardiovascular
disease (Safdar & Mangi, 2020), and diabetes (Tuomilehto et al., 2001). There is now growing
interest to consider the predictive value and effects of improved CRF on brain aging and
dementia.
Assessment of maximal oxygen consumption (VO2max) during a graded exercise test is
considered the gold standard measure for evaluating CRF (Lea & Febiger, 1995). Obtaining a
true measure of VO2max, where a plateau in oxygen consumption is observed despite further
increases in intensity of exercise, is often challenging in certain populations, including older
adults, individuals with physical limitations, and with cognitive impairment. In at-risk
individuals, maximal exercise testing requires immediate oversight by a trained physician and in
some cases may not be feasible due to the increased risk of adverse events. Peak exercise testing
also requires the tested individuals to give a high level of effort and understanding of the test in
order to exercise to volitional exhaustion. Furthermore, measurement of VO2max testing
requires expensive equipment for gas analyses, which is burdensome on the clinical and research
teams to acquire and maintain. Importantly, all of these challenges might restrict cohorts that can
participate in important studies relating CRF to health and cognitive outcomes.
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Submaximal exercise testing is therefore commonly used to predict VO2max, as a proxy
measure of CRF, particularly when laboratory equipment or physician supervision is unavailable
or when the target population is unlikely to go to volitional exhaustion. Interest in the role of
maintaining CRF throughout life to help protect against age-related diseases, such as Alzheimer
disease, is rapidly increasing (Hamer & Chida, 2009; Pentikainen et al., 2019). The need to
develop and validate submaximal exercise tests that will be more reliable given a mixed
population across a wide range of age, physical functioning, and cognitive functioning thus
cannot be overstated.
Submaximal tests are typically based on heart rate response at one or more submaximal
work rates and often utilize a regression-equation method to predict VO2max. A range of
submaximal exercise testing protocols exist, which each have optimal testing populations that are
validated to have only moderate reliability and predictability (correlation coefficients of 0.520.93) of VO2max (Noonan & Dean, 2000). Furthermore, some studies suggest that submaximal
test based estimates of VO2max might be less accurate in ethnic populations (Vehrs &
Fellingham, 2006).
A recently developed Ekblom-Bak (EB) cycle ergometer test (Bjorkman et al., 2016;
Ekblom-Bak et al., 2014) for prediction of VO2max is low-risk, easy to administer, and shown to
be valid for a wide range of aerobic capacities and ages (Vaisanen et al., 2020). The initially
reported (Ekblom-Bak et al., 2014) association between estimated and observed VO2max using
the EB method was r = 0.91, and showed significant improvements on corresponding coefficient
of variation (9.3%) compared to the Åstrand-Rhyming method (18.0%). The EB test has been
further recently tested in an older population showing good agreement with maximal test
VO2max estimates, which further improved when applying the EB equation designed for women
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to both sexes. While these results are highly promising for use of the EB method in aging
studies, they were performed in a Scandinavian population and may or may not be replicable in
other ethnic populations.
The goal of the current study was to determine feasibility and validity of the EB method
in a Midwestern United States population of diverse races, ages, including “Young” (25-34
years old) and “Older” (55-75 years old) individuals, and physical active levels.

7.3 Methods
7.3.1 Participants
The Washington University in St. Louis Institutional Review Board approved all study
procedures, and informed consent was obtained from all individual participants. Fifteen
individuals recruited from a larger pilot study focused on cardiorespiratory fitness and brain
metabolism were included in this small validation study based on completion of both
submaximal EB and maximal exercise tests. Participants were screened and deemed eligible
based on age (either 25-34 years old or 55 years or older) and current self-reported physical
activity levels on the International Physical Activity Questionnaire (IPAQ; either Sedentary
[MET minutes/week <1000] or Active [MET minutes/week > 3000]) (Booth, 2000). Individuals
were excluded from maximal exercise testing for any of the following: documented
cardiovascular disease, type 1 or 2 diabetes mellitus, self-reported body mass index > 35, and
severe untreated hypertension (>200/100mmHg). Further, a study physician reviewed a
screening electrocardiogram (ECG) prior to the testing.
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7.3.2 Submaximal exercise test
Participants were instructed not to perform any heavy or prolonged physical activity the day
before or on the day of the test. Participant body mass and height were obtained upon arrival to
the testing center. The participants were informed of test procedures and equipped with 12-lead
continuous ECG.
Tests were conducted on a recumbent cycle ergometer (Lode, The Netherlands) with
continuous 12-lead ECG monitoring (General Electric, Case, V6.73). Participants were
instructed to pedal at a cadence of 60 RPM for the duration of the test. The test consisted of an
initial stage at a fixed work rate of 30 W for four minutes, directly followed by a higher
individualized work rate that varied between 60-200 W. The individualized work rate was
subjectively chosen by the test leader (SAS) with regards to gender, age, training background
and current engagement in physical activity. Mean HR was recorded during the last minute of
each work rate calculated as the average of the heart rate recorded at 3:15, 3:30, 3:45, and 4:00
minutes. Participants reported a Borg rating of perceived exertion (RPE) during both stages of
the test, with the goal of reaching 13-15 during the second stage of testing.
VO2max was predicted using the EB prediction equation (Bjorkman et al., 2016) for
women and men separately. For women, the equation used was ln VO2max = 1.84390 – 0.00673
x age – 0.62578 (∆HR/∆PO) + 0.00175 x (∆PO) – 0.00471 x HR at initial work rate. Where the
difference in HR between the high and initial work rate is denoted as ΔHR and the difference in
work rate between the high and initial work rate ∆PO. For men the equation used was ln
VO2max = 2.04900 − 0.00858 x age − 0.90742 x (∆HR/∆PO) + 0.00178 x ∆PO − 0.00290 x HR
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at initial work rate. After entering the corresponding values into the equation, VO2max (in L min1

) was estimated by putting in the obtained value as an exponent in the natural logarithm.

7.3.3 Maximal exercise test
Maximal exercise testing was performed on the same recumbent cycle ergometer (Lode, The
Netherlands) with continuous 12-lead ECG monitoring following the submaximal test.
Participants were allowed a short break of 5 minutes after the end of the submaximal exercise
test. Participants were instructed to pedal at a cadence of 60 RPM for the duration of the test. The
work rate started between 20 and 30 W and increased by 20 W every minute until an RPE of 15
was reached, after which work rate was increased by 10 W every minute until volitional
exhaustion. Continuous measurements of oxygen uptake (VO2), carbon dioxide production, and
minute ventilation were obtained using a metabolic cart and two-way non-rebreathing valve
(ParvoMedics TrueOne, Sandy, UT). The system was calibrated prior to each test using standard
gases with known concentrations and with a calibrated three-liter syringe. Maximum effort was
determined based on the American College of Sports Medicine criteria (ACSM, 2014) that
require meeting at least two of the following: (1) respiratory exchange ratio ≥ 1.1, (2) change in
VO2 < 200 ml with an increase in work, (3) rating of perceived exertion of 17 or greater, and (4)
achieving at least 90% of age predicted maximal heart rate.

7.3.4 Statistics
Pearson correlation coefficients were calculated between the estimated and measured VO2max L
min-1and mL kg-1 min-1.To determine whether validity was different for different demographics,
Pearson correlation coefficient for continuous demographic variables (VO2max and maximal
HR) or t-test and Cohen’s d effect sizes for categorical demographic variables (age
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dichotomized, self-rated physical activity dichotomized, and gender) were used to compare the
difference of estimated and measured VO2max mL kg-1 min-1 and demographic variables of
interest. Age and self-rated physical activity were considered as dichotomous variables due to the
bimodal distribution introduced by our recruitment criteria.
Lastly, while correlations test the relationship between estimated VO2max and measured
VO2max, we additionally performed a Bland-Altman plot analysis to evaluate bias between the
mean differences, and to estimate an agreement interval, within which 95% of the differences of
the estimated VO2max, compared to the measured VO2max, fall. Limits of Agreement (LoA)
were calculated using the equation: mean of the difference between estimated and measured
VO2max ± 1.96 multiplied by the SD of difference between the measured and estimated
VO2max. R software version 3.5.0 was used for the statistical analyses.

7.4 Results
Participant characteristics are presented in Table 7.1. The age and self-reported physical activity
ranges for the participants were 25-73 years and 198 - 25,992 MET minutes per week,
respectively. All 15 individuals were able to fully tolerate and complete both the submaximal
and maximal exercise tests and met ACSM criteria for maximal effort on the latter test.
In our diverse sample, there was good agreement between the estimated VO2max by the
EB test equation with respect to measured VO2max (r = 0.97, p = 3.80 x 10-9 and r = 0.98, p =
1.51 x 10-10 for L min-1 and mL kg-1 min-1, respectively; Figure 7.1).

176

The absolute difference between measured and estimated VO2max L min-1 were not
associated with maximal HR (r = - 0.30, p = 0.271), age (d [95% CI] = -0.03 [-1.3 to 1.2], p =
0.968), gender (d [95% CI] = -0.23 [-0.91 to 1.37], p = 0.705), nor VO2max L min-1 (r = -0.48, p
= 0.07). Self-reported physical activity (d [95% CI] = 1.40 [-2.67 to – 0.14], p = 0.019) was,
however, associated with a difference between measured and estimated VO2max L min-1 levels.
As shown in Figure 7.2, the upper and lower LoA for L min-1 was -0.06 and -0.91,
respectively, and for ml kg-1 min-1 was -1.06 and -11.29, respectively. The mean bias between the
estimated and measured VO2max was -0.48 for L min-1 and -6.17 for ml kg-1 min-1.

7.5. Discussion
The current study was aimed at examining the feasibility and validity of the Ekblom-Bak
submaximal exercise test in a small diverse cohort typical of a Midwestern United States
community. We found that all fifteen individuals were able to perform the EB submaximal
testing method without issue, showing feasibility of this protocol in a diverse population.
Importantly, we observed strong correlations between the EB method estimated VO2max values
and the observed VO2max values (rrange = 0.97 - 0.98), without significant bias, as observed with
Bland-Altman Plot analyses. Our findings thus suggest that the EB method is a valid method to
estimate VO2max in a representative US cohort.
Prior submaximal testing protocols have only moderate validity in predicting VO2max,
including a 12-minute walk test (McGavin, Gupta, & McHardy, 1976), 1-mile Rockport Fitness
Test (Kline et al., 1987), and Åstrand and Ryhming Cycle Ergometer Test (P. O. Astrand &
Ryhming, 1954), with reported correlations between measured and estimated VO2max of 0.52,
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0.93, 0.71, respectively (I. Astrand, 1960; Kline et al., 1987; McGavin et al., 1976). The Åstrand
test is one of the most commonly used submaximal cycle ergometer tests and utilizes the heart
rate response to one submaximal work rate. This test has been validated for a population up to
only 65 years old. In comparison, the EB showed to have the highest prediction validity in the
current study population, highlighting the EB method as potentially a superior method versus
other submaximal methods.
However, similar to our findings that self-reported physical activity was associated with
difference between measured and estimated VO2max L min-1 levels, prior studies (Bjorkman et
al., 2016; Vaisanen et al., 2020) have found that individuals with lower CRF levels are more
likely to have overestimated VO2max values on EB method. One possible explanation of the
increased frequency of the EB method overestimating the observed VO2max in low CRF and
sedentary individuals could reflect the order of the submaximal and maximal testing procedures.
For consistency and safety reasons, the submaximal testing was always performed immediately
before the maximal exercise testing. It may be that individuals who have lower CRF and are less
active are challenged more by performing two exercise tests in a row, compared to the high CRF
and highly active individuals. This discrepancy could lead to a biased underestimation of the
observed VO2max in this sedentary population. However, we investigated this in our sample and
found neither physical activity level nor CRF level (observed VO2max) was associated with
percent of age-predicted HR (220-age) or respiratory exchange ratio (RER) at peak effort during
maximal exercise test, suggesting all participants performed similarly valid maximal exercise
tests. Nonetheless, future validation studies might consider performing multiple submaximal and
maximal tests, in varying order, in individuals with a range of age and fitness levels.
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These findings advance the existing body of literature suggesting submaximal exercise
tests, including the EB method, are a feasible and valid method for estimation of VO2max and
assessment of CRF across adulthood, genders, and physical activity levels. A limitation of this
study is its small sample size, which precludes precise estimates of validity for subgroups within
this cohort. Future studies validating the EB method in the US would be strengthened by a larger
testing sample, testing on clinical populations, longitudinal assessment, and an experimental
structure where submaximal and maximal testing procedure order is performed both ways across
age, gender, and physical activity level groupings.
The current study supports the notion that the EB method should be considered when
designing research studies and clinical interventions aimed at evaluating CRF levels, especially
in populations where maximal exercise testing is not accessible, due to equipment, physician
supervision, or physical functioning constraints or populations that are not willing or able to
perform maximal effort. Importantly, submaximal tests such as the EB method might be critical
to avoid cohort effects in studies of aging.
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Table 7.1. Background characteristics.
Characteristic

Range

Mean value (SD) or %(n)

Total

25 - 73

51.9 (16.5)

Young (n=4)

25-28

26.5 (1.7)

Older (n=11)

56-73

61.1 (5.5)

20-42

27.8 (5.9)

Female

-

60.0 (9)

Caucasian

-

86.7 (13)

198 - 25,992

7471 (8779)

198 - 900

499 (293)

4,236 - 25, 992

12,120 (8,605)

113-183 / 72-106

135.8 (21.0) / 83.5 (10.0)

103 - 179

137.0 (24.1)

Peak RPE

13 - 16

14.3 (0.9)

Estimated VO2max, L min-1

1.7 - 4.1

2.8 (0.8)

17.3 - 58.7

36.9 (12.8)

129 - 206

166.5 (24.1)

16-19

17.7 (1.0)

VO2max, L min-1

0.91 - 3.94

2.3 (0.8)

VO2max, mL kg-1 min-1

11.9 - 51.7

30.7 (13.2)

Age, years

Body Mass Index

Self-report PA, MET-min/week
Total
Sedentary (n=6)
Active (n=9)
Resting Sys/Dia BP
Submaximal Exercise Test
Peak HR, BPM

Estimated VO2max, mL kg-1 min-1
Maximal Exercise Test
Peak HR, BPM
Peak RPE
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Key: PA = Physical Activity; Sys = Systolic; Dia = Diastolic; BP = Blood pressure; HR = Heart
rate; BPM = Beats per minute; RPE = Borg Rating of perceived exertion; VO2max = maximal
oxygen consumption.
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Figure 7.1. Correlation between estimated and measured VO2max. The submaximal EkblomBak method estimate of VO2max compared to the measured maximal VO2max L min-1 (A) and
mL kg-1 min-1 (B). Linear regression equation for interpretation of intercept and slope are
presented where measured VO2max is the dependent variable and estimated VO2max is the
independent variable. Pearson correlation coefficient and p-value are reported for each
association examined. Shading represents 95% confidence interval. Individuals are coded by
gender, age (Young = 25-28 years old; Older = 56-73 years old), and current physical activity
level (Sedentary = 198 – 900 MET-minutes/week; Active = 4,236 - 25, 992 METminutes/week).
Key: VO2max = maximal oxygen consumption; Sed = Sedentary.
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Figure 7.2. Bland-Altman Plot. Bland-Altman Analyses Plot between differences in estimated
and measured VO2max compared to mean VO2max in L min-1 (A) and mL kg-1 min-1 (B).
Horizontal lines represent mean bias (black line), upper Limit of Agreement (blue line), lower
Limit of Agreement (red line). Shaded areas represent 95% confidence intervals around mean
bias (grey), upper Limit of Agreement (blue), and lower Limit of Agreement (red). Individuals
are coded by gender, age (Young = 25-28 years old; Older = 56-73 years old), and current
physical activity level (Sedentary = 198 – 900 MET-minutes/week; Active = 4,236 - 25, 992
MET-minutes/week).
Key: VO2max = maximal oxygen consumption; Sed = Sedentary.
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Chapter 8

Association between personality and tau-PET
binding in cognitively normal older adults.

This chapter is adapted from a manuscript published in Brain Imaging and Behavior.

Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Morris, J. C., Ances, B. M., Duchek, J. M.,
Balota, D. A. and Benzinger, T. L. S. (2019) 'Association between personality and tau-PET
binding in cognitively normal older adults', Brain Imaging Behav.
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8.1 Summary
Personality traits such as Neuroticism and Conscientiousness are associated with Alzheimer
disease (AD) pathophysiology in cognitively normal (CN) and impaired individuals, and may
represent potential risk or resilience factors, respectively. This study examined the crosssectional relationship between personality traits and regional tau deposition using positron
emission tomography (PET) in cognitively normal older adults. A cohort of CN (Clinical
Dementia Rating (CDR) 0, n=128) older adults completed the NEO Five-Factor Inventory to
assess traits of Neuroticism, Extroversion, Openness, Agreeableness, and Conscientiousness and
underwent tau-PET and β-amyloid (Aβ)-PET imaging. We utilized linear regression models,
adjusting for age, sex, geriatric depression score, and Aβ to evaluate the association between
each of the personality traits and regional tau-PET accumulation. Elevated Neuroticism scores
were associated with higher tau-PET accumulation in the amygdala (p=.002), entorhinal cortex
(p=.012), and inferior temporal cortex (p=.016), as well as with a composite tau-PET measure
(p=.002). In contrast, Extroversion, Openness, Agreeableness, and Conscientiousness were not
associated with tau deposition in any of these regions (p’s >0.160). Our results indicate that
increased Neuroticism is associated with higher tau pathophysiology in regions known to be
vulnerable to AD pathophysiology in CN participants. High Neuroticism scores may therefore
serve as a potential risk factor for tau accumulation. Alternatively, personality has been shown to
change with the onset of AD, thus increased tau levels may affect Neuroticism scores. While
future longitudinal studies are needed to determine directionality, our findings suggest early
associations between Neuroticism and tau accumulation in CN adults.
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8.2 Introduction
Personality represents a stable organization of character and temperament of a person. It
can be quantified for study using personality inventories such as the Neuroticism, Extroversion,
and Openness to experience Five-Factor Inventory (NEO; Costa & McCrae, 1985). The NEO
provides estimates of Neuroticism, Extraversion, Conscientiousness, Agreeableness, and
Openness. Prior work has demonstrated ties between personality, measured by the NEO, and
physical activity (Rhodes & Smith, 2006), longevity (Friedman et al., 1993), obesity (Brummett
et al., 2006), depression (Chioqueta & Stiles, 2005), and Alzheimer disease (Duchek, Balota,
Storandt, & Larsen, 2007; Tautvydaite, Antonietti, Henry, von Gunten, & Popp, 2017). Thus, it
appears that certain personality traits are associated with both diverse health habits and health
outcomes, including AD.
For example, previous work has noted personality changes in demented individuals
(Dawson, Welsh-Bohmer, & Siegler, 2000; Petry, Cummings, Hill, & Shapira, 1988) and that
these changes may precede the clinical diagnosis of dementia (Balsis, Carpenter, & Storandt,
2005). Work by Duchek and colleagues (2007) has indicated that self-reported neurotic traits are
higher in individuals with very mild AD dementia compared with cognitively normal (CN)
adults. Similarly, in this study, they also found lower self-reported Openness to experience
scores in individuals in the very mild and mild AD dementia cohorts compared to CN controls.
Rather than being altered with the onset of impairment, a resilient personality profile may
be associated with a lower risk of developing symptomatic dementia. Specifically, Wilson and
colleagues (2007) found that individuals with a high Conscientiousness score had an 89%
reduction in their risk for AD. Another study, utilizing a meta-analytic approach (Antonio
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Terracciano et al., 2014), reported higher Neuroticism and lower Conscientiousness associated
with a threefold increased risk of AD.
Furthermore, qualities of anxiety, depression, impulsiveness, and vulnerability to stress
are often used to describe Neuroticism (John & Srivastava, 1999). These qualities may confer
risk for psychological illness and AD dementia, suggesting a possible common mechanism
linking stress, neuroticism and AD pathology. However, there remains a dearth of studies
investigating the role of personality traits as risk and resilience factors for AD within CN
cohorts.
AD is the most common form of dementia, and currently there are no successful
pharmacological interventions for preventing or combating AD pathophysiology. In turn, there
has been a new focus on non-pharmacological interventions to prevent or delay the onset of
cognitive decline. Modifiable lifestyle habits, such as engagement in cognitively-stimulating
activities (S. A. Schultz, Larson, et al., 2015) and physical activity (Barnes & Yaffe, 2011; Boots
et al., 2015; S. A. Schultz, Boots, et al., 2015), are potential approaches. These lifestyle habits
may be driven by personality traits. With the established relationship between personality and
health habits and disease (Brummett et al., 2006; Chioqueta & Stiles, 2005; Friedman et al.,
1993; Rhodes & Smith, 2006), personality may represent an identifier of those who may benefit
most from lifestyle interventions aimed at altering the trajectory of pathological aging in
individuals.
Neuroimaging techniques have been implemented in prior studies to investigate the
relationship between personality traits and AD-related neuropathology. A prior study (Jackson,
Balota, & Head, 2011) has shown that there are associations between Neuroticism and
Conscientiousness and cortical volumes in CN individuals, such that higher Neuroticism and
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lower Conscientiousness scores corresponded to lower cortical volumes. Additionally, recent
work (Tautvydaite, Antonietti, et al., 2017; Tautvydaite, Kukreja, et al., 2017) has evaluated the
relationship between personality and in vivo cerebrospinal fluid levels of amyloid-beta (A) and
tau in a heterogeneous sample of older adults with and without dementia. Others have reported
that CSF AD biomarkers are associated with increases in Neuroticism and decreases in
Conscientiousness, further bolstering the link between personality traits and AD (Tautvydaite,
Antonietti, et al., 2017).
Prior work using in vivo imaging has also demonstrated that tau, rather than Aβ, is more
strongly tied to proximal measures of cognition and symptomatic AD (Matthew R. Brier et al.,
2016). Importantly, pathologic tau begins to accumulate in asymptomatic individuals (A. J.
Aschenbrenner, B. A. Gordon, T. L. S. Benzinger, J. C. Morris, & J. J. Hassenstab, 2018; S. A.
Schultz et al., 2018). The introduction of tau-PET ligands that bind to neurofibrillary tangles
(NFT)(Johnson et al., 2016) provide a new in vivo biomarker of tau pathology. The association
between personality and PET measures of tau pathophysiology in cognitively normal (CN)
individuals remains unexamined. Therefore, this study examined the cross-sectional relationship
between personality traits, focusing on Neuroticism and Conscientiousness, and regional tauPET deposition, as well as the stability of the personality traits over time in CN older adults.

8.3 Methods
8.3.1 Participants
Data from 128 participants from local studies at the Knight Alzheimer Disease Research Center,
Washington University in St Louis (including the Adult Children Study and the Healthy Aging
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and Senile Dementia Study) were used. Inclusion criteria included: having undergone Aβ- and
tau-PET scans, completion of a personality assessment, and Geriatric Depression Scale (GDS),
and normal cognition (defined by having a Clinical Dementia Rating (CDR) score of 0 at the
visit closest to the personality assessment)(J. C. Morris, 1997). The Washington University in St.
Louis Institutional Review Board approved all procedures and each participant provided signed
informed consent for the study.

8.3.2 Personality measure
A shortened version of the Revised NEO Personality Inventory (NEO-PI-R) called the NEO Five
Factor Inventory Test (NEO-FFI) was administered to each participant (P. T. Costa & McCrae,
1992b). This 60-item questionnaire measures the personality traits within five factors:
Neuroticism, Extraversion, Openness, Agreeableness and Conscientiousness. Every item is rated
on a 1-5 scale from ‘strongly agree’ to ‘strongly disagree’. The NEO-FFI is a commonly used
personality trait questionnaire, which is highly correlated with the full-length Revised NEO
Personality Inventory and has strong internal consistency (P. T. Costa & McCrae, 1992b). The
descriptive statistics for the NEO-FFI factors are presented in Table 8.1. The mean scores on the
NEO-FFI for the present sample are consistent with mean scores obtained from a similar adult
sample (Duchek et al., 2007). Neuroticism and Conscientiousness are our personality factors of
primary interest; Extraversion, Openness, and Agreeableness are included for completeness.
Additionally, a subset of our cohort had two or more total NEO-FFI assessments (N=113),
collected prior to the tau-PET imaging, which were used to determine the stability of the
personality measures.
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8.3.3. MRI
Imaging data were acquired on a Siemens Biograph mMR (n=125) or Trio 3T scanner (n=3). T1weighted images were acquired using a magnetization prepared rapid acquisition gradient echo
(MPRAGE) sequence with repetition time = 2300 ms, echo time = 2.95 ms, flip angle = 9°, 176
slices, in plane resolution 240 x 256, and slice thickness = 1.2 mm acquired in sagittal
orientation. Images underwent volumetric segmentation using FreeSurfer 5.3
(http://freesurfer.net) (Fischl et al., 2004) and Desikan Killany atlas to identify regions of interest
(ROIs) used in the PET analyses.

8.3.4 PET imaging
Tau-PET
Tau-PET imaging was performed using 18F-AV-1451 (flortaucipir), a radioligand that
preferentially binds to neurofibrillary tau. Scans were acquired on a PET/CT scanner. Data were
processed using a Freesurfer ROI approach as done in prior work using flortaucipir (M. R. Brier
et al., 2016; B. A. Gordon et al., 2016; S. A. Schultz et al., 2018; L. Wang et al., 2016). In each
ROI, data from the 80–100 minute post-injection window were converted to standardized uptake
value ratio (SUVRs) using the cerebellar grey matter as the reference region and partial volume
corrected using a regional spread function approach (Su et al., 2015). We focused on bilateral
SUVR averages from FreeSurfer ROIs including the entorhinal cortex, amygdala, inferior
temporal cortex, and lateral occipital regions (Figure 8.1a), which have previously been
identified as the regions that best discriminate CN participants from those with preclinical AD
(Mishra et al., 2017). For our main analyses, a summary composite measure was created using
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the average across these four regions. The average time between NEO-FFI assessment and tauPET imaging was a mean (SD) of 3.44 (3.31) months.
Aβ-PET
Participants underwent Aβ-PET imaging with 18F-AV-45 (florbetapir). Scans were acquired on a
PET/MR scanner and attenuation corrected with corresponding PET/CT. FreeSurfer ROI data
between the 50–70 minute post-injection window were converted to SUVRs using the cerebellar
grey matter as the reference region and partial volume corrected using a regional spread function
approach (Su et al., 2013). As previously described, a summary Aβ deposition measure which
represents regions with earliest Aβ burden was created using the average across the left and right
ROIs from FreeSurfer areas corresponding to the lateral orbitofrontal, medial orbitofrontal,
rostral middle frontal, superior frontal, superior temporal, middle temporal, and precuneus
regions (Figure 8.1b) (Su et al., 2016; Su et al., 2013). The summary Aβ deposition measure
was treated as a continuous measure. For descriptive purposes only we split our sample based on
a partial volume corrected florbetapir SUVR cutoff of 1.22 (S. A. Schultz et al., 2018). The
average time between NEO-FFI assessment and Aβ-PET imaging was a mean (SD) of 4.12
(5.91) months.

8.3.5 Statistical analyses
Association between tau-PET and personality
First, to determine whether there were global associations between tau-PET and each of the
personality traits (Neuroticism, Extraversion, Openness, Agreeableness and Conscientiousness),
we fitted a linear regression model for the composite tau-PET measure with each of the five
personality factors as the independent variable of interest. Additionally, all models included
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covariates for age, sex, and GDS. We included GDS as a covariate in order to ensure that people
with high Neuroticism and low Conscientiousness don’t primarily have more tau deposition due
to depressive symptoms.
Next, to determine where there were region-specific effects of personality on NFT
burden, we repeated our analyses for each of the four individual regions that comprise the
composite tau-PET measure, including the entorhinal cortex, amygdala, inferior temporal cortex,
and lateral occipital region, with each of the five personality factors as the independent variable
of interest.
Association between Aβ-PET and personality
Since the relationship between Aβ and personality in AD as well as Aβ load and tau levels in AD
have been reported in previous studies (S. A. Schultz et al., 2018; Tautvydaite, Antonietti, et al.,
2017) we evaluated the relationship between Aβ and personality. We fitted a linear regression
model for the composite Aβ-PET SUVR, with the independent variable of interest being each of
the five personality factors, adjusting for age, sex, and GDS. For analyses that showed an
association between Aβ-PET SUVRs and personality factors, we repeated the original linear
regression models evaluating the relationship between tau-PET and that personality factor,
including Aβ-PET SUVRs as a covariate in order to ensure that people with high Neuroticism
and low Conscientiousness don’t primarily have more tau deposition due to Aβ deposition.
Stability of NEO factors
Although we are unable to evaluate the longitudinal relationship between tau-PET SUVRs and
personality traits in our current cohort, and therefore have limited ability to infer causation, we
were able to investigate the stability of the NEO-FFI assessments in our CN study sample. To
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determine the stability of the personality measures in a subset of our cohort who had two or more
total NEO-FFI assessments (N=113) collected prior to flortaucipir imaging, we ran a linear
mixed effects model for each of the five personality factors to determine if the factors
significantly changed over time. Fixed effect terms included the time from the first NEO-FFI
assessment (in years) and a random slope and intercept terms for each participant. We
additionally examined the intraclass correlation coefficient (ICC) for each factor for the first two
NEO-FFI assessments available.
The demographics for the longitudinal cohort are reported in Table 8.1. The average
number of NEO-FFI assessments was 2.23 visits and the time interval between first and last
NEO-FFI assessment span between 2.74 and 13.53 years.
Only findings with values of p ≤ 0.05 (2-tailed) were considered significant. Crosssectional analyses and longitudinal analyses were conducted with lme4 package in R.

8.4 Results
8.4.1 Participant characteristics
Table 8.1 details the relevant characteristics of the participants. The average age of the crosssectional sample was 67.5 ± 8.7 years and 29.7% were APOE4 positive.

8.4.2 Association between composite tau-PET measure and personality
There was a significant positive association between Neuroticism and our composite measure of
flortaucipir SUVR (B=0.007, p=0.002) (Figure 8.2). There were no associations between
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Extroversion, Openness, Agreeableness, or Conscientiousness and our composite flortaucipir
SUVR measure (p’s≥0.298) (Table 8.2).

8.4.3 Association between tau-PET ROIs and personality
There were significant positive associations between Neuroticism and flortaucipir SUVR in the
entorhinal cortex (B=0.009, p=0.012), inferior temporal lobe (B=0.005, p=0.016), and amygdala
(B=0.010, p=0.002), but not in the lateral occipital cortex (B= 0.004, p=0.154) (Figure 8.2).
There were no associations between regional tau-PET SUVRS and Openness (p’s≥0.572),
Agreeableness (p’s≥0.296), Extraversion (p’s≥0.160), or Conscientiousness (p’s≥0.236) factors
(Table 8.2).

8.4.4 Association between composite Aβ-PET measure and personality
As expected, there was a strong relationship between tau-PET and Aβ-PET SUVRs, after
adjusting for age and sex, in our sample (B[SE]=0.156[.027], p=6.73e-08). Additionally, there
was a positive association between Neuroticism scores and the composite Aβ-PET SUVRs
(B[SE]=0.014 [.007], p=0.038). There was no relationship between Extroversion, Openness,
Agreeableness, or Conscientiousness and Aβ-PET SUVRs (p’s≥0.189, Table 8.2).
Next, to determine whether Aβ deposition was driving the relationship between tau-PET
SUVRs and Neuroticism scores, we repeated our analyses, with Aβ-PET SUVRs included in the
models as a covariate. After adjusting for Aβ-PET SUVRs, results remained essentially the same
for our composite measure of flortaucipir SUVR (B=0.005, p=0.018) and flortaucipir amygdala
SUVRs (B=0.007, p=0.014), but were non-significant for the entorhinal cortex (B=0.006,
p=0.104), and inferior temporal cortex (B=0.004, p=0.064).
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8.4.5 Stability of NEO factors
In a subset of our sample (N=113) with longitudinal NEO-FFI assessments, Neuroticism and
Openness scores showed a decrease over time (B=-0.140, p=0.025 and B=-0.140, p=0.003,
respectively), while Agreeableness (B=0.054, p=0.245), Extroversion (B=-0.004, p=0.927), and
Conscientiousness (B=0.013, p=0.749) scores remained stable. These results are presented in
Table 8.3 and Figure 8.3. ICC for Neuroticism, Openness, Agreeableness, Extroversion, and
Conscientiousness scores were 0.832, 0.886, 0.780, 0.887, and 0.883, respectively.

8.5 Discussion
This study showed that, in a cohort of CN older adults, Neuroticism is associated with increased
tau and Aβ levels, detected by tau- and Aβ-PET. Specifically, individuals with higher
Neuroticism scores had higher flortaucipir SUVR in regions including the amygdala, entorhinal
cortex, and inferior temporal cortex, as well as a composite measure of tauopathy. Similarly,
higher Neuroticism scores were associated with higher Aβ deposition. These relationships were
selective, as there were no associations between Agreeableness, Openness, Extroversion, or
Conscientiousness, with tau-PET or Aβ-PET SUVRs. Importantly, the relationship between
Neuroticism and tau was not driven by depressive symptoms.
Furthermore, when we re-examined the relationship between neuroticism and tau-PET
SUVRs, accounting for Aβ levels, results remained the same for select regions, including the
amygdala, with a trend towards significant for the inferior temporal cortex tau-PET SUVRs.
However, after adjusting for Aβ levels, there was no association between Neuroticism and
entorhinal tau-PET. This could suggest that Aβ may be moderating the effect of tau on
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personality traits in some regions, but not others. Larger cohort studies with sufficient ranges of
Aβ levels are needed to test the interaction between personality traits and Aβ on flortaucipir PET
SUVRs.
Initial studies from our group and others report relationships between personality traits
and cognitive functioning in older individuals with (Duchek et al., 2007) and without (Jackson et
al., 2011) dementia. For example, Duchek and colleagues (2007) examined the differences in
personality traits in the earliest stages of AD and found that informant ratings of Neuroticism,
Extraversion, Openness, Agreeableness, and Conscientiousness were able to discriminate CN
controls from individuals with very mild AD. Furthermore, informant ratings of Neuroticism and
Conscientiousness discriminated these groups as well as was associated with a composite
episodic memory measure. These results suggest that personality, including Neuroticism, may
serve as an early marker for onset of AD. Interestingly, our sample had relatively low scores for
Neuroticism, albeit within a normal range, suggesting the associations could be even more
pronounced if the cohort had higher levels of Neuroticism.
Additionally, in a more recent study, Jackson and colleagues (2011) have examined the
relationship between personality traits and common pathophysiological features of cognitive
dysfunction and dementia, including grey and white matter volumes. They found that higher
Neuroticism was associated with smaller regional volumes and greater decreases in volume with
advancing age, and conversely, higher Conscientiousness was associated with larger regional
volumes and less decline in volumes with aging. While these results and others (Zufferey et al.,
2017) point to a potential detrimental effect of Neuroticism on age-related volume loss in CN
individuals a major limitation of these past studies is that they did not screen for presence of AD-
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related pathology including Aβ or tau, which are known to accumulate in the brain decades
proceeding any cognitive deficits in healthy control individuals.
Animal models have shown that prolonged stress, a trait of individuals with high
neuroticism, has negative effects on neural integrity, particularly in medial temporal lobe regions
such as the hippocampus and amygdala. Specifically, chronic stress has been shown to lead to
dendritic atrophy, synaptic loss, and suppression of neurogenesis in the hippocampus (Radley &
Morrison, 2005) and alterations of limbic connectivity (Poeggel et al., 2003). In human studies,
results suggest that stress and anxiety may confer risk for psychological illness and dementia
through interaction with the hypothalamus-pituitary-adrenal (HPA)-axis. The HPA axis is
required for stress adaptations and mechanisms involved in regulating function of the HPA axis
and sensitivity to stress include the amygdala and medial temporal regions such as hippocampus
and entorhinal cortex (Herman et al., 2016). Similar to animal studies mentioned above these
limbic and medial temporal regions have been shown to be vulnerable to negative effects of
abnormal HPA axis functioning in humans (Valli et al., 2016).
The results of our study highlight region-specific associations of higher Neuroticism with
higher in vivo tau-PET SUVRs bilaterally in the amygdala, entorhinal cortex and inferior
temporal cortex, which are HPA axis-associated brain regions. Since these regions are known to
be the most sensitive to early accumulation of tau, it may be that chronic stress, expressed by a
neurotic personality, creates region-specific vulnerability for future tauopathy. However,
intricate molecular and behavioral animal and human translational studies are needed to explore
this mechanism in further detail. Furthermore, PET tracer limitations, including non-specific offtarget binding, make it difficult to disentangle the associations between Neuroticism and tau
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within subcortical structure of HPA-associated areas including hypothalamus and pituitary
regions in vivo.
A limitation of this study is the cross-sectional nature of the imaging data therefore we
cannot determine causality. Prior work has shown that personality measures are stable over time
(P. T. Costa & McCrae, 1992a, 1992b), but this may not be true in the case of pathological aging.
However, a recent study in the Baltimore Longitudinal Study of Aging cohort (A. Terracciano,
An, Sutin, Thambisetty, & Resnick, 2017) analyzed longitudinal personality trait data from over
2,000 individuals and examined whether the trajectory of personality traits was dependent on
conversion to MCI or dementia from baseline. They found that MCI and AD individuals had
higher mean levels of Neuroticism and lower Conscientiousness, compared to non-impaired
older adults. Importantly, personality traits remained stable even in those who converted to MCI
or dementia; there were no differences in trajectory of personality traits in individuals who
converted to MCI or dementia, compared to non-impaired older adults. These data suggest that
personality changes do not occur as a function of underlying proteinopathy, and that personality
changes may not be a useful tool in identifying individuals at risk for conversion. Instead, these
data, and results from the current study suggest cross-sectional assessment of personality traits
may provide indicators of individuals who may be at increased risk for developing dementia.
We do not yet have enough longitudinal tau-PET data to directly compare change in tau
pathophysiology to change in personality factors in our cohort. Therefore, we are unable to infer
causality of the cross-sectional results we report. However, we do have longitudinal NEO-FFI
assessments, collected prior to the tau-PET data, and examined whether the personality traits
changed over time. Using a linear mixed effects model, Neuroticism and Openness decreased
over time, while Extroversion, Agreeableness, and Conscientiousness remained stable, in our
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subset of individuals with longitudinal data. However, with our small sample size, the change of
over time may be partially due to noise. In contrast, when comparing our longitudinal
assessments with an ICC, all of the NEO-FFI appeared relatively stable. Personality traits,
including Neuroticism, have been reported to decrease with advancing age in some (Donnellan &
Lucas, 2008; A. Terracciano, McCrae, Brant, & Costa, 2005), but not all (P. J. Costa & RR,
1988) prior studies. Larger samples and samples with concurrent longitudinal tau measures are
needed to better understand the implications of decreasing neuroticism on tau pathophysiology in
CN adults.
Overall, the present study provides evidence for a link between Neuroticism and tau
deposition in CN individuals, independent of depressive symptoms or Aβ burden. While others
have reported associations between Neuroticism and cognitive decline and dementia, our
findings suggest that Neuroticism is associated with early pathophysiologic features of
neurodegenerative diseases, including AD. While we cannot draw strong conclusions regarding
causation in this study, our findings, in the context of the literature, suggest that Neuroticism is
related to tau burden in the absence of cognitive impairment. This work makes a critical
contribution to the efforts to determine the risk and resilience of AD-related pathophysiology
that certain personality traits confer.
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Table 8.1. Participant characteristics.
Characteristic

Value

Cross-sectional cohort (N=128)
Age, Years

66.7 (8.1)

Female, %

60.9

APOE4 positive, %

32.5

Mini Mental State Exam§⌃

29.4 (0.9)

Geriatric Depression Scale*

0.98 (1.3)

Summary tau-PET SUVR,

1.12 (0.2)

Summary beta-amyloid-PET SUVR

1.15 (0.5)

beta-amyloid- positive, % (n)

21.0 (27)

NEO Factors, raw score (SD), T score
Neuroticism†

13.6 (7.5), 42.9

Extroversion†

30.2 (6.3), 54.3

Agreeableness†

35.5 (5.2), 55.4

Conscientiousness†

35.3 (6.1), 51.2

Openness†

29.3 (5.9), 53.9

Age, Years

67.6 (7.7)

Female, %

61.9

APOE4 positive, %

31.9

Longitudinal Subset (N=113)

Mini Mental State Exam§
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29.4 (0.9)

Geriatric Depression Scale*

0.89 (1.1)

Summary tau-PET SUVR

1.19 (0.2)

Summary beta-amyloid-PET SUVR

1.18 (0.6)

NEO Factors, raw score (SD), T score
Neuroticism†

13.6 (7.4), 42.9

Extroversion†

30.3 (6.4), 54.5

Agreeableness†

35.5 (5.1), 55.4

Conscientiousness†

35.3 (6.1), 51.2

Openness†

29.1 (6.1), 53.9

Number of NEO assessments, N (%),
2/3/4/5/6/7

40 (35)/ 28 (25)/ 25 (22)/ 18 (16)/ 1 (1)/ 1
(1)

Characteristics reported for cross-sectional sample are from study visit closest in time to the tauPET imaging date. Characteristics reported for the subset with longitudinal data are from the
baseline study visit. Mean (SD) is presented unless otherwise noted.
scores are on scale of 0-60; § Scored on a scale of 0-30; * Scored on a scale of 0-10; ⌃Note
that from 2 participants APOE4 genotype was not available.
† Raw
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Table 8.2. Association between tau-PET and personality traits.
Composite
Tau

Amygdala
Tau

Entorhinal
Tau

Inferior
Temporal
Tau

B
(SE)

B
(SE)

B
(SE)

NEO Factor
B
(SE)

p

p

p

p

Lateral
Occipital
Tau
B
(SE)

p

Composite
Aβ
B
(SE)

p

Neuroticism

.007
(.002)

0.002

.010
(.003)

0.002

.009
(.004)

0.012

.005
(.002)

0.016

.004
(.003)

0.154

.014
(.007)

0.038

Extroversion

-.002
(.003)

0.417

-.005
(.004)

0.218

.002
(.004)

0.693

-.003
(.002)

0.160

-.002
(.003)

0.422

-.002
(.002)

0.491

Openness

-.0004
(.003)

0.894

.002
(.004)

0.572

-.002
(.005)

0.704

-.001
(.002)

0.559

-.0004
(.003)

0.891

.002
(.002)

0.512

Agreeableness

-.002
(.003)

0.484

-.005
(.005)

0.296

-.001
(.005)

0.844

-.002
(.003)

0.475

-.001
(.004)

0.759

.001
(.003)

0.612

Conscientiousness

-.003
(.003)

0.298

-.004
(.004)

0.327

-.003
(.005)

0.236

-.001
(.002)

0.785

-.001
(.003)

0.654

-.002
(.002)

0.308

Association between each of the five personality traits and composite or regional tau-PET SUVR
and composite Aβ-PET SUVR levels. Unstandardized regression coefficients (B) and p-values
correspond to multivariate models, adjusted for age, sex, and geriatric depression scale score.
Key: PET= Positron emission tomography; SUVR= Standardized uptake value ratio.
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Table 8.3. Stability of NEO factors.
NEO Factor

B (SE)

p

Neuroticism

-0.140 (.061)

.025

Conscientiousness

0.013 (.039)

.749

Openness

-0.140 (.037)

<.001

Extroversion

-0.004 (.046)

.927

Agreeableness

0.054 (.046)

.245

Change in personality traits over time. Unstandardized regression coefficients B values and pvalues from linear mixed effects model. Fixed effect terms included the time from the first NEO
assessment (in years), and random slope and intercept terms, for each participant.
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Figure 8.1. Regions of interest. Selected regions of interest included in the composite tau-PET
measure (a), and Aβ-PET measure (b).
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Figure. 8.2. Association between Neuroticism and regional tau-PET. Covariate-adjusted
residuals from linear regression models examining the relationship between Neuroticism and tauPET SUVR in the composite (a), amygdala (b), inferior temporal cortex (c), entorhinal cortex
(d), and lateral occipital cortex (e).
Key: PET= Positron emission tomography; SUVR= Standardized uptake value ratio.
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Figure 8.3. Neuroticism and Openness decrease over time. Spaghetti plot showing longitudinal
Neuroticism (a), Conscientiousness (b), Openness (c), Extroversion (d), and Agreeableness (e)
scores over time.
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Chapter 9
Conclusions
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9.1 Summary: Overall
Pathophysiological brain changes that occur during normal aging and in neurodegenerative
diseases, such as AD, can begin several decades prior to overt cognitive symptoms or the
diagnosis of clinical dementia (J. C. Morris, 2005). The vast majority of adults will experience
age- and disease-related alterations in cognition driven by pathological changes in the brain.
Importantly, the advent of neuroimaging and fluid biomarkers to study structural, protein, and
metabolic brain changes now permits in vivo identification and monitoring of these of complex
process throughout adulthood. Investigating biomarkers throughout adulthood uniquely allows us
to understand how proteins in specific pathways are temporally and spatially related to one
another, and to the eventual manifestation of cognitive decline and disease symptoms. To this
end, there has been an emergence of several novel biomarkers to study healthy aging and agerelated neurodegenerative diseases including in vivo assessments of tau/neurofibrillary tangle
burden and brain metabolism via positron emission tomography (PET) imaging and neurofilament
light chain (NfL), a marker of neurodegeneration, via fluid biomarkers.
Additionally, there is a need to develop interventions that delay or prevent age- and
disease-related cognitive decline and pathological brain changes. Unfortunately, currently
available drugs for AD only treat AD symptoms and do not alter the course of further
pathophysiological changes. Furthermore, findings from clinical trials testing disease-modifying
therapeutics have been unsuccessful. Physical activity is important physiological and behavioral
measures that predict health outcomes throughout the lifespan. In adulthood, a sedentary lifestyle
increases an individual’s risk for cardiovascular disease. There is now growing interest to
consider the predictive value and effects of improved fitness on brain aging and dementia.
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The overall goal of my thesis research was to gain an understanding of emerging biomarkers in
field of healthy aging and Alzheimer’s disease (AD) and apply this knowledge to evaluate the role
of physical activity and personality traits in aging and AD. Therefore, my objectives were to
evaluate (1) first- and second-generation PET tracers developed to measure neurofibrillary tangles
in vivo, (2) cerebrospinal fluid (CSF) and blood-based measurements of NfL protein, and (3) multitracer PET measurements for assessment of brain metabolism. Secondarily, I aimed to utilize goldstandard techniques to examine effects of objectively-measured physical activity engagement and
established personality trait assessments on brain pathophysiology related to aging and AD using
these emerging biomarkers.

9.2 Summary: Tau-PET
Results from my thesis work have demonstrated the importance of utilizing tau-PET tracers
to identify early neurofibrillary tangle pathology in older adults, showing that there is widespread
neurofibrillary tangle accumulation in cognitively normal individuals who have increased betaamyloid deposition, a hallmark feature of AD, compared to individuals void of beta-amyloid
pathology. Additionally, I furthered the field’s understanding of an emerging second-generation
tau-PET tracer, MK-6240. My work resulted in the discovery of visually-identified neurofibrillary
tangle distribution patterns (subtypes) that relate to distinct cognitive performance deficits. Next
steps include characterizing whether and to what extent these subtypes accumulate additional NFT
pathology and cognitive symptoms over time. Additionally, further work is needed to complete a
head-to-head comparison of these first- and second- generation tau-PET tracers.
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9.3 Summary: Blood-based NfL
Next, NfL has emerged as a promising fluid biomarker of disease progression for various
cerebral proteopathies. In collaboration with Dr. Mathias Jucker at the University of Tuebingen in
Germany, I translated initial work performed in an APP/PSEN1 mouse model showing increases in
blood-based measures of NfL are a reflection of AD-related neurodegeneration, into a human
population with an autosomal dominant form of AD. I leveraged the unique characteristics of the
Dominantly Inherited Alzheimer Network (DIAN) and ultrasensitive immunoassay technology
to demonstrate that NfL levels in cerebrospinal fluid (CSF) (n=187) and serum (n=409) are
strongly correlated and increase already at presymptomatic stages of AD. Longitudinal withinperson analysis of serum NfL (n=330) confirmed the increase at presymptomatic disease stages
and, strikingly, revealed that rate of change of serum NfL could discriminate mutation carriers
from the non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels
(i.e. 16.2 vs. 6.8 years before estimated symptom onset). Serum NfL rate of change peaked in
subjects converting from the presymptomatic to the symptomatic stage. The tight association of
serum NfL rate of change with cortical (precuneus) thinning (MRI), but less so with Aβ
deposition or glucose metabolism (assessed by PET) underlines serum NfL utility as a marker for
brain neurodegeneration. Retrospectively, but also prospectively, serum NfL was predictive for
the rate of cortical thinning and cognitive changes assessed by mini-mental state examination
and logical memory assessment. In conclusion, I found that NfL changes in serum predict
disease progression at a very early presymptomatic stage and will become important for subject
enrichment and outcome of clinical AD trials and likely also other cerebral proteopathies.
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In this initial study we showed NfL is likely reflecting neurodegeneration. However,
there have been limited investigations relating NfL to concurrent measures of white matter
(WM) decline that it should reflect. In a follow-up study I wanted to investigate the relationship
between NfL and in vivo measures of WM health in same DIAN cohort.
I hypothesized that serum levels of NfL would associate with WM lesion volume and
diffusion tensor imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation
carriers (MC) compared to 84 non-carrier (NC) familial controls as well as in a subset (N=41) of
MC with longitudinal NfL and MRI data.
I found that in MC elevated cross-sectional NfL was positively associated with WM
hyperintensity lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and
negatively with fractional anisotropy. Greater change in NfL levels in MC was associated with
larger changes in fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of
reduced WM integrity. These results demonstrate that blood-based NfL levels reflect WM
integrity and supports the view that blood levels of NfL are predictive of WM damage in the
brain. This is a critical result in improving the interpretability of NfL as a marker of brain
integrity, and for validating this emerging biomarker for future use in clinical and research
settings across multiple neurodegenerative diseases.

9.4 Summary: Multi-tracer PET for brain metabolism
Lastly, AG is an emerging biomarker measured via multi-tracer PET, of a group of
metabolic functions, which includes biosynthesis of glycogen, proteins, lipids, and nucleic acids;
and neuroprotection. Metabolic dysfunction appears to be a prominent feature of AD and is
known to occur early in the disease process. Recent studies suggest that a specific component of
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brain glucose metabolism, that which is outside of oxidative phosphorylation (referred to as AG),
not only plays an important role in brain function, but also carries with it a risk for AD. In an
initial study, in collaboration with Dr. Manu Goyal and Dr. Andrei Vlassenko, we enrolled 90
individuals between the ages of 25 and 85 years old. Individuals underwent intensive multi-tracer
positron emission tomography to evaluate total glucose use (CMRglc), oxygen metabolism
(CMRO2), and AG, which were normalized to literature-based whole brain metabolism
estimates. We found that there was age-related decrease in CMRGlc and AG in a specific region
of interest, the rostral middle frontal gyrus. In contrast, age was not related to CMRO2.
Additional ongoing research is extending these results to a longitudinal design of cognitively
normal and impaired individuals.

9.5 Summary: Physical activity and brain metabolism
The brain retains the potential for neuroplasticity throughout adulthood and it is possible
that maintained utilization glycolytic metabolism is a proxy for measuring a component of this
neuroplasticity. Prior research in mouse models and humans has suggested mechanisms by
which physical activity may preserve neuroprotective pathways, including utilization of cerebral
brain metabolism. Under faculty supervision of Dr. Manu Goyal, in the same cohort of
individuals mentioned above who underwent multi-tracer brain metabolism PET imaging, we
assessed participant’s free-living physical activity habits using accelerometry. I found that
individuals who were physically active had maintained CMRGlc in the rostral middle frontal
cortex, compared to inactive individuals. Furthermore, my results suggest that the maintenance
of CMRGlc is more likely due to a difference in AG than CMRO2. Taken together, these
findings suggests a mechanism by which physical activity may provide resilience aging brain
aging and dysfunction. Further analysis of other brain regions is now ongoing.
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9.6 Summary: Submaximal exercise testing
An important next step is to translate these cross-sectional results to an exercise
intervention aimed at maintaining or improving CMRGlc or AG. A limitation of current exercise
interventions in older adults is the ability to accurately measure and monitor cardiorespiratory
fitness (CRF), a measure of habitual exercise, in this population. Assessment of maximal oxygen
consumption (VO2max) during a graded exercise test is considered the gold standard measure for
evaluating CRF. However, there is concern regarding obtaining a true measure of VO2max in
certain populations, including older adults, individuals with physical limitations, and with
cognitive impairment. Submaximal exercise testing is therefore commonly used to predict
VO2max, as a proxy measure of CRF, particularly when laboratory equipment or physician
supervision is unavailable or when the target population is unlikely to go to volitional
exhaustion. The need to develop and validate submaximal exercise tests that will be more
reliable given a mixed population across a wide range of age, physical functioning, and cognitive
functioning thus cannot be overstated.
Therefore, I sought to validate and determine feasibility of a recently developed EkblomBak cycle ergometer submaximal exercise test for use in a diverse US population. I enrolled 15
who were either “Young” (25-34 years old) or “Older” (55-75 years old) as well as either
sedentary or highly active. Participants completed the submaximal exercise test, followed
immediately by a maximal exercise test. I found that all fifteen individuals were able to
successfully perform the EB submaximal testing method, showing feasibility of this protocol in a
diverse population. Importantly, we observed strong correlations between the Ekblom-bak
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method estimated volume of maximal oxygen consumption (VO2max) values and the observed
VO2max values without significant bias. My findings thus suggest that the EB method likely
retains similar validity in a diverse US cohort as has been found in Scandinavian cohorts. Future
studies further assessing validity in cognitively impaired populations will be useful for assessing
utility of exercise interventions aimed at increase CRF in this population.

9.7 Summary: Personality traits and tau-PET
An additional environmental factor that has been linked to risk and resilience of cognitive decline
and brain health is personality. Prior work by Duchek and colleagues (2007) has indicated that
self-reported neurotic personality traits are higher in individuals with very mild AD dementia
compared with cognitively normal adults. Similarly, in this study, they also found lower selfreported Openness to experience scores in individuals in the very mild and mild AD dementia
cohorts compared to cognitively normal controls. It is possible a resilient personality profile,
such as decreased neurotic traits and increased Openness traits, may be associated with a lower
risk of developing cognitive impairment. I therefore sought to better understand the relationship
between personality traits and an age- and AD-related pathology. In vivo imaging has
demonstrated that tau, rather than other know AD pathophysiology, such as Aβ, is more strongly
tied to proximal measures of cognition and symptomatic AD (M. R. Brier et al., 2016).
Therefore, I examined the cross-sectional relationship between personality traits, focusing on
Neuroticism and Conscientiousness, and regional tau-PET deposition. In a cohort of 128
cognitively normal older adults, Neuroticism was associated with increased tau levels.
Specifically, individuals with higher Neuroticism scores had higher flortaucipir SUVR in regions
including the amygdala, entorhinal cortex, and inferior temporal cortex, as well as a composite
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measure of tauopathy. These relationships were selective, as there were no associations between
Agreeableness, Openness, Extroversion, or Conscientiousness, with tau-PET.
Importantly, there is an established relationship between personality and health habits and
disease (Brummett et al., 2006; Chioqueta & Stiles, 2005; Friedman et al., 1993; Rhodes &
Smith, 2006). There may be an intersection between lifestyle factors of personality and physical
activity habits, whereby physical activity habits may be partially driven by personality traits and
therefore personality may represent an identifier of those who may benefit most from exercise
interventions aimed at altering the trajectory of pathological aging in individuals.

9.8 Conclusions
Overall, my thesis work advances our understanding of emerging biomarkers to study and monitor
pathophysiology underlying brain aging and neurodegenerative diseases. Additionally, my thesis
research has provided evidence for a potential mechanism between lifestyle factors and cerebral
glycolytic metabolism, which will need to be extended to cognitive functioning. Ultimately, these
findings may lead to novel approaches and nonpharmacological interventions, involving exercise,
for age- and AD- related brain changes.
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